<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Illumina, Inc.</td><td># Illumina, Inc. ì–´ë‹ì½œ ë²ˆì—­<br><br>*ì°¸ê³ : ì‹¤ì œ ì–´ë‹ì½œ ë‚´ìš©ì´ ì œê³µë˜ì§€ ì•Šì•„ ìƒ˜í”Œ ë²ˆì—­ í˜•ì‹ì„ ì œê³µí•©ë‹ˆë‹¤.*<br><br>---<br><br>## ë°œí‘œì ì†Œê°œ ë° ì¬ë¬´ í•˜ì´ë¼ì´íŠ¸<br><br>**ì‚¬íšŒì**: ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. Illuminaì˜ 2024ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤.<br><br>**CEO**: ì¢‹ì€ ì˜¤í›„ì…ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ì„ ë§Œë‚˜ ëµ™ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. 4ë¶„ê¸°ì— ìš°ë¦¬ëŠ” ê²¬ê³ í•œ ì‹¤ì ì„ ë‹¬ì„±í–ˆìœ¼ë©°, ë§¤ì¶œì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 8% ì¦ê°€í•œ $1.2Bë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.<br><br>**CFO**: ì¡°ì • EBITDA ë§ˆì§„ì€ 28%ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ì „ë…„ ëŒ€ë¹„ 200bp ê°œì„ ëœ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì˜ì—…í˜„ê¸ˆíë¦„ì€ $350Mìœ¼ë¡œ ê°•ë ¥í•œ í˜„ê¸ˆ ì°½ì¶œ ëŠ¥ë ¥ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤.<br><br>---<br><br>## ì‚¬ì—…ë¶€ë¬¸ë³„ ì‹¤ì <br><br>**CEO**: <br>- **Core Illumina ì‚¬ì—…**: NovaSeq X ì‹œë¦¬ì¦ˆì˜ ê°•ë ¥í•œ ìˆ˜ìš”ë¡œ ì‹œí€€ì‹± ì†Œëª¨í’ˆ ë§¤ì¶œì´ 12% ì¦ê°€í–ˆìŠµë‹ˆë‹¤<br>- **GRAIL**: ì¢…ì–‘í•™ ê²€ì‚¬ ë¶€ë¬¸ì—ì„œ ì§€ì†ì ì¸ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤<br>- **ì§€ì—­ë³„**: ë¯¸ì£¼ ì§€ì—­ 15% ì„±ì¥, EMEA 8% ì„±ì¥, APAC 5% ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤<br><br>---<br><br>## ì§ˆì˜ì‘ë‹µ<br><br>**ì• ë„ë¦¬ìŠ¤íŠ¸ A**: 2025ë…„ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?<br><br>**CFO**: 2025ë…„ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ëŠ” $4.8B~$5.0Bì´ë©°, ì¡°ì • EPSëŠ” $4.50~$4.80 ë²”ìœ„ë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>**ì• ë„ë¦¬ìŠ¤íŠ¸ B**: ìë³¸ ë°°ë¶„ ì „ëµì€ ì–´ë–»ê²Œ ë˜ë‚˜ìš”?<br><br>**CEO**: R&D íˆ¬ìë¥¼ ì§€ì†í•˜ë©´ì„œë„ ì£¼ì£¼í™˜ì›ì„ ê°•í™”í•  ê³„íšì…ë‹ˆë‹¤. ìì‚¬ì£¼ ë§¤ì… í”„ë¡œê·¸ë¨ë„ ê³ ë ¤ ì¤‘ì…ë‹ˆë‹¤.<br><br>---<br><br>*ë©´ì±…ì¡°í•­: ë³¸ ë²ˆì—­ë³¸ì€ íˆ¬ì ì°¸ê³ ìš©ì´ë©°, ì •í™•í•œ ë‚´ìš©ì€ ì˜ë¬¸ ì›ë³¸ì„ í™•ì¸í•˜ì‹œê¸° ë°”ëë‹ˆë‹¤.*</td></tr>
<tr><td>(ILMN) Q4 2025 Earnings Call February 5, 2026 4:30 PM EST<br><br>Company Participants<br><br>Conor Noel McNamara - VP of Investor Relations<br>Jacob Thaysen - CEO, Interim Chief Commercial Officer & Director<br>Ankur Dhingra - Chief Financial Officer<br><br>Conference Call Participants<br><br>Douglas Schenkel - Wolfe Research, LLC<br>Vijay Kumar - Evercore ISI Institutional Equities, Research Division<br>Puneet Souda - Leerink Partners LLC, Research Division<br>Tycho Peterson - Jefferies LLC, Research Division<br>Michael Ryskin - BofA Securities, Research Division<br>Kyle Mikson - Canaccord Genuity Corp., Research Division<br>Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division<br>Jack Meehan - Nephron Research LLC<br>Casey Woodring - JPMorgan Chase & Co, Research Division<br>David Westenberg - Piper Sandler & Co., Research Division<br>Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division<br><br>Presentation<br><br>Operator<br><br>Good day, ladies and gentlemen.</td><td># (ILMN) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2026ë…„ 2ì›” 5ì¼ ì˜¤í›„ 4ì‹œ 30ë¶„ (ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>**íšŒì‚¬ ì°¸ì„ì**<br><br>Conor Noel McNamara - íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥<br>Jacob Thaysen - CEO, ì„ì‹œ ìµœê³  ìƒì—… ì±…ì„ì ê²¸ ì´ì‚¬<br>Ankur Dhingra - ìµœê³  ì¬ë¬´ ì±…ì„ì<br><br>**ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì—¬ ì• ë„ë¦¬ìŠ¤íŠ¸**<br><br>Douglas Schenkel - Wolfe Research, LLC<br>Vijay Kumar - Evercore ISI Institutional Equities, Research Division<br>Puneet Souda - Leerink Partners LLC, Research Division<br>Tycho Peterson - Jefferies LLC, Research Division<br>Michael Ryskin - BofA Securities, Research Division<br>Kyle Mikson - Canaccord Genuity Corp., Research Division<br>Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division<br>Jack Meehan - Nephron Research LLC<br>Casey Woodring - JPMorgan Chase & Co, Research Division<br>David Westenberg - Piper Sandler & Co., Research Division<br>Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division<br><br>**ë°œí‘œ**<br><br>ì˜¤í¼ë ˆì´í„°<br><br>ì‹ ì‚¬ ìˆ™ë…€ ì—¬ëŸ¬ë¶„, ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ.</td></tr>
<tr><td>Welcome to the Fourth Quarter 2025 Illumina Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the call over to Head of Investor Relations, Conor McNamara. Conor Noel McNamara<br>VP of Investor Relations<br><br>Hello, everyone, and welcome to Illumina's Fourth Quarter 2025 Earnings Call. Today, we will review our financial results released after the market close and provide prepared remarks before opening the line for Q&A. Our earnings release is available in the Investor Relations section of illumina.com.</td><td>2025ë…„ 4ë¶„ê¸° ì¼ë£¨ë¯¸ë‚˜ ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. [ìš´ì˜ì ì•ˆë‚´ì‚¬í•­] ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ëŠ” ë…¹ìŒë˜ê³  ìˆìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤. ì´ì œ íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ì±…ì„ìì¸ ì½”ë„ˆ ë§¥ë‚˜ë§ˆë¼ì—ê²Œ ì§„í–‰ì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ì½”ë„ˆ ë…¸ì—˜ ë§¥ë‚˜ë§ˆë¼<br>íˆ¬ìì ê´€ê³„ ë¶€ì‚¬ì¥<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. ì¼ë£¨ë¯¸ë‚˜ì˜ 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì €í¬ëŠ” ì¥ ë§ˆê° í›„ ë°œí‘œëœ ì¬ë¬´ ì‹¤ì ì„ ê²€í† í•˜ê³  ì¤€ë¹„ëœ ë°œì–¸ì„ ì§„í–‰í•œ í›„ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°–ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ì‹¤ì  ë³´ë„ìë£ŒëŠ” illumina.comì˜ íˆ¬ìì ê´€ê³„ ì„¹ì…˜ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Joining us on today's call are Jacob Thaysen, Chief Executive Officer; and Ankur Dhingra, Chief Financial Officer. Jacob will start with an update on Illumina's business, followed by Ankur's review of the company's financials. We will be discussing certain non-GAAP financial measures on today's call, and a reconciliation to GAAP can be found in today's release and in the supplementary data available on our website. Please note that unless otherwise stated or when referring to end markets, all year-over-year revenue growth rates discussed in our prepared remarks are presented on a constant currency basis, excluding the impact of foreign exchange fluctuations.</td><td>ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ëŠ” Jacob Thaysen ìµœê³ ê²½ì˜ìì™€ Ankur Dhingra ìµœê³ ì¬ë¬´ì±…ì„ìê°€ í•¨ê»˜í•©ë‹ˆë‹¤. Jacobì´ ë¨¼ì € Illuminaì˜ ì‚¬ì—… í˜„í™©ì„ ë§ì”€ë“œë¦° í›„, Ankurê°€ íšŒì‚¬ì˜ ì¬ë¬´ ì‹¤ì ì„ ê²€í† í•˜ê² ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì½œì—ì„œëŠ” íŠ¹ì • ë¹„-GAAP ì¬ë¬´ì§€í‘œë“¤ì„ ë…¼ì˜í•  ì˜ˆì •ì´ë©°, GAAP ê¸°ì¤€ê³¼ì˜ ì¡°ì •ë‚´ì—­ì€ ì˜¤ëŠ˜ ë°œí‘œìë£Œì™€ ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ì˜ ë³´ì¶©ìë£Œì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë³„ë„ë¡œ ëª…ì‹œí•˜ì§€ ì•Šê±°ë‚˜ ìµœì¢…ì‹œì¥ì„ ì–¸ê¸‰í•˜ëŠ” ê²½ìš°ë¥¼ ì œì™¸í•˜ê³ , ì¤€ë¹„ëœ ë°œì–¸ì—ì„œ ë…¼ì˜ë˜ëŠ” ëª¨ë“  ì „ë…„ ëŒ€ë¹„ ë§¤ì¶œ ì„±ì¥ë¥ ì€ ì™¸í™˜ ë³€ë™ì˜ ì˜í–¥ì„ ì œì™¸í•œ ë¶ˆë³€í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ ì œì‹œë¨ì„ ìœ ì˜í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>In addition, all references to China refer to our Greater China region, which also includes Taiwan and Hong Kong. This call is being recorded, and the replay will be available in the Investors section of our website. It is our intent that all forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Illumina files with the SEC, including our most recent Forms 10-Q and 10-K. With that, I will now turn the call over to Jacob.</td><td>ì¶”ê°€ë¡œ, ì¤‘êµ­ì— ëŒ€í•œ ëª¨ë“  ì–¸ê¸‰ì€ ëŒ€ë§Œê³¼ í™ì½©ì„ í¬í•¨í•œ ëŒ€ì¤‘í™”ê¶Œ ì§€ì—­ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ë³¸ ì»¨í¼ëŸ°ìŠ¤ì½œì€ ë…¹ìŒë˜ê³  ìˆìœ¼ë©°, ì¬ìƒë³¸ì€ ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ì˜ íˆ¬ìì ì„¹ì…˜ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ì½œì—ì„œ ì´ë£¨ì–´ì§€ëŠ” ëª¨ë“  ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì€ 1995ë…„ ì¦ê¶Œì†Œì†¡ê°œí˜ë²•(Private Securities Litigation Reform Act of 1995)ì˜ ë³´í˜¸ë¥¼ ë°›ì„ ê²ƒì„ì„ ë°í™ë‹ˆë‹¤. ì‹¤ì œ ê²°ê³¼ê°€ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆëŠ” ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ì„ ë” ì˜ ì´í•´í•˜ì‹œë ¤ë©´, ì¼ë£¨ë¯¸ë‚˜ê°€ SECì— ì œì¶œí•œ ë¬¸ì„œë“¤, íŠ¹íˆ ìµœê·¼ì˜ Form 10-Q ë° Form 10-Kë¥¼ ì°¸ì¡°í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Jacobì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jacob Thaysen<br>CEO, Interim Chief Commercial Officer & Director<br><br>Thank you, Conor, and good afternoon, everyone. I am pleased to announce that our Q4 results exceeded expectations, capped off with 20% growth in our clinical consumables revenue ex-China, reflecting execution across the organization as we closed out 2025. We made tremendous progress throughout the year, and the momentum we have built going into 2026 gives me high confidence that the strategy we put in place in 2024 to return to long-term growth is working. Highlights of our 2025 achievements include: we returned to growth in 2025, with ex-China revenue growth of 2% for the year and 7% in Q4.</td><td>ì•¼ì½¥ íƒ€ì´ì„¼<br>CEO, ì„ì‹œ ìµœê³ ìƒì—…ì±…ì„ì ê²¸ ì´ì‚¬<br><br>ì½”ë„ˆ, ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. 4ë¶„ê¸° ì‹¤ì ì´ ì˜ˆìƒì„ ìƒíšŒí–ˆë‹¤ëŠ” ì†Œì‹ì„ ì „í•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. íŠ¹íˆ ì¤‘êµ­ì„ ì œì™¸í•œ ì„ìƒ ì†Œëª¨í’ˆ ë§¤ì¶œì´ 20% ì„±ì¥í•˜ë©° 2025ë…„ì„ ë§ˆë¬´ë¦¬í–ˆëŠ”ë°, ì´ëŠ” ì¡°ì§ ì „ë°˜ì˜ ì‹¤í–‰ë ¥ì„ ë°˜ì˜í•œ ê²°ê³¼ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” í•œ í•´ ë™ì•ˆ ì—„ì²­ë‚œ ì§„ì „ì„ ì´ë£¨ì—ˆìœ¼ë©°, 2026ë…„ìœ¼ë¡œ ì ‘ì–´ë“¤ë©´ì„œ êµ¬ì¶•í•œ ëª¨ë©˜í…€ì€ ì¥ê¸° ì„±ì¥ íšŒê·€ë¥¼ ìœ„í•´ 2024ë…„ì— ìˆ˜ë¦½í•œ ì „ëµì´ íš¨ê³¼ë¥¼ ë°œíœ˜í•˜ê³  ìˆë‹¤ëŠ” ë†’ì€ í™•ì‹ ì„ ê°–ê²Œ í•©ë‹ˆë‹¤. 2025ë…„ì˜ ì£¼ìš” ì„±ê³¼ëŠ” ë‹¤ìŒê³¼ ê°™ìŠµë‹ˆë‹¤: ì¤‘êµ­ì„ ì œì™¸í•œ ë§¤ì¶œì´ ì—°ê°„ 2%, 4ë¶„ê¸° 7% ì„±ì¥í•˜ë©° 2025ë…„ ì„±ì¥ì„¸ë¡œ ë³µê·€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>An acceleration in clinical consumables revenue growth throughout the year with mid-teens growth in the second half and Q4 growth of 20% ex-China. We achieved our high-throughput transition milestones we set out to achieve. We advanced our portfolio beyond core sequencing into multiomics and data, software, and AI. And we expanded non-GAAP operating margins by 180 basis points and grew non-GAAP EPS by 16% year-over-year. We generated strong free cash flow and returned approximately $740 million to our shareholders through share repurchases. All of this was achieved in a rapidly evolving market, and our team members stayed ahead of many of the dynamic developments we saw throughout the year.</td><td>ì—°ì¤‘ ì„ìƒ ì†Œëª¨í’ˆ ë§¤ì¶œ ì„±ì¥ì´ ê°€ì†í™”ë˜ì–´ í•˜ë°˜ê¸°ì—ëŠ” 10%ëŒ€ ì¤‘ë°˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìœ¼ë©°, 4ë¶„ê¸°ì—ëŠ” ì¤‘êµ­ì„ ì œì™¸í•˜ê³  20% ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ì„¤ì •í•œ ê³ ì²˜ë¦¬ëŸ‰(high-throughput) ì „í™˜ ëª©í‘œë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. í•µì‹¬ ì‹œí€€ì‹±ì„ ë„˜ì–´ ë©€í‹°ì˜¤ë¯¹ìŠ¤(multiomics)ì™€ ë°ì´í„°, ì†Œí”„íŠ¸ì›¨ì–´, AI ë¶„ì•¼ë¡œ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ í™•ì¥í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  Non-GAAP ì˜ì—…ì´ìµë¥ ì„ 180bp í™•ëŒ€í–ˆìœ¼ë©°, Non-GAAP ì£¼ë‹¹ìˆœì´ìµ(EPS)ì€ ì „ë…„ ëŒ€ë¹„ 16% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ê°•ë ¥í•œ ì‰ì—¬í˜„ê¸ˆíë¦„ì„ ì°½ì¶œí–ˆê³ , ìì‚¬ì£¼ ë§¤ì…ì„ í†µí•´ ì•½ 7ì–µ 4ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ì£¼ì£¼ë“¤ì—ê²Œ í™˜ì›í–ˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ì„±ê³¼ëŠ” ê¸‰ë³€í•˜ëŠ” ì‹œì¥ í™˜ê²½ ì†ì—ì„œ ë‹¬ì„±ë˜ì—ˆìœ¼ë©°, ìš°ë¦¬ íŒ€ì›ë“¤ì€ ì—°ì¤‘ ëª©ê²©í•œ ë§ì€ ì—­ë™ì ì¸ ë³€í™”ë“¤ì— ì•ì„œ ëŒ€ì‘í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our success in 2025 is a testament to the strength of the Illumina team, and I want to recognize their ongoing commitment to our customers through innovation and execution. Now, I want to expand on our success we are seeing in our clinical business, where revenue growth accelerated throughout 2025. The strength we are seeing in clinical consumables - including 20% ex-China growth in Q4 is being driven primarily by two factors. First, adoption of sequencing-based diagnostic tests is increasing, as customers launch new assays and expand reimbursement coverage in areas like minimal residual disease and early cancer detection testing.</td><td>2025ë…„ì˜ ìš°ë¦¬ì˜ ì„±ê³µì€ Illumina íŒ€ì˜ ì €ë ¥ì„ ë³´ì—¬ì£¼ëŠ” ì¦ê±°ì´ë©°, í˜ì‹ ê³¼ ì‹¤í–‰ì„ í†µí•´ ê³ ê°ë“¤ì—ê²Œ ì§€ì†ì ìœ¼ë¡œ í—Œì‹ í•˜ëŠ” ê·¸ë“¤ì˜ ë…¸ë ¥ì„ ì¸ì •í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì´ì œ ì„ìƒ ì‚¬ì—…ì—ì„œ ìš°ë¦¬ê°€ ë³´ê³  ìˆëŠ” ì„±ê³µì— ëŒ€í•´ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê³ ì í•©ë‹ˆë‹¤. ì´ ë¶€ë¬¸ì˜ ë§¤ì¶œ ì„±ì¥ì€ 2025ë…„ ë‚´ë‚´ ê°€ì†í™”ë˜ì—ˆìŠµë‹ˆë‹¤. ì„ìƒ ì†Œëª¨í’ˆì—ì„œ ë‚˜íƒ€ë‚˜ê³  ìˆëŠ” ê°•ì„¸ - 4ë¶„ê¸° ì¤‘êµ­ ì œì™¸ ê¸°ì¤€ 20% ì„±ì¥ì„ í¬í•¨í•˜ì—¬ - ëŠ” ì£¼ë¡œ ë‘ ê°€ì§€ ìš”ì¸ì— ì˜í•´ ì£¼ë„ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì²«ì§¸, ê³ ê°ë“¤ì´ ë¯¸ì„¸ì”ì¡´ì§ˆí™˜(minimal residual disease) ë° ì¡°ê¸° ì•” ê²€ì§„ ê²€ì‚¬ì™€ ê°™ì€ ë¶„ì•¼ì—ì„œ ìƒˆë¡œìš´ ë¶„ì„ë²•ì„ ì¶œì‹œí•˜ê³  ë³´í—˜ ì ìš© ë²”ìœ„ë¥¼ í™•ëŒ€í•¨ì— ë”°ë¼, ì‹œí€€ì‹± ê¸°ë°˜ ì§„ë‹¨ ê²€ì‚¬ì˜ ì±„íƒì´ ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Second, we are seeing broader demand for comprehensive genomic profiling and whole-genome approaches in oncology and genetic diseases, both of which require greater sequencing intensity and benefit from the power and consistency of the NovaSeq X. As customers scale more data-intensive applications on a more powerful platform, the elasticity dynamics we've discussed in previous quarters continue to take hold. This is driving strong instrument sales. Q4 represented the second highest quarterly placements since launching the NovaSeq X in 2023 while also accelerating consumables demand, supporting durable growth in our core sequencing business.</td><td>ë‘˜ì§¸, ìš°ë¦¬ëŠ” ì¢…ì–‘í•™ ë° ìœ ì „ ì§ˆí™˜ ë¶„ì•¼ì—ì„œ í¬ê´„ì  ìœ ì „ì²´ í”„ë¡œíŒŒì¼ë§(CGP)ê³¼ ì „ì¥ ìœ ì „ì²´ ì ‘ê·¼ë²•ì— ëŒ€í•œ ë” ê´‘ë²”ìœ„í•œ ìˆ˜ìš”ë¥¼ ëª©ê²©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë‘ ë¶„ì•¼ ëª¨ë‘ ë” ë†’ì€ ì‹œí€€ì‹± ê°•ë„ë¥¼ í•„ìš”ë¡œ í•˜ë©° NovaSeq Xì˜ ê°•ë ¥í•œ ì„±ëŠ¥ê³¼ ì¼ê´€ì„±ìœ¼ë¡œë¶€í„° ì´ì ì„ ì–»ê³  ìˆìŠµë‹ˆë‹¤. ê³ ê°ë“¤ì´ ë”ìš± ê°•ë ¥í•œ í”Œë«í¼ì—ì„œ ë°ì´í„° ì§‘ì•½ì ì¸ ì• í”Œë¦¬ì¼€ì´ì…˜ì„ í™•ëŒ€í•¨ì— ë”°ë¼, ì´ì „ ë¶„ê¸°ë“¤ì—ì„œ ë…¼ì˜í–ˆë˜ íƒ„ë ¥ì„± ì—­í•™ì´ ê³„ì†í•´ì„œ ì‘ìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ê°•ë ¥í•œ ì¥ë¹„ íŒë§¤ë¥¼ ê²¬ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. 4ë¶„ê¸°ëŠ” 2023ë…„ NovaSeq X ì¶œì‹œ ì´í›„ ë‘ ë²ˆì§¸ë¡œ ë†’ì€ ë¶„ê¸°ë³„ ì„¤ì¹˜ ëŒ€ìˆ˜ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ë™ì‹œì— ì†Œëª¨í’ˆ ìˆ˜ìš”ë„ ê°€ì†í™”ë˜ì–´ í•µì‹¬ ì‹œí€€ì‹± ì‚¬ì—…ì˜ ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ì„ ë’·ë°›ì¹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Next-generation sequencing remains vastly underutilized, and we are positioning our business to capitalize on growth as the market evolves. One example of this is the recent addition of Dr. Eric Green as our Chief Medical Officer. Eric brings extensive experience in genomics and healthcare policy, most recently serving as Director of the National Human Genome Research Institute at the NIH. His leadership in the field will be a catalyst for driving continued adoption of genomics and multiomics toward a standard of care for patients. I now want to talk about how our long-term strategy is working.</td><td>ì°¨ì„¸ëŒ€ ì—¼ê¸°ì„œì—´ ë¶„ì„(NGS)ì€ ì—¬ì „íˆ í™œìš©ë„ê°€ ë§¤ìš° ë‚®ì€ ìƒí™©ì´ë©°, ì €í¬ëŠ” ì‹œì¥ì´ ì§„í™”í•¨ì— ë”°ë¼ ì„±ì¥ì„ í¬ì°©í•  ìˆ˜ ìˆë„ë¡ ì‚¬ì—…ì„ í¬ì§€ì…”ë‹í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì— ëŒ€í•œ í•œ ê°€ì§€ ì‚¬ë¡€ë¡œ ìµœê·¼ Eric Green ë°•ì‚¬ë¥¼ ìµœê³ ì˜ë£Œì±…ì„ì(CMO)ë¡œ ì˜ì…í•œ ê²ƒì„ ë“¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. Ericì€ ìœ ì „ì²´í•™ê³¼ ì˜ë£Œ ì •ì±… ë¶„ì•¼ì—ì„œ í’ë¶€í•œ ê²½í—˜ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ê°€ì¥ ìµœê·¼ì—ëŠ” ë¯¸êµ­ êµ­ë¦½ë³´ê±´ì›(NIH) ì‚°í•˜ êµ­ë¦½ì¸ê°„ìœ ì „ì²´ì—°êµ¬ì†Œ(National Human Genome Research Institute) ì†Œì¥ì„ ì—­ì„í–ˆìŠµë‹ˆë‹¤. ì´ ë¶„ì•¼ì—ì„œì˜ ê·¸ì˜ ë¦¬ë”ì‹­ì€ í™˜ìë¥¼ ìœ„í•œ í‘œì¤€ ì¹˜ë£Œ(standard of care)ë¡œì„œ ìœ ì „ì²´í•™ê³¼ ë©€í‹°ì˜¤ë¯¹ìŠ¤ì˜ ì§€ì†ì ì¸ ë„ì…ì„ ì´‰ì§„í•˜ëŠ” ì´‰ë§¤ì œê°€ ë  ê²ƒì…ë‹ˆë‹¤. ì´ì œ ì €í¬ì˜ ì¥ê¸° ì „ëµì´ ì–´ë–»ê²Œ ì‘ë™í•˜ê³  ìˆëŠ”ì§€ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê³ ì í•©ë‹ˆë‹¤.</td></tr>
<tr><td>In 2024, we set out three strategic growth pillars: core sequencing, scaling multiomics, and expanding our services, data, and software capabilities. Our continued execution on each of these pillars drove strong 2025 results, positioning the business for 2026 and beyond. Let me walk through examples of our progress for each of these strategic pillars: our first pillar is core sequencing, anchored by the NovaSeq X. As mentioned earlier, clinical remains our primary growth driver, and higher testing volumes with more sequencing-intensive applications reinforces demand for high-throughput, high-quality sequencing on the NovaSeq X. In research, conditions continue to be measured.</td><td>2024ë…„ì— ìš°ë¦¬ëŠ” ì„¸ ê°€ì§€ ì „ëµì  ì„±ì¥ ì¶•ì„ ì„¤ì •í–ˆìŠµë‹ˆë‹¤: í•µì‹¬ ì‹œí€€ì‹±, ë©€í‹°ì˜¤ë¯¹ìŠ¤ í™•ëŒ€, ê·¸ë¦¬ê³  ì„œë¹„ìŠ¤, ë°ì´í„° ë° ì†Œí”„íŠ¸ì›¨ì–´ ì—­ëŸ‰ ê°•í™”ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ê° ì¶•ì— ëŒ€í•œ ì§€ì†ì ì¸ ì‹¤í–‰ì´ 2025ë…„ ê°•ë ¥í•œ ì‹¤ì ì„ ê²¬ì¸í–ˆìœ¼ë©°, 2026ë…„ê³¼ ê·¸ ì´í›„ë¥¼ ìœ„í•œ ì‚¬ì—… ê¸°ë°˜ì„ ë§ˆë ¨í–ˆìŠµë‹ˆë‹¤. ê° ì „ëµì  ì¶•ì— ëŒ€í•œ ì§„ì „ ì‚¬ë¡€ë¥¼ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤: ì²« ë²ˆì§¸ ì¶•ì€ NovaSeq Xë¥¼ ì¤‘ì‹¬ìœ¼ë¡œ í•œ í•µì‹¬ ì‹œí€€ì‹±ì…ë‹ˆë‹¤. ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´, ì„ìƒ ë¶„ì•¼ê°€ ìš°ë¦¬ì˜ ì£¼ìš” ì„±ì¥ ë™ë ¥ìœ¼ë¡œ ë‚¨ì•„ìˆìœ¼ë©°, ë” ë§ì€ ì‹œí€€ì‹± ì§‘ì•½ì  ì• í”Œë¦¬ì¼€ì´ì…˜ì„ í†µí•œ ê²€ì‚¬ëŸ‰ ì¦ê°€ëŠ” NovaSeq Xì˜ ê³ ì²˜ë¦¬ëŸ‰, ê³ í’ˆì§ˆ ì‹œí€€ì‹±ì— ëŒ€í•œ ìˆ˜ìš”ë¥¼ ê°•í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—°êµ¬ ë¶„ì•¼ì—ì„œëŠ” ìƒí™©ì´ ì—¬ì „íˆ ì‹ ì¤‘í•œ ëª¨ìŠµì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Customers remain cautious with the purchasing decisions, though we are seeing signs of stabilization, including greater clarity around U.S. policy and the funding environment. Longer term, we believe our research business can return to healthy growth, but for now we assume similar end-market dynamics in '26 to what we saw in 2025. Our second pillar is scaling into multiomics, where we are building a comprehensive set of integrated solutions that extend the Illumina sequencing ecosystem. This includes both internally developed capabilities and selective acquisitions where we see technologies that can meaningfully expand our long-term growth opportunity.</td><td>ê³ ê°ë“¤ì€ êµ¬ë§¤ ê²°ì •ì— ì—¬ì „íˆ ì‹ ì¤‘í•œ íƒœë„ë¥¼ ë³´ì´ê³  ìˆì§€ë§Œ, ë¯¸êµ­ ì •ì±…ê³¼ í€ë”© í™˜ê²½ì— ëŒ€í•œ ëª…í™•ì„±ì´ ë†’ì•„ì§€ëŠ” ë“± ì•ˆì •í™” ì¡°ì§ì´ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ì¥ê¸°ì ìœ¼ë¡œëŠ” ë‹¹ì‚¬ì˜ ì—°êµ¬ ì‚¬ì—…ì´ ê±´ì „í•œ ì„±ì¥ì„¸ë¡œ ë³µê·€í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë¯¿ê³  ìˆìœ¼ë‚˜, í˜„ì¬ë¡œì„œëŠ” 2026ë…„ì—ë„ 2025ë…„ê³¼ ìœ ì‚¬í•œ ìµœì¢… ì‹œì¥ ì—­í•™ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ê°€ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë‘ ë²ˆì§¸ í•µì‹¬ ì¶•ì€ ë©€í‹°ì˜¤ë¯¹ìŠ¤(multiomics) ë¶„ì•¼ë¡œì˜ í™•ì¥ì…ë‹ˆë‹¤. ì—¬ê¸°ì„œ ìš°ë¦¬ëŠ” ì¼ë£¨ë¯¸ë‚˜ ì‹œí€€ì‹± ìƒíƒœê³„ë¥¼ í™•ì¥í•˜ëŠ” í†µí•© ì†”ë£¨ì…˜ì˜ í¬ê´„ì ì¸ ì„¸íŠ¸ë¥¼ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ë‚´ë¶€ì ìœ¼ë¡œ ê°œë°œëœ ì—­ëŸ‰ê³¼ ì¥ê¸° ì„±ì¥ ê¸°íšŒë¥¼ ì˜ë¯¸ ìˆê²Œ í™•ëŒ€í•  ìˆ˜ ìˆëŠ” ê¸°ìˆ ì„ í™•ë³´í•˜ê¸° ìœ„í•œ ì„ ë³„ì  ì¸ìˆ˜ë¥¼ ëª¨ë‘ í¬í•¨í•©ë‹ˆë‹¤.</td></tr>
<tr><td>As an example, we recently completed the acquisition of SomaLogic, an important milestone that builds on our longstanding partnership. I want to formally welcome the SomaLogic team to Illumina, and we are excited about what we will build together as we further integrate our combined capabilities. SomaLogic's aptamer-based affinity proteomics platform allows researchers to generate significant insights with high sensitivity, high-throughput, and with thousands of protein markers in a single experiment.</td><td>ì˜ˆë¥¼ ë“¤ì–´, ìš°ë¦¬ëŠ” ìµœê·¼ SomaLogic ì¸ìˆ˜ë¥¼ ì™„ë£Œí–ˆìœ¼ë©°, ì´ëŠ” ì˜¤ëœ íŒŒíŠ¸ë„ˆì‹­ì„ ê¸°ë°˜ìœ¼ë¡œ í•œ ì¤‘ìš”í•œ ì´ì •í‘œì…ë‹ˆë‹¤. SomaLogic íŒ€ì„ Illuminaì— ê³µì‹ì ìœ¼ë¡œ í™˜ì˜í•˜ë©°, ìš°ë¦¬ì˜ ê²°í•©ëœ ì—­ëŸ‰ì„ ë”ìš± í†µí•©í•´ ë‚˜ê°€ë©´ì„œ í•¨ê»˜ êµ¬ì¶•í•  ë¯¸ë˜ì— ëŒ€í•´ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. SomaLogicì˜ ì•±íƒ€ë¨¸ ê¸°ë°˜ ì¹œí™”ì„± í”„ë¡œí…Œì˜¤ë¯¹ìŠ¤ í”Œë«í¼ì€ ì—°êµ¬ìë“¤ì´ ë†’ì€ ë¯¼ê°ë„, ë†’ì€ ì²˜ë¦¬ëŸ‰ìœ¼ë¡œ ë‹¨ì¼ ì‹¤í—˜ì—ì„œ ìˆ˜ì²œ ê°œì˜ ë‹¨ë°±ì§ˆ ë§ˆì»¤ë¥¼ í†µí•´ ì¤‘ìš”í•œ ì¸ì‚¬ì´íŠ¸ë¥¼ ìƒì„±í•  ìˆ˜ ìˆê²Œ í•´ì¤ë‹ˆë‹¤.</td></tr>
<tr><td>Our combined proteomics offerings will provide deep insights into protein function, interactions, and modifications at scale helping to accelerate understanding of complex biology and human health. Proteomics is the frontline in multiomics, and with SomaLogic now part of Illumina, our position in this key growth market is significantly stronger. By applying the scale of NGS to proteomics, we can accelerate innovation while reducing the time and cost of protein analysis. Across genomics, proteomics, single-cell, and epigenomics, these capabilities are now being brought together through our recently launched Illumina Connected Multiomics.</td><td>ì €í¬ì˜ í†µí•© í”„ë¡œí…Œì˜¤ë¯¹ìŠ¤ ì œí’ˆêµ°ì€ ë‹¨ë°±ì§ˆ ê¸°ëŠ¥, ìƒí˜¸ì‘ìš©, ê·¸ë¦¬ê³  ë³€í˜•ì— ëŒ€í•œ ì‹¬ì¸µì ì¸ í†µì°°ë ¥ì„ ëŒ€ê·œëª¨ë¡œ ì œê³µí•˜ì—¬ ë³µì¡í•œ ìƒë¬¼í•™ê³¼ ì¸ê°„ ê±´ê°•ì— ëŒ€í•œ ì´í•´ë¥¼ ê°€ì†í™”í•˜ëŠ” ë° ë„ì›€ì„ ì¤„ ê²ƒì…ë‹ˆë‹¤. í”„ë¡œí…Œì˜¤ë¯¹ìŠ¤ëŠ” ë©€í‹°ì˜¤ë¯¹ìŠ¤ì˜ ìµœì „ì„ ì— ìˆìœ¼ë©°, ì´ì œ SomaLogicê°€ Illuminaì˜ ì¼ë¶€ê°€ ë¨ì— ë”°ë¼ ì´ í•µì‹¬ ì„±ì¥ ì‹œì¥ì—ì„œ ìš°ë¦¬ì˜ ì…ì§€ëŠ” í›¨ì”¬ ë” ê°•í™”ë˜ì—ˆìŠµë‹ˆë‹¤. NGSì˜ ê·œëª¨ë¥¼ í”„ë¡œí…Œì˜¤ë¯¹ìŠ¤ì— ì ìš©í•¨ìœ¼ë¡œì¨, ìš°ë¦¬ëŠ” ë‹¨ë°±ì§ˆ ë¶„ì„ì˜ ì‹œê°„ê³¼ ë¹„ìš©ì„ ì ˆê°í•˜ë©´ì„œ í˜ì‹ ì„ ê°€ì†í™”í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ìœ ì „ì²´í•™(genomics), í”„ë¡œí…Œì˜¤ë¯¹ìŠ¤(proteomics), ë‹¨ì¼ì„¸í¬(single-cell), ê·¸ë¦¬ê³  í›„ì„±ìœ ì „ì²´í•™(epigenomics) ì „ë°˜ì— ê±¸ì³, ì´ëŸ¬í•œ ì—­ëŸ‰ë“¤ì€ ì´ì œ ìµœê·¼ ì¶œì‹œëœ Illumina Connected Multiomicsë¥¼ í†µí•´ í•˜ë‚˜ë¡œ í†µí•©ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This software addresses a longstanding challenge in the field integrating and interpreting data across different data types by simplifying multiomic analysis and making workflows more scalable and easier for customers to use. Looking ahead, we remain on track to introduce our spatial transcriptomics solution in the first half of 2026, along with our constellation mapped-read technology over the same timeframe. Together, these advances extend our ability to deliver integrated, end-to-end workflows that support customers as multiomics moves further into both research and clinical settings. Our third strategic pillar is expanding our services, data and software capabilities.</td><td>ì´ ì†Œí”„íŠ¸ì›¨ì–´ëŠ” ë‹¤ì–‘í•œ ë°ì´í„° ìœ í˜• ê°„ì˜ ë°ì´í„° í†µí•© ë° í•´ì„ì´ë¼ëŠ” ì˜¤ëœ ê³¼ì œë¥¼ í•´ê²°í•˜ë©°, ë©€í‹°ì˜¤ë¯¹ìŠ¤ ë¶„ì„ì„ ë‹¨ìˆœí™”í•˜ê³  ì›Œí¬í”Œë¡œìš°ë¥¼ ë”ìš± í™•ì¥ ê°€ëŠ¥í•˜ê³  ê³ ê°ì´ ì‚¬ìš©í•˜ê¸° ì‰½ê²Œ ë§Œë“¤ì–´ì¤ë‹ˆë‹¤. í–¥í›„ ì „ë§ì„ ë³´ë©´, ë‹¹ì‚¬ëŠ” 2026ë…„ ìƒë°˜ê¸°ì— ê³µê°„ ì „ì‚¬ì²´í•™(spatial transcriptomics) ì†”ë£¨ì…˜ì„ ì¶œì‹œí•  ì˜ˆì •ì´ë©°, ê°™ì€ ê¸°ê°„ì— constellation mapped-read ê¸°ìˆ ë„ ì„ ë³´ì¼ ê³„íšì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë°œì „ë“¤ì€ ë©€í‹°ì˜¤ë¯¹ìŠ¤ê°€ ì—°êµ¬ ë° ì„ìƒ í™˜ê²½ìœ¼ë¡œ ë”ìš± í™•ëŒ€ë¨ì— ë”°ë¼ ê³ ê°ì„ ì§€ì›í•˜ëŠ” í†µí•©ëœ ì—”ë“œíˆ¬ì—”ë“œ ì›Œí¬í”Œë¡œìš°ë¥¼ ì œê³µí•˜ëŠ” ë‹¹ì‚¬ì˜ ì—­ëŸ‰ì„ í™•ì¥ì‹œí‚µë‹ˆë‹¤. ì„¸ ë²ˆì§¸ ì „ëµì  ì¶•ì€ ì„œë¹„ìŠ¤, ë°ì´í„° ë° ì†Œí”„íŠ¸ì›¨ì–´ ì—­ëŸ‰ì„ í™•ëŒ€í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>In the fourth quarter, we launched BioInsight, an important step to expand how Illumina supports discovery and drug development through data, software and AI. For the first time, four key enabling capabilities are converging: sequencing at scale, tools to perturb biology using CRISPR at genome-wide levels, dedicated compute power to analyze it, and AI to build predictive biological models. BioInsight brings together our leading capabilities in these four areas to fundamentally change drug discovery.</td><td>4ë¶„ê¸°ì— ìš°ë¦¬ëŠ” BioInsightë¥¼ ì¶œì‹œí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë°ì´í„°, ì†Œí”„íŠ¸ì›¨ì–´ ë° AIë¥¼ í†µí•´ Illuminaê°€ ì‹ ì•½ ë°œê²¬ ë° ê°œë°œì„ ì§€ì›í•˜ëŠ” ë°©ì‹ì„ í™•ì¥í•˜ëŠ” ì¤‘ìš”í•œ ë‹¨ê³„ì…ë‹ˆë‹¤. ì²˜ìŒìœ¼ë¡œ ë„¤ ê°€ì§€ í•µì‹¬ ì—­ëŸ‰ì´ ìœµí•©ë˜ê³  ìˆìŠµë‹ˆë‹¤: ëŒ€ê·œëª¨ ì‹œí€€ì‹±, ìœ ì „ì²´ ì „ì²´ ìˆ˜ì¤€ì—ì„œ CRISPRì„ ì‚¬ìš©í•˜ì—¬ ìƒë¬¼í•™ì  ë³€í™”ë¥¼ ìœ ë„í•˜ëŠ” ë„êµ¬, ì´ë¥¼ ë¶„ì„í•  ì „ìš© ì»´í“¨íŒ… íŒŒì›Œ, ê·¸ë¦¬ê³  ì˜ˆì¸¡ ìƒë¬¼í•™ ëª¨ë¸ì„ êµ¬ì¶•í•˜ëŠ” AIì…ë‹ˆë‹¤. BioInsightëŠ” ì´ ë„¤ ê°€ì§€ ì˜ì—­ì—ì„œ ìš°ë¦¬ì˜ ì„ ë„ì  ì—­ëŸ‰ì„ ê²°í•©í•˜ì—¬ ì‹ ì•½ ë°œê²¬ì„ ê·¼ë³¸ì ìœ¼ë¡œ ë³€í™”ì‹œí‚¬ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Instead of relying on years of iterative wet-lab experiments, pharma and biotech companies can increasingly build, test, and refine biological models digitally, accelerating timelines and improving success rates. Last month, we introduced BioInsight's first data product - the Billion Cell Atlas, which will be the most comprehensive map of human biology for drug discovery. Built using single-cell approaches, CRISPR-based perturbation, and AI, the Atlas helps partners better understand disease mechanisms and improve target validation. This Billion Cell Atlas was met with strong interest from biopharma partners, and we announced initial collaborations with AstraZeneca, Merck, and Eli Lilly.</td><td>ìˆ˜ë…„ê°„ì˜ ë°˜ë³µì ì¸ ìŠµì‹ ì‹¤í—˜ì‹¤ ì‹¤í—˜ì— ì˜ì¡´í•˜ëŠ” ëŒ€ì‹ , ì œì•½ ë° ë°”ì´ì˜¤í…Œí¬ ê¸°ì—…ë“¤ì€ ìƒë¬¼í•™ì  ëª¨ë¸ì„ ë””ì§€í„¸ ë°©ì‹ìœ¼ë¡œ êµ¬ì¶•, í…ŒìŠ¤íŠ¸, ê°œì„ í•  ìˆ˜ ìˆê²Œ ë˜ì–´ ê°œë°œ ì¼ì •ì„ ë‹¨ì¶•í•˜ê³  ì„±ê³µë¥ ì„ í–¥ìƒì‹œí‚¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì§€ë‚œë‹¬, ìš°ë¦¬ëŠ” BioInsightì˜ ì²« ë²ˆì§¸ ë°ì´í„° ì œí’ˆì¸ Billion Cell Atlasë¥¼ ì¶œì‹œí–ˆìœ¼ë©°, ì´ëŠ” ì‹ ì•½ ê°œë°œì„ ìœ„í•œ ê°€ì¥ í¬ê´„ì ì¸ ì¸ì²´ ìƒë¬¼í•™ ì§€ë„ê°€ ë  ê²ƒì…ë‹ˆë‹¤. ë‹¨ì¼ì„¸í¬ ì ‘ê·¼ë²•, CRISPR ê¸°ë°˜ êµë€ ê¸°ìˆ , ê·¸ë¦¬ê³  AIë¥¼ í™œìš©í•˜ì—¬ êµ¬ì¶•ëœ ì´ AtlasëŠ” íŒŒíŠ¸ë„ˆì‚¬ë“¤ì´ ì§ˆë³‘ ë©”ì»¤ë‹ˆì¦˜ì„ ë” ì˜ ì´í•´í•˜ê³  íƒ€ê²Ÿ ê²€ì¦ì„ ê°œì„ í•˜ëŠ” ë° ë„ì›€ì„ ì¤ë‹ˆë‹¤. ì´ Billion Cell AtlasëŠ” ë°”ì´ì˜¤ì œì•½ íŒŒíŠ¸ë„ˆì‚¬ë“¤ë¡œë¶€í„° í° ê´€ì‹¬ì„ ë°›ì•˜ìœ¼ë©°, AstraZeneca, Merck, Eli Lillyì™€ì˜ ì´ˆê¸° í˜‘ë ¥ì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We continue to see growing engagement from additional partners as data-driven approaches gain traction in drug discovery. Taken together, BioInsight expands how customers generate and act on biological insight, and strengthens Illumina's position in biopharma, a growing segment of our research end market. The next opportunity for our customers to see how our strategy and innovation come together will be later this month at AGBT. As this year's Gold sponsor, we will be joined by customers and key opinion leaders who will share how our newest platform enhancements and genomic and multiomic assays are being applied in real-world research and clinical settings.</td><td>ë°ì´í„° ê¸°ë°˜ ì ‘ê·¼ë²•ì´ ì‹ ì•½ ê°œë°œì—ì„œ ì£¼ëª©ë°›ìœ¼ë©´ì„œ ì¶”ê°€ íŒŒíŠ¸ë„ˆë“¤ì˜ ì°¸ì—¬ê°€ ê³„ì† ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¢…í•©ì ìœ¼ë¡œ ë³¼ ë•Œ, BioInsightëŠ” ê³ ê°ë“¤ì´ ìƒë¬¼í•™ì  ì¸ì‚¬ì´íŠ¸ë¥¼ ìƒì„±í•˜ê³  í™œìš©í•˜ëŠ” ë°©ì‹ì„ í™•ì¥í•˜ë©°, ì—°êµ¬ ìµœì¢… ì‹œì¥ì—ì„œ ì„±ì¥í•˜ëŠ” ë¶€ë¬¸ì¸ ë°”ì´ì˜¤ì œì•½ ë¶„ì•¼ì—ì„œ Illuminaì˜ ì…ì§€ë¥¼ ê°•í™”í•©ë‹ˆë‹¤. ê³ ê°ë“¤ì´ ìš°ë¦¬ì˜ ì „ëµê³¼ í˜ì‹ ì´ ì–´ë–»ê²Œ ê²°í•©ë˜ëŠ”ì§€ í™•ì¸í•  ìˆ˜ ìˆëŠ” ë‹¤ìŒ ê¸°íšŒëŠ” ì´ë‹¬ ë§ AGBTì—ì„œ ìˆì„ ì˜ˆì •ì…ë‹ˆë‹¤. ì˜¬í•´ ê³¨ë“œ ìŠ¤í°ì„œë¡œì„œ, ìš°ë¦¬ëŠ” ê³ ê°ë“¤ê³¼ ì£¼ìš” ì˜¤í”¼ë‹ˆì–¸ ë¦¬ë”ë“¤ê³¼ í•¨ê»˜í•˜ë©°, ê·¸ë“¤ì€ ìš°ë¦¬ì˜ ìµœì‹  í”Œë«í¼ ê°œì„  ì‚¬í•­ê³¼ ìœ ì „ì²´ ë° ë©€í‹°ì˜¤ë¯¹ìŠ¤ ë¶„ì„ë²•ì´ ì‹¤ì œ ì—°êµ¬ ë° ì„ìƒ í™˜ê²½ì—ì„œ ì–´ë–»ê²Œ ì ìš©ë˜ê³  ìˆëŠ”ì§€ ê³µìœ í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>A key theme we will showcase is the value of our complete, end-to-end solutions for our customers. The conversations we are having with customers have shifted from cost per gigabase to the total cost of workflow, from sample preparation through analysis and interpretation where integrated workflows and data quality matter most. This approach continuing to innovate as the market evolves gives customers confidence in the long-term, durable value of our flagship sequencing instruments, while supporting them where the field is headed, including deeper adoption of genomic and multiomic approaches. Now, let's turn to our 2026 outlook.</td><td>ê³ ê°ì„ ìœ„í•œ ì™„ì „í•œ ì—”ë“œíˆ¬ì—”ë“œ ì†”ë£¨ì…˜ì˜ ê°€ì¹˜ë¥¼ ë³´ì—¬ë“œë¦¬ëŠ” ê²ƒì´ í•µì‹¬ ì£¼ì œê°€ ë  ê²ƒì…ë‹ˆë‹¤. ê³ ê°ë“¤ê³¼ì˜ ëŒ€í™”ëŠ” ê¸°ê°€ë² ì´ìŠ¤ë‹¹ ë¹„ìš©ì—ì„œ ì›Œí¬í”Œë¡œìš° ì „ì²´ ë¹„ìš©ìœ¼ë¡œ ì „í™˜ë˜ì—ˆìœ¼ë©°, ìƒ˜í”Œ ì¤€ë¹„ë¶€í„° ë¶„ì„ ë° í•´ì„ê¹Œì§€ í†µí•© ì›Œí¬í”Œë¡œìš°ì™€ ë°ì´í„° í’ˆì§ˆì´ ê°€ì¥ ì¤‘ìš”í•œ ìš”ì†Œì…ë‹ˆë‹¤. ì‹œì¥ ì§„í™”ì— ë§ì¶° ì§€ì†ì ìœ¼ë¡œ í˜ì‹ í•˜ëŠ” ì´ëŸ¬í•œ ì ‘ê·¼ ë°©ì‹ì€ ê³ ê°ë“¤ì—ê²Œ ë‹¹ì‚¬ì˜ ì£¼ë ¥ ì‹œí€€ì‹± ì¥ë¹„ì˜ ì¥ê¸°ì ì´ê³  ì§€ì† ê°€ëŠ¥í•œ ê°€ì¹˜ì— ëŒ€í•œ í™•ì‹ ì„ ì œê³µí•˜ëŠ” ë™ì‹œì—, ìœ ì „ì²´í•™ ë° ë©€í‹°ì˜¤ë¯¹ìŠ¤ ì ‘ê·¼ë²•ì˜ ì‹¬í™”ëœ ë„ì…ì„ í¬í•¨í•˜ì—¬ í•´ë‹¹ ë¶„ì•¼ê°€ ë‚˜ì•„ê°€ëŠ” ë°©í–¥ì„ ì§€ì›í•©ë‹ˆë‹¤. ì´ì œ 2026ë…„ ì „ë§ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Building on the momentum we saw in the second half of 2025, we expect organic revenue growth of 2% to 4% in 2026, excluding China, with overall demand similar to what we saw in the second half of 2025. Clinical consumables grew approximately 16% ex-China in the second half of the year, and we expect robust growth to continue into 2026. Our outlook assumes double-digit to mid-teens clinical growth in 2026. We expect no fundamental change in the academic end-markets in 2026, resulting in mid-to-high single-digit revenue declines in our research and applied consumables revenue.</td><td>2025ë…„ í•˜ë°˜ê¸°ì— ë‚˜íƒ€ë‚œ ëª¨ë©˜í…€ì„ ë°”íƒ•ìœ¼ë¡œ, ë‹¹ì‚¬ëŠ” 2026ë…„ ì¤‘êµ­ì„ ì œì™¸í•œ ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥ ì´ 2%ì—ì„œ 4%ì— ì´ë¥¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì „ë°˜ì ì¸ ìˆ˜ìš”ëŠ” 2025ë…„ í•˜ë°˜ê¸°ì™€ ìœ ì‚¬í•œ ìˆ˜ì¤€ì„ ë³´ì¼ ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ì„ìƒìš© ì†Œëª¨í’ˆì€ ì—°ì¤‘ í•˜ë°˜ê¸°ì— ì¤‘êµ­ì„ ì œì™¸í•˜ê³  ì•½ 16% ì„±ì¥í–ˆìœ¼ë©°, ì´ëŸ¬í•œ ê²¬ì¡°í•œ ì„±ì¥ì„¸ê°€ 2026ë…„ì—ë„ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë‹¹ì‚¬ì˜ ì „ë§ì€ 2026ë…„ ì„ìƒ ë¶€ë¬¸ì—ì„œ ë‘ ìë¦¿ìˆ˜ì—ì„œ 10%ëŒ€ ì¤‘ë°˜ì˜ ì„±ì¥ë¥ ì„ ê°€ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ í•™ìˆ  ìµœì¢… ì‹œì¥ì—ì„œëŠ” ê·¼ë³¸ì ì¸ ë³€í™”ê°€ ì—†ì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ì´ì— ë”°ë¼ ì—°êµ¬ ë° ì‘ìš© ì†Œëª¨í’ˆ ë§¤ì¶œì€ ì¤‘ê°„ì—ì„œ ë†’ì€ í•œ ìë¦¿ìˆ˜ ê°ì†Œë¥¼ ë³´ì¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>Instruments are expected to be roughly flat to slightly down, resulting in a total company revenue of $4.5 billion to $4.6 billion, representing reported growth of 4% to 6%. Operating margins are expected to be 23.3% to 23.5% in 2026, up approximately 130 basis points excluding the acquisition impact. EPS guidance is $5.05 to $5.20 including $0.18 of dilution from the SomaLogic acquisition. Excluding dilution, this represents year-over-year growth of 10%. Before turning it over to Ankur for more details on our Q4 results and 2026 guidance, I just want to say I am confident that our long-term strategy is working, reinforced by the progress we made in 2025 and where Illumina stands today.</td><td>ì¸ìŠ¤íŠ¸ë£¨ë¨¼íŠ¸ëŠ” ëŒ€ëµ ë³´í•©ì—ì„œ ì†Œí­ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ì´ì— ë”°ë¼ ì „ì‚¬ ë§¤ì¶œì€ 45ì–µ ë‹¬ëŸ¬ì—ì„œ 46ì–µ ë‹¬ëŸ¬ë¡œ ë³´ê³  ê¸°ì¤€ 4%ì—ì„œ 6% ì„±ì¥ì„ ë‚˜íƒ€ë‚¼ ê²ƒì…ë‹ˆë‹¤. 2026ë…„ ì˜ì—…ì´ìµë¥ ì€ 23.3%ì—ì„œ 23.5%ë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” ì¸ìˆ˜ ì˜í–¥ì„ ì œì™¸í•˜ë©´ ì•½ 130bp ìƒìŠ¹í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì£¼ë‹¹ìˆœì´ìµ(EPS) ê°€ì´ë˜ìŠ¤ëŠ” 5.05ë‹¬ëŸ¬ì—ì„œ 5.20ë‹¬ëŸ¬ì´ë©°, ì—¬ê¸°ì—ëŠ” SomaLogic ì¸ìˆ˜ë¡œ ì¸í•œ 0.18ë‹¬ëŸ¬ì˜ í¬ì„íš¨ê³¼ê°€ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. í¬ì„íš¨ê³¼ë¥¼ ì œì™¸í•˜ë©´ ì „ë…„ ëŒ€ë¹„ 10% ì„±ì¥ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. Ankurì—ê²Œ 4ë¶„ê¸° ì‹¤ì ê³¼ 2026ë…„ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•œ ìì„¸í•œ ë‚´ìš©ì„ ë„˜ê¸°ê¸° ì „ì—, ì €ëŠ” ìš°ë¦¬ì˜ ì¥ê¸° ì „ëµì´ íš¨ê³¼ë¥¼ ë°œíœ˜í•˜ê³  ìˆë‹¤ê³  í™•ì‹ í•˜ë©°, ì´ëŠ” 2025ë…„ì— ì´ë£¬ ì§„ì „ê³¼ í˜„ì¬ Illuminaê°€ ì„œ ìˆëŠ” ìœ„ì¹˜ë¡œ ì…ì¦ëœë‹¤ëŠ” ë§ì”€ì„ ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Over the past year, we have advanced the strategy we laid out in 2024 and delivered meaningful progress across the business, entering 2026 with very encouraging momentum. We proved resilience, and we are a stronger company today. And we remain on track toward achieving our long-term financial targets for 2027. I want to thank our employees for their commitment and performance this past year. I am very proud of the Illumina team for staying focused through a dynamic year and delivering for our customers and the patients they serve. With that, I'll turn it over to Ankur to walk through the financials details before we move to Q&A. Ankur Dhingra<br>Chief Financial Officer<br><br>Thank you, Jacob.</td><td>ì§€ë‚œ 1ë…„ ë™ì•ˆ ìš°ë¦¬ëŠ” 2024ë…„ì— ì œì‹œí•œ ì „ëµì„ ì§„ì „ì‹œì¼°ìœ¼ë©°, ì‚¬ì—… ì „ë°˜ì— ê±¸ì³ ì˜ë¯¸ ìˆëŠ” ì§„ì „ì„ ì´ë£¨ì–´ 2026ë…„ì„ ë§¤ìš° ê³ ë¬´ì ì¸ ëª¨ë©˜í…€ê³¼ í•¨ê»˜ ì‹œì‘í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” íšŒë³µíƒ„ë ¥ì„±ì„ ì…ì¦í–ˆìœ¼ë©°, ì˜¤ëŠ˜ë‚  ë”ìš± ê°•í•œ íšŒì‚¬ê°€ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  2027ë…„ ì¥ê¸° ì¬ë¬´ ëª©í‘œ ë‹¬ì„±ì„ í–¥í•´ ê³„íšëŒ€ë¡œ ë‚˜ì•„ê°€ê³  ìˆìŠµë‹ˆë‹¤. ì§€ë‚œ 1ë…„ê°„ í—Œì‹ ê³¼ ì„±ê³¼ë¥¼ ë³´ì—¬ì¤€ ì„ì§ì›ë“¤ì—ê²Œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì—­ë™ì ì¸ í•œ í•´ë¥¼ ë³´ë‚´ë©´ì„œë„ ì§‘ì¤‘ë ¥ì„ ìœ ì§€í•˜ê³  ê³ ê°ê³¼ ê·¸ë“¤ì´ ì„œë¹„ìŠ¤í•˜ëŠ” í™˜ìë“¤ì„ ìœ„í•´ ì„±ê³¼ë¥¼ ë‹¬ì„±í•œ ì¼ë£¨ë¯¸ë‚˜ íŒ€ì„ ë§¤ìš° ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ ì§ˆì˜ì‘ë‹µìœ¼ë¡œ ë„˜ì–´ê°€ê¸° ì „ì— ì¬ë¬´ ì„¸ë¶€ì‚¬í•­ì„ ì„¤ëª…ë“œë¦´ ìˆ˜ ìˆë„ë¡ Ankurì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Ankur Dhingra<br>ìµœê³ ì¬ë¬´ì±…ì„ì(CFO)<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Jacob.</td></tr>
<tr><td>And good afternoon, everyone. I will give you an overview of our fourth quarter financial results, provide more color on revenue, expenses, earnings, and updates on our balance sheet and capital deployment, and then discuss our outlook going forward. Before I get into the details of the financial performance, let me provide a high-level view of how the fourth quarter played out. During the fourth quarter, Illumina's revenue of $1.16 billion came in above our expectations, driven by strength in our clinical consumable's revenue, better than expected NovaSeq X placements, and outperformance in China, we also saw a small benefit from some year-end budget purchasing.</td><td>ì•ˆë…•í•˜ì„¸ìš”, ì—¬ëŸ¬ë¶„. 4ë¶„ê¸° ì¬ë¬´ ì‹¤ì ì— ëŒ€í•œ ê°œìš”ë¥¼ ë§ì”€ë“œë¦¬ê³ , ë§¤ì¶œ, ë¹„ìš©, ìˆ˜ìµì— ëŒ€í•´ ë³´ë‹¤ ìì„¸íˆ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë˜í•œ ëŒ€ì°¨ëŒ€ì¡°í‘œì™€ ìë³¸ ë°°ë¶„ì— ëŒ€í•œ ì—…ë°ì´íŠ¸ë¥¼ ì œê³µí•œ í›„, í–¥í›„ ì „ë§ì— ëŒ€í•´ ë…¼ì˜í•˜ê² ìŠµë‹ˆë‹¤. ì¬ë¬´ ì„±ê³¼ì˜ ì„¸ë¶€ ì‚¬í•­ì„ ì„¤ëª…í•˜ê¸° ì „ì—, 4ë¶„ê¸°ê°€ ì–´ë–»ê²Œ ì§„í–‰ë˜ì—ˆëŠ”ì§€ ì „ë°˜ì ì¸ ê´€ì ì—ì„œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ë™ì•ˆ Illuminaì˜ ë§¤ì¶œì€ 11ì–µ 6ì²œë§Œ ë‹¬ëŸ¬ë¡œ ìš°ë¦¬ì˜ ì˜ˆìƒì„ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì„ìƒ ì†Œëª¨í’ˆ ë§¤ì¶œì˜ ê°•ì„¸, ì˜ˆìƒë³´ë‹¤ ìš°ìˆ˜í•œ NovaSeq X ì„¤ì¹˜ ì‹¤ì , ê·¸ë¦¬ê³  ì¤‘êµ­ì—ì„œì˜ ì´ˆê³¼ ë‹¬ì„±ì— í˜ì…ì€ ê²ƒì´ë©°, ì—°ë§ ì˜ˆì‚° ì§‘í–‰ìœ¼ë¡œ ì¸í•œ ì†Œí­ì˜ ê¸ì •ì  íš¨ê³¼ë„ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The higher revenue resulted in margins and EPS both coming in ahead of our guidance, while also reflecting the benefits of the cost actions we took earlier in the year. Now let me provide you with the details. During the fourth quarter, Illumina's revenue of $1.16 billion was up 5% year-over-year on a reported basis and 4% on a constant currency basis. Greater China revenue of $55 million was ahead of expectations and represented a $25 million decline from Q4 of 2024 . Excluding Greater China, Illumina revenue was up 7% year-over-year. Sequencing consumables revenue of $755 million was up 8% year-over-year , and up 11% excluding China.</td><td>ì´ëŸ¬í•œ ë†’ì€ ë§¤ì¶œì€ ë§ˆì§„ê³¼ ì£¼ë‹¹ìˆœì´ìµ(EPS) ëª¨ë‘ ê°€ì´ë˜ìŠ¤ë¥¼ ìƒíšŒí•˜ëŠ” ê²°ê³¼ë¡œ ì´ì–´ì¡Œìœ¼ë©°, ì˜¬í•´ ì´ˆ ë‹¨í–‰í•œ ë¹„ìš© ì ˆê° ì¡°ì¹˜ì˜ íš¨ê³¼ë„ ë°˜ì˜ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ì œ ì„¸ë¶€ ë‚´ìš©ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ë™ì•ˆ ì¼ë£¨ë¯¸ë‚˜ì˜ ë§¤ì¶œì€ 11ì–µ 6ì²œë§Œ ë‹¬ëŸ¬ë¡œ ë³´ê³  ê¸°ì¤€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 5% ì¦ê°€í–ˆìœ¼ë©°, ê³ ì •í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œëŠ” 4% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì¤‘í™”ê¶Œ ë§¤ì¶œì€ 5,500ë§Œ ë‹¬ëŸ¬ë¡œ ì˜ˆìƒì„ ìƒíšŒí–ˆìœ¼ë©°, 2024ë…„ 4ë¶„ê¸° ëŒ€ë¹„ 2,500ë§Œ ë‹¬ëŸ¬ ê°ì†Œí•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì¤‘í™”ê¶Œì„ ì œì™¸í•œ ì¼ë£¨ë¯¸ë‚˜ ë§¤ì¶œì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 7% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì‹œí€€ì‹± ì†Œëª¨í’ˆ ë§¤ì¶œì€ 7ì–µ 5,500ë§Œ ë‹¬ëŸ¬ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 8% ì¦ê°€í–ˆìœ¼ë©°, ì¤‘êµ­ì„ ì œì™¸í•˜ë©´ 11% ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>High-throughput volume growth drove the strength in consumables, as customers across research and clinical ramped utilization of their NovaSeq X instruments. More broadly, the clinical market maintained its momentum, growing 20% outside of China, driven by broader adoption of NGS based testing and customers converting current assays to ones that require significantly more sequencing data, such as transitions from whole exome to whole genome sequencing in oncology and genetic disease.</td><td>ê³ ì²˜ë¦¬ëŸ‰ ë³¼ë¥¨ ì„±ì¥ì´ ì†Œëª¨í’ˆ ë¶€ë¬¸ì˜ ê°•ì„¸ë¥¼ ê²¬ì¸í–ˆìœ¼ë©°, ì´ëŠ” ì—°êµ¬ ë° ì„ìƒ ë¶„ì•¼ì˜ ê³ ê°ë“¤ì´ NovaSeq X ì¥ë¹„ì˜ í™œìš©ë„ë¥¼ ë†’ì˜€ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë³´ë‹¤ ê´‘ë²”ìœ„í•˜ê²ŒëŠ”, ì„ìƒ ì‹œì¥ì´ ì¤‘êµ­ ì™¸ ì§€ì—­ì—ì„œ 20% ì„±ì¥í•˜ë©° ëª¨ë©˜í…€ì„ ìœ ì§€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” NGS ê¸°ë°˜ ê²€ì‚¬ì˜ ê´‘ë²”ìœ„í•œ ì±„íƒê³¼ ê³ ê°ë“¤ì´ ê¸°ì¡´ ë¶„ì„ë²•ì„ í›¨ì”¬ ë” ë§ì€ ì‹œí€€ì‹± ë°ì´í„°ë¥¼ í•„ìš”ë¡œ í•˜ëŠ” ë¶„ì„ë²•ìœ¼ë¡œ ì „í™˜í•œ ë° ë”°ë¥¸ ê²ƒì…ë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´ ì¢…ì–‘í•™ ë° ìœ ì „ì§ˆí™˜ ë¶„ì•¼ì—ì„œ ì „ì²´ ì—‘ì†œ ì‹œí€€ì‹±ì—ì„œ ì „ì²´ ê²Œë†ˆ ì‹œí€€ì‹±ìœ¼ë¡œì˜ ì „í™˜ì´ ì´ë£¨ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Consumables sales in research and applied markets were roughly flat year-over-year in the quarter, a notable improvement versus Q3, but still below historical levels due to continued uncertainty in the funding environment and year-over-year pricing dynamics related to conversion to the X. As of Q4, roughly 80% of volumes and 55% of revenue has transitioned to the NovaSeq X. The research transition is nearing its end, as now roughly 90% of the high-throughput sequencing volumes for these customers have transitioned to X. As a result, we expect pricing headwinds from the transition to continue to dissipate for our research customers, especially in the second half of 2026.</td><td>ì—°êµ¬ ë° ì‘ìš© ì‹œì¥ì˜ ì†Œëª¨í’ˆ ë§¤ì¶œì€ 4ë¶„ê¸°ì— ì „ë…„ ë™ê¸° ëŒ€ë¹„ ê±°ì˜ ë³´í•©ì„ ìœ ì§€í–ˆìœ¼ë©°, ì´ëŠ” 3ë¶„ê¸° ëŒ€ë¹„ ëˆˆì— ë„ëŠ” ê°œì„ ì´ì§€ë§Œ, ì§€ì†ë˜ëŠ” í€ë”© í™˜ê²½ì˜ ë¶ˆí™•ì‹¤ì„±ê³¼ X ì‹œë¦¬ì¦ˆë¡œì˜ ì „í™˜ê³¼ ê´€ë ¨ëœ ì „ë…„ ëŒ€ë¹„ ê°€ê²© ì—­í•™ìœ¼ë¡œ ì¸í•´ ì—¬ì „íˆ ê³¼ê±° ìˆ˜ì¤€ì„ í•˜íšŒí•˜ê³  ìˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° ê¸°ì¤€ìœ¼ë¡œ ì•½ 80%ì˜ ë¬¼ëŸ‰ê³¼ 55%ì˜ ë§¤ì¶œì´ NovaSeq Xë¡œ ì „í™˜ë˜ì—ˆìŠµë‹ˆë‹¤. ì—°êµ¬ ë¶€ë¬¸ì˜ ì „í™˜ì€ ê±°ì˜ ë§ˆë¬´ë¦¬ ë‹¨ê³„ì— ìˆìœ¼ë©°, í˜„ì¬ ì´ë“¤ ê³ ê°ì˜ ê³ ì²˜ë¦¬ëŸ‰ ì‹œí€€ì‹± ë¬¼ëŸ‰ ì¤‘ ì•½ 90%ê°€ X ì‹œë¦¬ì¦ˆë¡œ ì „í™˜ë˜ì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì „í™˜ìœ¼ë¡œ ì¸í•œ ê°€ê²© ì—­í’ì€ ì—°êµ¬ ê³ ê°ë“¤ì—ê²Œ ê³„ì†í•´ì„œ ì™„í™”ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, íŠ¹íˆ 2026ë…„ í•˜ë°˜ê¸°ì— ê·¸ëŸ¬í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Clinical volume is now more than two-thirds converted to the X, and we believe pricing dynamics going forward will be tied more to new applications like whole-genome sequencing adoption, which drives higher volumes. Given these two dynamics, near-complete conversion within research, clinical volume growth driven by X, we expect the conversion to be substantially complete by the end of 2026. On sequencing activity, total sequencing Gb output on our connected high- and mid-throughput instruments grew at a rate of more than 30% year-over-year, driven by robust strength in clinical, but more muted growth among our research customers.</td><td>ì„ìƒ ë¶„ì•¼ ë¬¼ëŸ‰ì˜ 3ë¶„ì˜ 2 ì´ìƒì´ ì´ë¯¸ X ì‹œë¦¬ì¦ˆë¡œ ì „í™˜ë˜ì—ˆìœ¼ë©°, í–¥í›„ ê°€ê²© ê²°ì • ë™í–¥ì€ ì „ì¥ìœ ì „ì²´ ì‹œí€€ì‹±(whole-genome sequencing) ë„ì…ê³¼ ê°™ì€ ì‹ ê·œ ì• í”Œë¦¬ì¼€ì´ì…˜ê³¼ ë” ë°€ì ‘í•˜ê²Œ ì—°ê´€ë  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì´ëŠ” ë” ë†’ì€ ë¬¼ëŸ‰ì„ ê²¬ì¸í•˜ê²Œ ë©ë‹ˆë‹¤. ì´ëŸ¬í•œ ë‘ ê°€ì§€ ë™í–¥, ì¦‰ ì—°êµ¬ ë¶„ì•¼ ë‚´ ì „í™˜ì´ ê±°ì˜ ì™„ë£Œë˜ì—ˆê³  X ì‹œë¦¬ì¦ˆê°€ ì„ìƒ ë¶„ì•¼ ë¬¼ëŸ‰ ì„±ì¥ì„ ê²¬ì¸í•˜ê³  ìˆë‹¤ëŠ” ì ì„ ê³ ë ¤í•  ë•Œ, 2026ë…„ ë§ê¹Œì§€ ì „í™˜ì´ ì‹¤ì§ˆì ìœ¼ë¡œ ì™„ë£Œë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì‹œí€€ì‹± í™œë™ ì¸¡ë©´ì—ì„œ, ë‹¹ì‚¬ì˜ ì—°ê²°ëœ ê³ ì²˜ë¦¬ëŸ‰ ë° ì¤‘ì²˜ë¦¬ëŸ‰ ì¥ë¹„ì—ì„œì˜ ì´ ì‹œí€€ì‹± Gb ì‚°ì¶œëŸ‰ì€ ì „ë…„ ëŒ€ë¹„ 30% ì´ìƒì˜ ì„±ì¥ë¥ ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì„ìƒ ë¶„ì•¼ì˜ ê²¬ê³ í•œ ê°•ì„¸ì— í˜ì…ì€ ê²ƒì´ì§€ë§Œ, ì—°êµ¬ ê³ ê°ë“¤ ì‚¬ì´ì—ì„œëŠ” ë‹¤ì†Œ ì™„ë§Œí•œ ì„±ì¥ì„¸ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Sequencing instruments revenue of $154 million was approximately flat year-over-year in Q4, and up 3% ex-China, driven by strong placements of NovaSeq X and the MiSeq i100. Similar to our consumables mix, over 60% of X systems placed in Q4 were to clinical customers. In Greater China, our instruments business was down 55%, due to export restrictions. Globally, we placed over 100 NovaSeq X's, including about five on rental or lease contracts, bringing our total active installed base to 890 instruments. Sequencing service and other revenue of $157 million was up approximately 3% year-over-year, and up 4% ex-China.</td><td>ì‹œí€€ì‹± ì¥ë¹„ ë§¤ì¶œì€ 1ì–µ 5,400ë§Œ ë‹¬ëŸ¬ë¡œ 4ë¶„ê¸° ì „ë…„ ëŒ€ë¹„ ê±°ì˜ ë³´í•© ìˆ˜ì¤€ì´ì—ˆìœ¼ë©°, ì¤‘êµ­ì„ ì œì™¸í•˜ë©´ 3% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” NovaSeq Xì™€ MiSeq i100ì˜ ê°•ë ¥í•œ ì„¤ì¹˜ ì‹¤ì ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. ì†Œëª¨í’ˆ ë¯¹ìŠ¤ì™€ ìœ ì‚¬í•˜ê²Œ, 4ë¶„ê¸°ì— ì„¤ì¹˜ëœ X ì‹œìŠ¤í…œì˜ 60% ì´ìƒì´ ì„ìƒ ê³ ê°ì‚¬ë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. ì¤‘êµ­ ë³¸í† ì—ì„œëŠ” ìˆ˜ì¶œ ê·œì œë¡œ ì¸í•´ ì¥ë¹„ ì‚¬ì—…ì´ 55% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ì „ ì„¸ê³„ì ìœ¼ë¡œ ì•½ 5ëŒ€ì˜ ë Œíƒˆ ë˜ëŠ” ë¦¬ìŠ¤ ê³„ì•½ì„ í¬í•¨í•˜ì—¬ 100ëŒ€ ì´ìƒì˜ NovaSeq Xë¥¼ ì„¤ì¹˜í–ˆìœ¼ë©°, ì´ë¡œì¨ ì´ ê°€ë™ ì„¤ì¹˜ ê¸°ë°˜ì€ 890ëŒ€ì— ë‹¬í–ˆìŠµë‹ˆë‹¤. ì‹œí€€ì‹± ì„œë¹„ìŠ¤ ë° ê¸°íƒ€ ë§¤ì¶œì€ 1ì–µ 5,700ë§Œ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ ì•½ 3% ì¦ê°€í–ˆìœ¼ë©°, ì¤‘êµ­ì„ ì œì™¸í•˜ë©´ 4% ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Strategic partnerships and the timing of data deals have been lumpy in 2025, and we were pleased to see a return to growth in Q4. Moving to the rest of the P&L. Non-GAAP gross margin of 67% for the fourth quarter was down 40 bps year-over-year, primarily from the tariff impact of 205 basis points. Excluding tariffs, gross margins improved by 165 basis points. Sequentially, Q4 margins reflect the typical instruments heavy quarter in Q4. Non-GAAP operating expenses were $502 million, down 5% or $24 million year-over-year, reflecting the results of the multi-year cost reduction programs and prioritization of key growth investments.</td><td>ì „ëµì  íŒŒíŠ¸ë„ˆì‹­ê³¼ ë°ì´í„° ê±°ë˜ì˜ ì‹œê¸°ëŠ” 2025ë…„ì— ë“¤ì­‰ë‚ ì­‰í–ˆìœ¼ë©°, 4ë¶„ê¸°ì— ì„±ì¥ì„¸ë¡œ ë³µê·€í•œ ê²ƒì„ ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì†ìµê³„ì‚°ì„œì˜ ë‚˜ë¨¸ì§€ ë¶€ë¶„ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ë¹„-GAAP ë§¤ì¶œì´ì´ìµë¥ ì€ 67%ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 40bp ê°ì†Œí–ˆëŠ”ë°, ì´ëŠ” ì£¼ë¡œ ê´€ì„¸ ì˜í–¥ 205bpì— ê¸°ì¸í•©ë‹ˆë‹¤. ê´€ì„¸ë¥¼ ì œì™¸í•˜ë©´ ë§¤ì¶œì´ì´ìµë¥ ì€ 165bp ê°œì„ ë˜ì—ˆìŠµë‹ˆë‹¤. ì „ë¶„ê¸° ëŒ€ë¹„ë¡œ ë³´ë©´, 4ë¶„ê¸° ë§ˆì§„ì€ 4ë¶„ê¸°ì˜ ì „í˜•ì ì¸ ì¥ë¹„ ë¹„ì¤‘ì´ ë†’ì€ ë¶„ê¸°ë¥¼ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¹„-GAAP ì˜ì—…ë¹„ìš©ì€ 5ì–µ 200ë§Œ ë‹¬ëŸ¬ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 5% ë˜ëŠ” 2,400ë§Œ ë‹¬ëŸ¬ ê°ì†Œí–ˆìœ¼ë©°, ì´ëŠ” ë‹¤ë…„ê°„ì˜ ë¹„ìš© ì ˆê° í”„ë¡œê·¸ë¨ê³¼ í•µì‹¬ ì„±ì¥ íˆ¬ìì˜ ìš°ì„ ìˆœìœ„í™” ê²°ê³¼ë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Non-GAAP operating margin was 23.7% in Q4, expanding 400 basis points year-over-year. Operating profit grew approximately 26% year-over-year, reflecting increased operating leverage from the improved cost structure. Looking at our results below the line, non-GAAP other expense, which is largely comprised of net interest expense, was $16 million, and the non-GAAP tax rate was 19.5%. We continue to assess longer-term tax structure optimization to balance U.S. R&D benefits with efficient credit utilization across jurisdictions. Our average diluted shares were approximately 154 million, 6 million lower than Q4 of '24 reflecting share repurchases throughout the year.</td><td>4ë¶„ê¸° ë¹„-GAAP ì˜ì—…ì´ìµë¥ ì€ 23.7%ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 400bp(ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸) í™•ëŒ€ë˜ì—ˆìŠµë‹ˆë‹¤. ì˜ì—…ì´ìµì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ì•½ 26% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ê°œì„ ëœ ë¹„ìš© êµ¬ì¡°ë¡œ ì¸í•œ ì˜ì—… ë ˆë²„ë¦¬ì§€ ì¦ê°€ë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì˜ì—…ì™¸ í•­ëª©ì„ ì‚´í´ë³´ë©´, ì£¼ë¡œ ìˆœì´ìë¹„ìš©ìœ¼ë¡œ êµ¬ì„±ëœ ë¹„-GAAP ì˜ì—…ì™¸ë¹„ìš©ì€ 1,600ë§Œ ë‹¬ëŸ¬ì˜€ìœ¼ë©°, ë¹„-GAAP ì„¸ìœ¨ì€ 19.5%ì˜€ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ë¯¸êµ­ R&D ì„¸ì œ í˜œíƒê³¼ ê° ê´€í• ê¶Œì—­ì˜ íš¨ìœ¨ì ì¸ ì„¸ì•¡ê³µì œ í™œìš© ê°„ì˜ ê· í˜•ì„ ë§ì¶”ê¸° ìœ„í•´ ì¥ê¸°ì ì¸ ì„¸ë¬´ êµ¬ì¡° ìµœì í™”ë¥¼ ì§€ì†ì ìœ¼ë¡œ ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤. í‰ê·  í¬ì„ì£¼ì‹ìˆ˜ëŠ” ì•½ 1ì–µ 5,400ë§Œ ì£¼ë¡œ, ì—°ì¤‘ ìì‚¬ì£¼ ë§¤ì…ì„ ë°˜ì˜í•˜ì—¬ 2024ë…„ 4ë¶„ê¸° ëŒ€ë¹„ 600ë§Œ ì£¼ ê°ì†Œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Altogether, non-GAAP EPS of $1.35 per diluted share grew approximately 42% year-over-year and came in above our guidance range and was higher than our initial estimate disclosed in January. Moving to cash flow, balance sheet, and capital allocation items for the quarter. Cash flow provided by operations was $321 million for the quarter and $1.1 billion for the year. Capital expenditures were $54 million and free cash flow was $267 million for Q4. For the year, CapEx was $148 million and free cash flow was $931 million. In Q4, we repurchased 337,000 shares of Illumina stock for approximately $42 million at an average price of $124.12 per share.</td><td>ì „ì²´ì ìœ¼ë¡œ ë¹„-GAAP ì£¼ë‹¹ìˆœì´ìµ(EPS)ì€ í¬ì„ì£¼ì‹ ê¸°ì¤€ $1.35ë¡œ ì „ë…„ ëŒ€ë¹„ ì•½ 42% ì„±ì¥í–ˆìœ¼ë©°, ë‹¹ì‚¬ì˜ ê°€ì´ë˜ìŠ¤ ë²”ìœ„ë¥¼ ìƒíšŒí–ˆê³  1ì›”ì— ê³µì‹œí•œ ì´ˆê¸° ì¶”ì •ì¹˜ë³´ë‹¤ë„ ë†’ì•˜ìŠµë‹ˆë‹¤. ë¶„ê¸° í˜„ê¸ˆíë¦„, ì¬ë¬´ìƒíƒœí‘œ ë° ìë³¸ë°°ë¶„ í•­ëª©ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì˜ì—…í™œë™ í˜„ê¸ˆíë¦„ì€ ë¶„ê¸° ê¸°ì¤€ $3ì–µ 2,100ë§Œì´ì—ˆê³  ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œëŠ” $11ì–µì´ì—ˆìŠµë‹ˆë‹¤. ìë³¸ì ì§€ì¶œ(CapEx)ì€ $5,400ë§Œì´ì—ˆìœ¼ë©° 4ë¶„ê¸° ì‰ì—¬í˜„ê¸ˆíë¦„(FCF)ì€ $2ì–µ 6,700ë§Œì´ì—ˆìŠµë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ìë³¸ì ì§€ì¶œì€ $1ì–µ 4,800ë§Œì´ì—ˆê³  ì‰ì—¬í˜„ê¸ˆíë¦„ì€ $9ì–µ 3,100ë§Œì´ì—ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì— ë‹¹ì‚¬ëŠ” ì¼ë£¨ë¯¸ë‚˜ ì£¼ì‹ 337,000ì£¼ë¥¼ í‰ê·  ì£¼ë‹¹ $124.12ì˜ ê°€ê²©ìœ¼ë¡œ ì•½ $4,200ë§Œì— ìì‚¬ì£¼ ë§¤ì…í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>At quarter end we had $643 million remaining on our share repurchase authorization, and we intend to continue to repurchase shares opportunistically. Subsequent to the end of Q4, we closed the acquisition of SomaLogic on January 30th for an upfront payment of $350 million, plus potential royalties and milestone payments, subject to customary adjustments. We funded the upfront payment with cash on hand. We ended the quarter with approximately $1.63 billion in cash, cash equivalents and short-term investments, and gross leverage of approximately 1.6x gross debt to last twelve months EBITDA. So recapping the full year 2025, starting with revenue.</td><td>ë¶„ê¸° ë§ ê¸°ì¤€ìœ¼ë¡œ ìì‚¬ì£¼ ë§¤ì… ìŠ¹ì¸ ì”ì•¡ì€ 6ì–µ 4,300ë§Œ ë‹¬ëŸ¬ì´ë©°, ì•ìœ¼ë¡œë„ ê¸°íšŒê°€ ìˆì„ ë•Œë§ˆë‹¤ ê³„ì†í•´ì„œ ìì‚¬ì£¼ë¥¼ ë§¤ì…í•  ê³„íšì…ë‹ˆë‹¤. 4ë¶„ê¸° ì¢…ë£Œ í›„, 1ì›” 30ì¼ì— SomaLogic ì¸ìˆ˜ë¥¼ ì™„ë£Œí–ˆìœ¼ë©°, ì„ ê¸‰ê¸ˆ 3ì–µ 5,000ë§Œ ë‹¬ëŸ¬ì™€ í•¨ê»˜ ì¼ë°˜ì ì¸ ì¡°ì •ì‚¬í•­ì„ ì „ì œë¡œ í•œ ì ì¬ì  ë¡œì—´í‹° ë° ë§ˆì¼ìŠ¤í†¤ ì§€ê¸‰ê¸ˆì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì„ ê¸‰ê¸ˆì€ ë³´ìœ  í˜„ê¸ˆìœ¼ë¡œ ì¶©ë‹¹í–ˆìŠµë‹ˆë‹¤. ë¶„ê¸° ë§ í˜„ê¸ˆ, í˜„ê¸ˆì„±ìì‚° ë° ë‹¨ê¸°íˆ¬ì ìì‚°ì€ ì•½ 16ì–µ 3,000ë§Œ ë‹¬ëŸ¬ì˜€ìœ¼ë©°, ì´ì°¨ì…ê¸ˆ ëŒ€ë¹„ ì§€ë‚œ 12ê°œì›” EBITDA ê¸°ì¤€ ì´ë ˆë²„ë¦¬ì§€ëŠ” ì•½ 1.6ë°°ì…ë‹ˆë‹¤. ê·¸ëŸ¼ 2025 íšŒê³„ì—°ë„ ì „ì²´ë¥¼ ë§¤ì¶œë¶€í„° ìš”ì•½í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We returned to growth ex-China in Q3 and grew sales about 4% in the second half of the year. I'm extremely proud of the whole Illumina team for navigating through a very dynamic year to end the year on a high note. Through disciplined execution and cost optimization, we were able to expand margins nearly 200 basis points in 2025 despite approximately 200 basis points in macro-related headwinds. And finally, we grew EPS by 16%, and our 2025 EPS of $4.84 came in above the original guidance we gave at the start the year. The way we closed out 2025 gives me confidence about the progress we are making towards our long-range targets, and I am excited about our momentum going into 2026.</td><td>ì¤‘êµ­ì„ ì œì™¸í•˜ê³  3ë¶„ê¸°ì— ì„±ì¥ì„¸ë¡œ ëŒì•„ì„°ìœ¼ë©°, í•˜ë°˜ê¸°ì— ì•½ 4%ì˜ ë§¤ì¶œ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë§¤ìš° ì—­ë™ì ì¸ í•œ í•´ë¥¼ í—¤ì³ë‚˜ê°€ ì—°ë§ì„ ì¢‹ì€ ì„±ê³¼ë¡œ ë§ˆë¬´ë¦¬í•œ ì¼ë£¨ë¯¸ë‚˜ ì „ íŒ€ì›ë“¤ì´ ëŒ€ë‹¨íˆ ìë‘ìŠ¤ëŸ½ìŠµë‹ˆë‹¤. ê·œìœ¨ ìˆëŠ” ì‹¤í–‰ê³¼ ë¹„ìš© ìµœì í™”ë¥¼ í†µí•´ ì•½ 200bpì˜ ê±°ì‹œê²½ì œ ê´€ë ¨ ì—­í’ì—ë„ ë¶ˆêµ¬í•˜ê³  2025ë…„ ë§ˆì§„ì„ ê±°ì˜ 200bp í™•ëŒ€í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, EPSë¥¼ 16% ì„±ì¥ì‹œì¼°ìœ¼ë©°, 2025ë…„ EPS $4.84ëŠ” ì—°ì´ˆì— ì œì‹œí•œ ìµœì´ˆ ê°€ì´ë˜ìŠ¤ë¥¼ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. 2025ë…„ì„ ë§ˆë¬´ë¦¬í•œ ë°©ì‹ì€ ì¥ê¸° ëª©í‘œë¥¼ í–¥í•œ ìš°ë¦¬ì˜ ì§„ì „ì— ëŒ€í•´ í™•ì‹ ì„ ì£¼ë©°, 2026ë…„ìœ¼ë¡œ ì´ì–´ì§€ëŠ” ëª¨ë©˜í…€ì— ëŒ€í•´ ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤.</td></tr>
<tr><td>Now moving to guidance for the year 2026. Starting with revenue. We are expecting revenue of $4.5 billion to $4.6 billion dollars, representing ex-China Organic growth of 2% to 4%. Organic growth excludes the impacts of currency, which is expected to add roughly 1 point to our reported growth; and revenue associated with the SomaLogic acquisition, which is expected to add 1.5 to 2 points of revenue growth in 2026. China sales are expected to be a 1-point headwind to total company revenue growth. On a reported basis, overall revenue is expected to be up 4% to 6%.</td><td>ì´ì œ 2026ë…„ ê°€ì´ë˜ìŠ¤ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë¨¼ì € ë§¤ì¶œë¶€í„° ë§ì”€ë“œë¦¬ë©´, 45ì–µ ë‹¬ëŸ¬ì—ì„œ 46ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì¤‘êµ­ì„ ì œì™¸í•œ ìœ ê¸°ì  ì„±ì¥ë¥ (ex-China Organic growth) ê¸°ì¤€ 2%ì—ì„œ 4%ì— í•´ë‹¹í•©ë‹ˆë‹¤. ìœ ê¸°ì  ì„±ì¥ë¥ ì€ í™˜ìœ¨ ì˜í–¥ì„ ì œì™¸í•œ ìˆ˜ì¹˜ì´ë©°, í™˜ìœ¨ì€ ë³´ê³  ì„±ì¥ë¥ ì— ì•½ 1%í¬ì¸íŠ¸ë¥¼ ì¶”ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë˜í•œ ì†Œë§ˆë¡œì§(SomaLogic) ì¸ìˆ˜ì™€ ê´€ë ¨ëœ ë§¤ì¶œì€ 2026ë…„ì— 1.5%í¬ì¸íŠ¸ì—ì„œ 2%í¬ì¸íŠ¸ì˜ ë§¤ì¶œ ì„±ì¥ì„ ì¶”ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì¤‘êµ­ ë§¤ì¶œì€ ì „ì‚¬ ë§¤ì¶œ ì„±ì¥ë¥ ì— 1%í¬ì¸íŠ¸ì˜ ì—­í’(headwind)ì´ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë³´ê³  ê¸°ì¤€(reported basis)ìœ¼ë¡œëŠ” ì „ì²´ ë§¤ì¶œì´ 4%ì—ì„œ 6% ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>For rest-of-world organic sequencing revenue growth, we are expecting low-to-mid single-digit growth in consumables with clinical growing double-digit to mid-teens driven by continued strong volumes from our clinical customers. We are excited about the significant progress our customers are making with growth in their on-market tests and new sequencing-intensive whole-genome approaches. We expect research declining mid-to-high single-digit. Recent NIH budget announcements are a welcome development, and as fund flow resumes could provide a more favorable environment relative to what we are assuming in guidance.</td><td>ê¸°íƒ€ ì§€ì—­ì˜ ìœ ê¸°ì  ì‹œí€€ì‹± ë§¤ì¶œ ì„±ì¥ê³¼ ê´€ë ¨í•˜ì—¬, ì†Œëª¨í’ˆ ë¶€ë¬¸ì—ì„œëŠ” ë‚®ì€ í•œ ìë¦¿ìˆ˜ì—ì„œ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì„ìƒ ë¶€ë¬¸ì€ ì„ìƒ ê³ ê°ë“¤ì˜ ì§€ì†ì ìœ¼ë¡œ ê°•ë ¥í•œ ë¬¼ëŸ‰ì— í˜ì…ì–´ ë‘ ìë¦¿ìˆ˜ì—ì„œ 10%ëŒ€ ì¤‘ë°˜ì˜ ì„±ì¥ì„ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê³ ê°ë“¤ì´ ì‹œíŒ ì¤‘ì¸ ê²€ì‚¬ì˜ ì„±ì¥ê³¼ ìƒˆë¡œìš´ ì‹œí€€ì‹± ì§‘ì•½ì  ì „ì¥ìœ ì „ì²´ ì ‘ê·¼ë²•ì—ì„œ ì´ë£¨ê³  ìˆëŠ” ìƒë‹¹í•œ ì§„ì „ì— ëŒ€í•´ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—°êµ¬ ë¶€ë¬¸ì€ ì¤‘ê°„ì—ì„œ ë†’ì€ í•œ ìë¦¿ìˆ˜ ê°ì†Œë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ìµœê·¼ NIH ì˜ˆì‚° ë°œí‘œëŠ” í™˜ì˜í•  ë§Œí•œ ì§„ì „ì´ë©°, ìê¸ˆ íë¦„ì´ ì¬ê°œë˜ë©´ ê°€ì´ë˜ìŠ¤ì—ì„œ ê°€ì •í•˜ê³  ìˆëŠ” ê²ƒë³´ë‹¤ ë” ìš°í˜¸ì ì¸ í™˜ê²½ì„ ì œê³µí•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Instrument sales are expected to be down low-single-digit to flat year-over-year, and we believe our goal of placing 50 to 60 NovaSeq X instruments per quarter, on average, will continue through 2026. Our pull-through assumptions by platform can be found in our earnings presentation. In China, we expect sales of $210 million to $220 million with little or no step up in instrument sales in the first half of the year. We will revisit our assumptions as we work with the government about our ability to import instruments into the country. Moving to operating margins excluding SomaLogic, we are guiding for operating margins to expand 130 basis points next year at the midpoint.</td><td>ê¸°ê¸° ë§¤ì¶œì€ ì „ë…„ ëŒ€ë¹„ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ê°ì†Œì—ì„œ ë³´í•© ìˆ˜ì¤€ì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ë¶„ê¸°ë‹¹ í‰ê·  50~60ëŒ€ì˜ NovaSeq X ê¸°ê¸°ë¥¼ ì„¤ì¹˜í•œë‹¤ëŠ” ëª©í‘œëŠ” 2026ë…„ê¹Œì§€ ì§€ì†ë  ê²ƒìœ¼ë¡œ íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. í”Œë«í¼ë³„ í’€ìŠ¤ë£¨(pull-through) ê°€ì •ì¹˜ëŠ” ì‹¤ì  ë°œí‘œ ìë£Œì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì¤‘êµ­ì˜ ê²½ìš°, ìƒë°˜ê¸° ê¸°ê¸° ë§¤ì¶œ ì¦ê°€ê°€ ê±°ì˜ ì—†ê±°ë‚˜ ì „í˜€ ì—†ëŠ” ìƒí™©ì—ì„œ 2ì–µ 1ì²œë§Œ ë‹¬ëŸ¬ì—ì„œ 2ì–µ 2ì²œë§Œ ë‹¬ëŸ¬ì˜ ë§¤ì¶œì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¤‘êµ­ ë‚´ ê¸°ê¸° ìˆ˜ì… ê°€ëŠ¥ì„±ì— ëŒ€í•´ ì •ë¶€ì™€ í˜‘ì˜í•˜ë©´ì„œ ê°€ì •ì¹˜ë¥¼ ì¬ê²€í† í•  ì˜ˆì •ì…ë‹ˆë‹¤. SomaLogicì„ ì œì™¸í•œ ì˜ì—…ì´ìµë¥ ì˜ ê²½ìš°, ë‚´ë…„ ì¤‘ê°„ê°’ ê¸°ì¤€ìœ¼ë¡œ 130bp(ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸) í™•ëŒ€ë¥¼ ê°€ì´ë˜ìŠ¤ë¡œ ì œì‹œí•©ë‹ˆë‹¤.</td></tr>
<tr><td>SomaLogic is expected to have a 100-basis points impact to margins. All in for 2026, expecting operating margins of between 23.3% and 23.5%. We have made significant progress in improving Illumina operating margins and remained focused on achieving our 2027 targets. Now moving to EPS. Excluding SomaLogic, we are projecting EPS to grow 10% at the mid-point. SomaLogic is expected to be dilutive by $0.18 at mid-point. Hence, total Illumina 2026 EPS guidance is in the range of $5.05 to $5.20. For Q1'26, we are expecting rest-of-world organic revenue growth of 1% to 3%, equating to between $1.06 billion and $1.08 billion.</td><td>SomaLogicì€ ë§ˆì§„ì— 100ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸ì˜ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. 2026ë…„ ì „ì²´ì ìœ¼ë¡œ ì˜ì—…ì´ìµë¥ ì€ 23.3%ì—ì„œ 23.5% ì‚¬ì´ê°€ ë  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” Illuminaì˜ ì˜ì—…ì´ìµë¥  ê°œì„ ì— ìƒë‹¹í•œ ì§„ì „ì„ ì´ë£¨ì—ˆìœ¼ë©°, 2027ë…„ ëª©í‘œ ë‹¬ì„±ì— ê³„ì† ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ì£¼ë‹¹ìˆœì´ìµ(EPS)ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. SomaLogicì„ ì œì™¸í•˜ë©´, ì¤‘ê°„ê°’ ê¸°ì¤€ìœ¼ë¡œ EPSê°€ 10% ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. SomaLogicì€ ì¤‘ê°„ê°’ ê¸°ì¤€ìœ¼ë¡œ $0.18ì˜ í¬ì„ íš¨ê³¼ê°€ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë”°ë¼ì„œ 2026ë…„ ì „ì²´ Illumina EPS ê°€ì´ë˜ìŠ¤ëŠ” $5.05ì—ì„œ $5.20 ë²”ìœ„ì…ë‹ˆë‹¤. 2026ë…„ 1ë¶„ê¸°ì˜ ê²½ìš°, ê¸°íƒ€ ì§€ì—­(rest-of-world) ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥ ì€ 1%ì—ì„œ 3%ë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” $10.6ì–µì—ì„œ $10.8ì–µ ì‚¬ì´ì— í•´ë‹¹í•©ë‹ˆë‹¤.</td></tr>
<tr><td>We are expecting Q1 EPS of $1.02 to $1.07 including $0.04 of deal dilution. The rest of the details of our Q1 and 2026 guidance can be found in our earnings presentation. One housekeeping item, starting in January 2026 we changed the geographical reporting segments to better align with the respective commercial organizational structure. Beginning in Q1, we will report our new geographic segments and will provide historical financial reconciliation for the new structure. In closing, I want to once again express my sincere appreciation to the Illumina team for their continued focus and disciplined execution throughout the quarter.</td><td>1ë¶„ê¸° ì£¼ë‹¹ìˆœì´ìµ(EPS)ì€ ê±°ë˜ í¬ì„íš¨ê³¼ $0.04ë¥¼ í¬í•¨í•˜ì—¬ $1.02ì—ì„œ $1.07 ì‚¬ì´ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. 1ë¶„ê¸° ë° 2026ë…„ ê°€ì´ë˜ìŠ¤ì˜ ë‚˜ë¨¸ì§€ ì„¸ë¶€ì‚¬í•­ì€ ì‹¤ì  ë°œí‘œ ìë£Œì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•œ ê°€ì§€ ì•ˆë‚´ ë§ì”€ ë“œë¦¬ìë©´, 2026ë…„ 1ì›”ë¶€í„° ê° ìƒì—… ì¡°ì§ êµ¬ì¡°ì— ë” ì˜ ë¶€í•©í•˜ë„ë¡ ì§€ì—­ë³„ ë³´ê³  ë¶€ë¬¸ì„ ë³€ê²½í–ˆìŠµë‹ˆë‹¤. 1ë¶„ê¸°ë¶€í„° ìƒˆë¡œìš´ ì§€ì—­ë³„ ë¶€ë¬¸ì„ ë³´ê³ í•  ì˜ˆì •ì´ë©°, ìƒˆë¡œìš´ êµ¬ì¡°ì— ëŒ€í•œ ê³¼ê±° ì¬ë¬´ ì¡°ì • ìë£Œë¥¼ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. ë§ˆë¬´ë¦¬í•˜ë©´ì„œ, ë¶„ê¸° ë‚´ë‚´ ì§€ì†ì ì¸ ì§‘ì¤‘ê³¼ ê·œìœ¨ ìˆëŠ” ì‹¤í–‰ì„ ë³´ì—¬ì¤€ ì¼ë£¨ë¯¸ë‚˜ íŒ€ì—ê²Œ ë‹¤ì‹œ í•œë²ˆ ì§„ì‹¬ ì–´ë¦° ê°ì‚¬ë¥¼ í‘œí•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We entered 2026 with a lot of momentum, and I'm extremely encouraged by the progress we've made in returning Illumina to long-term sustainable revenue and earnings growth. Thank you for joining our call today. I will now invite the Operator to open the line for Q&A.</td><td>ì €í¬ëŠ” ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ê°€ì§€ê³  2026ë…„ì„ ì‹œì‘í–ˆìœ¼ë©°, ì¼ë£¨ë¯¸ë‚˜ë¥¼ ì¥ê¸°ì ì´ê³  ì§€ì† ê°€ëŠ¥í•œ ë§¤ì¶œ ë° ìˆ˜ìµ ì„±ì¥ ê¶¤ë„ë¡œ ë³µê·€ì‹œí‚¤ëŠ” ë° ìˆì–´ ì´ë£¬ ì§„ì „ì— ëŒ€í•´ ë§¤ìš° ê³ ë¬´ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì˜¤í¼ë ˆì´í„°ë¥¼ í†µí•´ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Illumina Q4 2025 ì‹¤ì  ë°œí‘œ ìš”ì•½<br><br>## í•µì‹¬ ì¬ë¬´ ì„±ê³¼<br>- **Q4 ë§¤ì¶œ $1.16B**, ì „ë…„ ëŒ€ë¹„ 5% ì¦ê°€ (ì¤‘êµ­ ì œì™¸ ì‹œ 7% ì„±ì¥)<br>- **ì„ìƒ ì†Œëª¨í’ˆ ë§¤ì¶œ ì¤‘êµ­ ì œì™¸ 20% ì„±ì¥**ìœ¼ë¡œ ê°€ì†í™”, 2025ë…„ í•˜ë°˜ê¸° 16% ì„±ì¥ ë‹¬ì„±<br>- **ë¹„GAAP ì˜ì—…ì´ìµë¥  23.7%** (ì „ë…„ ëŒ€ë¹„ 400bp í™•ëŒ€), EPS $1.35 (42% ì¦ê°€)<br>- **2026ë…„ ê°€ì´ë˜ìŠ¤**: ë§¤ì¶œ $4.5-4.6B (ì¤‘êµ­ ì œì™¸ ìœ ê¸°ì  ì„±ì¥ 2-4%), EPS $5.05-5.20 (SomaLogic í¬ì„ íš¨ê³¼ $0.18 í¬í•¨)<br><br>## ì „ëµì  ì„±ê³¼ ë° ê²½ì˜ì§„ í†¤<br>- **NovaSeq X ì „í™˜ ìˆœì¡°**: ì—°êµ¬ ë¶€ë¬¸ 90%, ì„ìƒ ë¶€ë¬¸ 67% ì „í™˜ ì™„ë£Œ, 2026ë…„ ë§ ì‹¤ì§ˆì  ì™„ë£Œ ì˜ˆìƒ<br>- **SomaLogic ì¸ìˆ˜ ì™„ë£Œ** ($350M)ë¡œ í”„ë¡œí…Œì˜¤ë¯¹ìŠ¤ ì—­ëŸ‰ ê°•í™”, ë©€í‹°ì˜¤ë¯¹ìŠ¤ ì „ëµ ê°€ì†í™”<br>- **BioInsight í”Œë«í¼ ì¶œì‹œ**: AstraZeneca, Merck, Eli Lillyì™€ í˜‘ë ¥ìœ¼ë¡œ AI ê¸°ë°˜ ì‹ ì•½ ê°œë°œ ì‹œì¥ ì§„ì¶œ<br>- ê²½ì˜ì§„ì€ 2025ë…„ ì„±ê³¼ì— ìì‹ ê°ì„ í‘œëª…í•˜ë©° **2027ë…„ ì¥ê¸° ëª©í‘œ ë‹¬ì„± ê¶¤ë„ ìœ ì§€** ê°•ì¡°<br><br>## ì£¼ìš” ë¦¬ìŠ¤í¬ ë° ê¸°íšŒ<br>- **ì—°êµ¬ ì‹œì¥ ë¶ˆí™•ì‹¤ì„±</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] Our first question will come from Doug Schenkel with Wolfe Research.</td><td>**Operator:** [êµí™˜ì› ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ Wolfe Researchì˜ Doug Schenkelë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Wolfe Research, LLC: I'm just going to ask a couple of financial questions, and then I'll get back in the queue. So first, on operating margin, does guidance embed an assumption that you essentially end the year at 26% to 27% operating margin? And building off of that, is there any change to your 2027 margin target factoring in SomaLogic? And then the second topic is really on capital deployment. The balance sheet is really clean at this point. You're generating about $1 billion of free cash flow. Clearly, the business has stabilized. How are you thinking about capital deployment? And specifically, what is your M&A criteria and priorities?</td><td>**Wolfe Research, LLC:** ì˜ì—…ì´ìµë¥ ì— ëŒ€í•´ ë¨¼ì € ë§ì”€ë“œë¦¬ë©´, ê°€ì´ë˜ìŠ¤ì—ëŠ” ì—°ë§ ê¸°ì¤€ìœ¼ë¡œ 26~27% ì˜ì—…ì´ìµë¥ ì„ ë‹¬ì„±í•œë‹¤ëŠ” ê°€ì •ì´ ë°˜ì˜ë˜ì–´ ìˆëŠ”ì§€ ê¶ê¸ˆí•˜ì‹œë‹¤ëŠ” ê±°ì£ ? ê·¸ë¦¬ê³  ì´ì™€ ê´€ë ¨í•´ì„œ, SomaLogicì„ ê³ ë ¤í–ˆì„ ë•Œ 2027ë…„ ë§ˆì§„ ëª©í‘œì¹˜ì— ë³€ê²½ì‚¬í•­ì´ ìˆëŠ”ì§€ë„ ì—¬ì­¤ë³´ì‹œëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤.<br><br>ë‘ ë²ˆì§¸ ì§ˆë¬¸ì€ ìë³¸ ë°°ë¶„ì— ê´€í•œ ê²ƒì¸ë°ìš”. í˜„ì¬ ëŒ€ì°¨ëŒ€ì¡°í‘œê°€ ìƒë‹¹íˆ ê±´ì „í•œ ìƒíƒœì´ê³ , ì•½ 10ì–µ ë‹¬ëŸ¬ì˜ ì‰ì—¬í˜„ê¸ˆíë¦„(free cash flow)ì„ ì°½ì¶œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‚¬ì—…ë„ ëª…ë°±íˆ ì•ˆì •í™”ë˜ì—ˆê³ ìš”. ì´ëŸ° ìƒí™©ì—ì„œ ìë³¸ ë°°ë¶„ì„ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ì§€, íŠ¹íˆ M&A ê¸°ì¤€ê³¼ ìš°ì„ ìˆœìœ„ëŠ” ë¬´ì—‡ì¸ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Jacob Thaysen: CEO, Interim Chief Commercial Officer & Director Thanks, Doug. And let me start by addressing your first question, which I believe it's around our long-term targets. And we feel definitely still great about those targets. Just as a step back in '24, we were out there presenting that we would bring the business back to high single-digit growth by '27 and also delivering 500 basis points that should bring us to 26% operating margin. We feel really good about what we have done the last year. We have stepped ourselves into growth, and we believe we are in the right direction to deliver on the high single-digit growth in '27 in our core business. We also are seeing that we have moved substantially on our operating margins with 200 basis points last year in really a tough environment where we had approximately 200 basis points headwinds from tariffs and other things. And now we are committing to another 130 basis points. So we are well on that trajectory. Obviously, now with the acquisition of SomaLogic, it will be, as we have mentioned also, it is dilutive as a starting point. We are working through the opportunities for synergies, and we will get as close to the 26% operating margin as possible in '27 also. But more, we will keep you updated on the way. We are doing everything we can.</td><td>**Jacob Thaysen:** ê°ì‚¬í•©ë‹ˆë‹¤, Doug. ì²« ë²ˆì§¸ ì§ˆë¬¸ì¸ ì¥ê¸° ëª©í‘œì— ëŒ€í•´ ë¨¼ì € ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì´ ëª©í‘œë“¤ì— ëŒ€í•´ ì—¬ì „íˆ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. 24ë…„ì„ ëŒì´ì¼œë³´ë©´, ë‹¹ì‹œ ì €í¬ëŠ” 27ë…„ê¹Œì§€ ì‚¬ì—…ì„ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ (high single-digit growth)ë¡œ íšŒë³µì‹œí‚¤ê³ , 500bpë¥¼ ê°œì„ í•˜ì—¬ ì˜ì—…ì´ìµë¥  26%ë¥¼ ë‹¬ì„±í•˜ê² ë‹¤ê³  ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì§€ë‚œ 1ë…„ê°„ ì´ë£¬ ì„±ê³¼ì— ëŒ€í•´ ì •ë§ ë§Œì¡±ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì €í¬ëŠ” ì„±ì¥ ê¶¤ë„ì— ì§„ì…í–ˆìœ¼ë©°, 27ë…„ í•µì‹¬ ì‚¬ì—…ì—ì„œ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” ì˜¬ë°”ë¥¸ ë°©í–¥ìœ¼ë¡œ ë‚˜ì•„ê°€ê³  ìˆë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤. ë˜í•œ ì‘ë…„ì— ê´€ì„¸ ë° ê¸°íƒ€ ìš”ì¸ìœ¼ë¡œ ì¸í•´ ì•½ 200bpì˜ ì—­í’ì´ ìˆì—ˆë˜ ë§¤ìš° ì–´ë ¤ìš´ í™˜ê²½ ì†ì—ì„œë„ ì˜ì—…ì´ìµë¥ ì„ 200bp ê°œì„ í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì œ ì¶”ê°€ë¡œ 130bp ê°œì„ ì„ ì•½ì†í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ê·¸ ê¶¤ë„ë¥¼ ì˜ ë”°ë¼ê°€ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë¬¼ë¡  ì´ì œ SomaLogic ì¸ìˆ˜ë¡œ ì¸í•´, ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ì¶œë°œì ì—ì„œëŠ” í¬ì„ íš¨ê³¼ê°€ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì‹œë„ˆì§€ ê¸°íšŒë¥¼ ê²€í† í•˜ê³  ìˆìœ¼ë©°, 2027ë…„ì—ë„ 26% ì˜ì—…ì´ìµë¥ ì— ìµœëŒ€í•œ ê·¼ì ‘í•˜ë„ë¡ í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ ì´ìƒì— ëŒ€í•´ì„œëŠ” ì§„í–‰ ìƒí™©ì„ ê³„ì† ì—…ë°ì´íŠ¸í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” í•  ìˆ˜ ìˆëŠ” ëª¨ë“  ê²ƒì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question will come...</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ ì£¼ì‹œê² ìŠµë‹ˆë‹¤...</td></tr>
<tr><td>Chief Financial Officer: This is Ankur. And Doug, you're premise that next year, excluding SomaLogic, that the exit rate operating margin for 2026 is higher than the average is that's usually our cyclicality in the business. So our full year guide ex-Soma is getting close to 24.5% and exit rate in Q4 generally tends to be higher than that.</td><td>**Chief Financial Officer:** ì•µì»¤ì…ë‹ˆë‹¤. ë”ê·¸, ë§ì”€í•˜ì‹  ì „ì œ, ì¦‰ ë‚´ë…„ì— ì†Œë§ˆë¡œì§ì„ ì œì™¸í•˜ê³  2026ë…„ ë§ ì˜ì—…ì´ìµë¥ ì´ í‰ê· ë³´ë‹¤ ë†’ì„ ê²ƒì´ë¼ëŠ” ì ì€ ì €í¬ ì‚¬ì—…ì˜ ì¼ë°˜ì ì¸ ê³„ì ˆì„± íŒ¨í„´ì…ë‹ˆë‹¤. ì†Œë§ˆë¡œì§ì„ ì œì™¸í•œ ì—°ê°„ ê°€ì´ë˜ìŠ¤ê°€ 24.5%ì— ê·¼ì ‘í•˜ê³  ìˆê³ , 4ë¶„ê¸° ë§ ìˆ˜ì¹˜ëŠ” ì¼ë°˜ì ìœ¼ë¡œ ê·¸ë³´ë‹¤ ë†’ì€ ê²½í–¥ì´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question will come from Vijay Kumar with Evercore ISI.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Evercore ISIì˜ Vijay Kumarë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Vijay Kumar: Evercore ISI Institutional Equities, Research Division Congrats on a nice one here. Maybe one on guidance here, Jacob or Ankur for you guys. The organic for Q4, when you look at clinical performance, ex-China, 6.5%, overall company 3.5%. Your guidance ex-China basis for fiscal '26, you're looking at 3%. What drives that step down from 6.5% exit rate in Q4? Q4, clearly, clinical was standard. Was there anything one-off about Q4? Any pull forward of revenues, et cetera, that perhaps calls for some moderation in '26 outlook?</td><td>**Vijay Kumar:** ì¢‹ì€ ì‹¤ì  ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ê°€ì´ë˜ìŠ¤ ê´€ë ¨í•´ì„œ Jacobì´ë‚˜ Ankurê»˜ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ìœ ê¸°ì  ì„±ì¥ë¥ ì„ ë³´ë©´, ì¤‘êµ­ ì œì™¸ ì„ìƒ ë¶€ë¬¸ ì‹¤ì ì´ 6.5%ì˜€ê³ , ì „ì‚¬ì ìœ¼ë¡œëŠ” 3.5%ì˜€ìŠµë‹ˆë‹¤. ê·¸ëŸ°ë° 26íšŒê³„ì—°ë„ ì¤‘êµ­ ì œì™¸ ê°€ì´ë˜ìŠ¤ëŠ” 3%ë¡œ ì œì‹œí•˜ì…¨ëŠ”ë°ìš”. 4ë¶„ê¸° 6.5% ì„±ì¥ë¥ ì—ì„œ 3%ë¡œ í•˜ë½í•˜ëŠ” ìš”ì¸ì´ ë¬´ì—‡ì¸ê°€ìš”? 4ë¶„ê¸° ì„ìƒ ë¶€ë¬¸ì€ í™•ì‹¤íˆ ê²¬ì¡°í–ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì— ì¼íšŒì„± ìš”ì¸ì´ ìˆì—ˆë‚˜ìš”? ë§¤ì¶œ ì¡°ê¸° ì¸ì‹ ê°™ì€ ë¶€ë¶„ì´ ìˆì–´ì„œ 26ë…„ ì „ë§ì„ ë³´ìˆ˜ì ìœ¼ë¡œ ì¡ìœ¼ì‹  ê±´ê°€ìš”?</td></tr>
<tr><td>Jacob Thaysen: CEO, Interim Chief Commercial Officer & Director Vijay, so thank you, first and foremost, we are super excited about how we ended out the year. Clearly, 2025 was a challenging year. So the momentum we started to build up here in the second half is really encouraging. And we truly believe that momentum is continuing into '26. As you can see, we ended out the year with very strong performance on clinical with 20% clinical consumables growth in '27 -- excuse me, in Q4 in '25 here. And we expect that momentum overall from second half to continue. So we believe that what we're building in is that we have high -- mid-teens growth for our clinical business. But we also continue to see the challenging in the research academic environment. It is definitely a good step forward that we are now seeing line of sight to the NIH budget. But if you dig a little bit deeper, there's still a lot of uncertainties for the institutes for how grants are being distributed and who's getting -- who's actually getting these grants. So that's why we see there's still a muted environment. And I think during the year, we will hopefully see that come out better, which could continue the performance or improve our performance. But we're not seeing any substantial step down. We know Q4 is always a strong quarter, and therefore, we feel good about how we're guiding at this point.</td><td>**Jacob Thaysen:** ë¨¼ì € ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì €í¬ëŠ” ì—°ë§ ì‹¤ì ì— ëŒ€í•´ ë§¤ìš° ê³ ë¬´ì ìœ¼ë¡œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2025ë…„ì´ ë¶„ëª… ì–´ë ¤ìš´ í•œ í•´ì˜€ë˜ ë§Œí¼, í•˜ë°˜ê¸°ì— êµ¬ì¶•í•˜ê¸° ì‹œì‘í•œ ëª¨ë©˜í…€ì€ ì •ë§ ê³ ë¬´ì ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ ëª¨ë©˜í…€ì´ 26ë…„ì—ë„ ì§€ì†ë  ê²ƒìœ¼ë¡œ í™•ì‹ í•©ë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼, ì €í¬ëŠ” ì„ìƒ ë¶€ë¬¸ì—ì„œ ë§¤ìš° ê°•ë ¥í•œ ì‹¤ì ìœ¼ë¡œ í•œ í•´ë¥¼ ë§ˆë¬´ë¦¬í–ˆìŠµë‹ˆë‹¤. 25ë…„ 4ë¶„ê¸° ì„ìƒ ì†Œëª¨í’ˆ ë§¤ì¶œì´ 20% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í•˜ë°˜ê¸°ì˜ ì „ë°˜ì ì¸ ëª¨ë©˜í…€ì´ ê³„ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” ì„ìƒ ì‚¬ì—…ì—ì„œ 10%ëŒ€ ì¤‘ë°˜ì˜ ë†’ì€ ì„±ì¥ë¥ ì„ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì—°êµ¬ ë° í•™ìˆ  í™˜ê²½ì—ì„œì˜ ì–´ë ¤ì›€ì€ ì—¬ì „íˆ ì§€ì†ë˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ NIH ì˜ˆì‚°ì— ëŒ€í•œ ê°€ì‹œì„±ì´ í™•ë³´ë˜ê³  ìˆë‹¤ëŠ” ì ì€ ë¶„ëª…íˆ ê¸ì •ì ì¸ ì§„ì „ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì¢€ ë” ìì„¸íˆ ë“¤ì—¬ë‹¤ë³´ë©´, ê° ì—°êµ¬ì†Œë“¤ì´ ì—°êµ¬ë¹„ë¥¼ ì–´ë–»ê²Œ ë°°ë¶„í•  ê²ƒì¸ì§€, ì‹¤ì œë¡œ ëˆ„ê°€ ì´ ì—°êµ¬ë¹„ë¥¼ ë°›ê²Œ ë  ê²ƒì¸ì§€ì— ëŒ€í•´ì„œëŠ” ì—¬ì „íˆ ë§ì€ ë¶ˆí™•ì‹¤ì„±ì´ ì¡´ì¬í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì•„ì§ê¹Œì§€ëŠ” ë‹¤ì†Œ ì¡°ì‹¬ìŠ¤ëŸ¬ìš´ í™˜ê²½ì´ ì§€ì†ë˜ê³  ìˆëŠ” ê²ƒì…ë‹ˆë‹¤. ì—°ì¤‘ ìƒí™©ì´ ê°œì„ ë˜ë©´ì„œ í˜„ì¬ ì‹¤ì ì„ ìœ ì§€í•˜ê±°ë‚˜ ë” ë‚˜ì•„ì§ˆ ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì‹¤ì ì´ í¬ê²Œ í•˜ë½í•˜ëŠ” ìƒí™©ì€ ë³´ì´ì§€ ì•ŠìŠµë‹ˆë‹¤. 4ë¶„ê¸°ëŠ” í•­ìƒ ê°•í•œ ë¶„ê¸°ë¼ëŠ” ì ì„ ì˜ ì•Œê³  ìˆê¸° ë•Œë¬¸ì—, í˜„ ì‹œì ì—ì„œ ì œì‹œí•œ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ í™•ì‹ ì„ ê°–ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: Vijay, let me just frame the 2% to 4% ex-China. When we approach the guidance, as Jacob said, we're not seeing any change in the momentum, especially in the clinical business. Our customers continue to do very well, both from the adoption of the on-market test as well as working on bringing new tests to the market. The way we have approached the guidance is to look at the half 2 of 2025 as we laid out during our Q3 earnings call, where in Q3, our growth was 2% ex-China. In Q4, up to 7%. And so we took the average for the second half to bracket our overall guidance. The Q3 of 2025 is what we're using as the low end, right, where clinical still grew in the double-digit rate. The research was down in the high single-digit rate as kind of the framework towards the low end. And then if research does improve, that certainly provides on an upside. Q4, just 1 quarter didn't feel like using as a base for a full year guide per se. But momentum is pretty good.</td><td>**Chief Financial Officer:** ë¹„ì œì´, ì¤‘êµ­ì„ ì œì™¸í•œ 2%ì—ì„œ 4% ì„±ì¥ë¥ ì— ëŒ€í•´ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê°€ì´ë˜ìŠ¤ë¥¼ ìˆ˜ë¦½í•  ë•Œ, ì œì´ì½¥ì´ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ íŠ¹íˆ ì„ìƒ ì‚¬ì—…ì—ì„œ ëª¨ë©˜í…€ì˜ ë³€í™”ëŠ” ì „í˜€ ë³´ì´ì§€ ì•Šê³  ìˆìŠµë‹ˆë‹¤. ê³ ê°ë“¤ì€ ì‹œíŒ ì¤‘ì¸ ê²€ì‚¬ì˜ ì±„íƒê³¼ ì‹ ê·œ ê²€ì‚¬ì˜ ì‹œì¥ ì¶œì‹œ ì‘ì—… ëª¨ë‘ì—ì„œ ë§¤ìš° ì¢‹ì€ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ê°€ì´ë˜ìŠ¤ ìˆ˜ë¦½ ë°©ì‹ì€ 3ë¶„ê¸° ì‹¤ì  ë°œí‘œ ë•Œ ì„¤ëª…ë“œë¦° 2025ë…„ í•˜ë°˜ê¸°ë¥¼ ê¸°ì¤€ìœ¼ë¡œ í–ˆìŠµë‹ˆë‹¤. 3ë¶„ê¸°ì—ëŠ” ì¤‘êµ­ì„ ì œì™¸í•˜ê³  2% ì„±ì¥í–ˆê³ , 4ë¶„ê¸°ì—ëŠ” 7%ê¹Œì§€ ì˜¬ë¼ê°”ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ í•˜ë°˜ê¸° í‰ê· ì„ í™œìš©í•´ì„œ ì „ì²´ ê°€ì´ë˜ìŠ¤ ë²”ìœ„ë¥¼ ì„¤ì •í–ˆìŠµë‹ˆë‹¤. 2025ë…„ 3ë¶„ê¸° ì‹¤ì ì„ í•˜ë‹¨ ê¸°ì¤€ìœ¼ë¡œ ì‚¬ìš©í–ˆëŠ”ë°, ë‹¹ì‹œ ì„ìƒ ë¶€ë¬¸ì€ ì—¬ì „íˆ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ê¸°ë¡í–ˆê³  ì—°êµ¬ ë¶€ë¬¸ì€ ë†’ì€ í•œ ìë¦¿ìˆ˜ ê°ì†Œìœ¨ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ì´ê²ƒì´ í•˜ë‹¨ ê°€ì´ë˜ìŠ¤ì˜ ê¸°ë³¸ í”„ë ˆì„ì›Œí¬ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¦¬ì„œì¹˜ ë¶€ë¬¸ì´ ê°œì„ ëœë‹¤ë©´, ê·¸ê²ƒì€ í™•ì‹¤íˆ ìƒìŠ¹ ì—¬ë ¥ì„ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. 4ë¶„ê¸°ëŠ” ë‹¨ í•œ ë¶„ê¸°ì— ë¶ˆê³¼í•´ì„œ ì—°ê°„ ê°€ì´ë˜ìŠ¤ì˜ ê¸°ì¤€ìœ¼ë¡œ ì‚¬ìš©í•˜ê¸°ì—ëŠ” ì ì ˆí•˜ì§€ ì•Šë‹¤ê³  íŒë‹¨í–ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ëª¨ë©˜í…€ì€ ìƒë‹¹íˆ ì¢‹ì€ ìƒí™©ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question will come from Puneet Souda with Leerink Partners.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Leerink Partnersì˜ Puneet Soudaë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Puneet Souda: Leerink Partners LLC, Research Division On the instrumentation, can you provide how the split was research versus clinical? I appreciate the momentum you're seeing in the clinical side. But on the research side, can you provide a little bit of context? And how are you thinking about the overall competition just beyond the academic pressure that we have seen in the market? How much of that is baked in just on the research side, both on the mid-throughput end and the high-throughput end?</td><td>**Puneet Souda:** ê¸°ê¸° ë¶€ë¬¸ì—ì„œ ì—°êµ¬ìš©ê³¼ ì„ìƒìš© ë¹„ì¤‘ì´ ì–´ë–»ê²Œ ë‚˜ë‰˜ëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ì„ìƒ ìª½ì—ì„œ ë³´ì´ëŠ” ëª¨ë©˜í…€ì€ ì´í•´í–ˆìŠµë‹ˆë‹¤ë§Œ, ì—°êµ¬ìš© ìª½ì— ëŒ€í•´ì„œë„ ì¢€ ë” ì„¤ëª…í•´ ì£¼ì‹œë©´ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì „ë°˜ì ì¸ ê²½ìŸ ìƒí™©ì— ëŒ€í•´ì„œëŠ” ì–´ë–»ê²Œ ë³´ê³  ê³„ì‹ ê°€ìš”? ì‹œì¥ì—ì„œ ë³´ì´ëŠ” í•™ìˆ  ë¶€ë¬¸ì˜ ì••ë°• ì™¸ì—ë„ ë§ì´ì£ . ì—°êµ¬ìš© ë¶€ë¬¸ì—ì„œ ì¤‘ì²˜ë¦¬ëŸ‰(mid-throughput)ê³¼ ê³ ì²˜ë¦¬ëŸ‰(high-throughput) ì–‘ìª½ ëª¨ë‘ì—ì„œ ì´ëŸ¬í•œ ìš”ì¸ë“¤ì´ ì–¼ë§ˆë‚˜ ë°˜ì˜ë˜ì–´ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Jacob Thaysen: CEO, Interim Chief Commercial Officer & Director Yes, Puneet, thank you. And we were very pleased with the performance we had in Q4 with more than 100 instruments placed in on the X instruments. And as expected, more than 60% of those placements were related to clinical. And we expect that to be the case, that the dynamic to continue into '26, where clinical will be majority of the placements of instruments. So we are -- we continue to see that customers are building their assays on our -- on the X instruments, and we're not seeing any slowdown in that part of the business. As you mentioned also, we have a mid-throughput business. That has been more -- as we talked about before, have been more challenged by some of the macro trends where some of our customers are maybe more conservative in how they have spent their funding over the past years, also in the research and academic market. So I think that market is still a little more muted than -- but not really a change from what we have seen in '25 also. So that's how we think about the business right now.</td><td>**Jacob Thaysen:** ë„¤, Puneet, ê°ì‚¬í•©ë‹ˆë‹¤. 4ë¶„ê¸°ì— X ì¥ë¹„ 100ëŒ€ ì´ìƒì„ ì„¤ì¹˜í•˜ëŠ” ì„±ê³¼ë¥¼ ê±°ë‘¬ ë§¤ìš° ë§Œì¡±ìŠ¤ëŸ¬ì› ìŠµë‹ˆë‹¤. ì˜ˆìƒëŒ€ë¡œ ì´ ì¤‘ 60% ì´ìƒì´ ì„ìƒ ë¶„ì•¼ì™€ ê´€ë ¨ëœ ì„¤ì¹˜ì˜€ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì—­í•™ ê´€ê³„ëŠ” 2026ë…„ì—ë„ ê³„ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì„ìƒ ë¶„ì•¼ê°€ ì¥ë¹„ ì„¤ì¹˜ì˜ ëŒ€ë¶€ë¶„ì„ ì°¨ì§€í•  ê²ƒì…ë‹ˆë‹¤. ê³ ê°ë“¤ì´ ìš°ë¦¬ X ì¥ë¹„ë¥¼ ê¸°ë°˜ìœ¼ë¡œ ë¶„ì„ë²•(assay)ì„ êµ¬ì¶•í•˜ê³  ìˆìœ¼ë©°, ì´ ë¶€ë¶„ì˜ ì‚¬ì—…ì—ì„œ ë‘”í™”ëŠ” ì „í˜€ ë³´ì´ì§€ ì•Šê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ ì¤‘ê°„ ì²˜ë¦¬ëŸ‰(mid-throughput) ì‚¬ì—…ë„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì „ì— ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì¼ë¶€ ê±°ì‹œê²½ì œ íŠ¸ë Œë“œë¡œ ì¸í•´ ë” ì–´ë ¤ì›€ì„ ê²ªê³  ìˆìŠµë‹ˆë‹¤. ì¼ë¶€ ê³ ê°ë“¤ì´ ì§€ë‚œ ëª‡ ë…„ê°„ ìê¸ˆ ì§‘í–‰ì— ìˆì–´ ì¢€ ë” ë³´ìˆ˜ì ì¸ íƒœë„ë¥¼ ë³´ì´ê³  ìˆê³ , ì—°êµ¬ ë° í•™ìˆ  ì‹œì¥ì—ì„œë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ë”°ë¼ì„œ í•´ë‹¹ ì‹œì¥ì€ ì—¬ì „íˆ ë‹¤ì†Œ ì¹¨ì²´ëœ ìƒí™©ì´ì§€ë§Œ, 25ë…„ì— ë³´ì•˜ë˜ ê²ƒê³¼ í¬ê²Œ ë‹¤ë¥´ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. í˜„ì¬ ì‚¬ì—…ì„ ì´ë ‡ê²Œ ë³´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: From a competitive perspective, Puneet, no, we didn't see much in Q4. As Jacob said, very strong instrument placements quarter overall across clinical and research as well. We're getting very good interest in the new launches. We've launched the 5-base. Our spatial is in early access and the demand and the interest from the research side looks very good. Our thinking on the research from 2026 perspective is more based on the funding environment and the evolution of the funding environment to say.</td><td>**Chief Financial Officer:** ê²½ìŸ ì¸¡ë©´ì—ì„œ ë³´ë©´, 4ë¶„ê¸°ì— íŠ¹ë³„í•œ ë³€í™”ëŠ” ì—†ì—ˆìŠµë‹ˆë‹¤. Jacobì´ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì„ìƒê³¼ ì—°êµ¬ ë¶€ë¬¸ ëª¨ë‘ì—ì„œ ì „ë°˜ì ìœ¼ë¡œ ë§¤ìš° ê°•ë ¥í•œ ì¥ë¹„ ì„¤ì¹˜ ì‹¤ì ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì‹ ì œí’ˆ ì¶œì‹œì— ëŒ€í•œ ë°˜ì‘ë„ ë§¤ìš° ì¢‹ìŠµë‹ˆë‹¤. 5-baseë¥¼ ì¶œì‹œí–ˆê³ , ê³µê°„ë¶„ì„(spatial) ì œí’ˆì€ ì–¼ë¦¬ ì•¡ì„¸ìŠ¤ ë‹¨ê³„ì¸ë° ì—°êµ¬ ë¶€ë¬¸ì—ì„œ ìˆ˜ìš”ì™€ ê´€ì‹¬ì´ ì•„ì£¼ ì¢‹ì•„ ë³´ì…ë‹ˆë‹¤. 2026ë…„ ì—°êµ¬ ë¶€ë¬¸ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì „ë§ì€ ìê¸ˆ ì¡°ë‹¬ í™˜ê²½ê³¼ ê·¸ í™˜ê²½ì˜ ë³€í™” ì¶”ì´ì— ë” ê¸°ë°˜ì„ ë‘ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question will come from Tycho Peterson with Jefferies.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Jefferiesì˜ Tycho Petersonë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Tycho Peterson: Jefferies LLC, Research Division A couple of quick ones. Just on clinical Jacob, you talked about growing use of whole genome, whole exome. Can you just talk on delineate how much of the growth is mix versus maybe volume? So that's kind of the first question. Second is on Onso. Just curious if you can touch on that thought process, how quickly could you incorporate that technology if you're planning to? And then maybe just lastly on adjacencies, a little bit more color on what you're baking in for spatial constellation and 5-base.</td><td>**Tycho Peterson:** ëª‡ ê°€ì§€ ê°„ë‹¨í•œ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € ì„ìƒ ë¶€ë¬¸ ê´€ë ¨í•´ì„œ Jacob, ì „ì¥ ìœ ì „ì²´ì™€ ì „ì¥ ì—‘ì†œ ì‚¬ìš© ì¦ê°€ì— ëŒ€í•´ ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. ì„±ì¥ì´ ë¯¹ìŠ¤ íš¨ê³¼ì™€ ë¬¼ëŸ‰ ì¦ê°€ ì¤‘ ì–´ëŠ ìª½ì—ì„œ ì–¼ë§ˆë‚˜ ê¸°ì¸í•˜ëŠ”ì§€ êµ¬ë¶„í•´ì„œ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ì´ê²Œ ì²« ë²ˆì§¸ ì§ˆë¬¸ì…ë‹ˆë‹¤.<br><br>ë‘ ë²ˆì§¸ëŠ” Onso ê´€ë ¨ì…ë‹ˆë‹¤. í•´ë‹¹ ê¸°ìˆ ì„ ë„ì…í•  ê³„íšì´ì‹œë¼ë©´ ì–¼ë§ˆë‚˜ ë¹ ë¥´ê²Œ í†µí•©í•  ìˆ˜ ìˆì„ì§€, ê·¸ ì‚¬ê³  ê³¼ì •ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.<br><br>ë§ˆì§€ë§‰ìœ¼ë¡œ ì¸ì ‘ ì‚¬ì—… ë¶€ë¬¸ì— ëŒ€í•´ì„œì¸ë°ìš”, ê³µê°„ ë¶„ì„(spatial), Constellation, ê·¸ë¦¬ê³  5-baseì— ëŒ€í•´ ì–´ë–¤ ê²ƒë“¤ì„ ë°˜ì˜í•˜ê³  ê³„ì‹ ì§€ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œë©´ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jacob Thaysen: CEO, Interim Chief Commercial Officer & Director Okay. So -- no, thanks for that, Tycho. And if you look at the opportunity with the X and what our customers are using it for, clearly, we continue to see, as you can see, many of our clinical customers are, of course, seeing a significant uptake in volume. Many more physicians are starting to use genetic profiling for the cancers, but also for monitoring diseases. So that is a strong momentum. But we're also seeing that our customers are choosing to make larger and larger panels. As you mentioned, some of them are going from exome to whole genome. That's more in the genetic space. But we're also seeing that customers are building larger panels for therapy selection. And the next thing here is to expand the panels for MRD. So we see all that. We're not splitting it down into the pieces at this point of time. But I would say, over time, I think actually the intensity, meaning the larger panels is going to be the main growth driver going forward. We see a lot of opportunities there. For the acquisition of the IP from PacBio, we saw that as a great opportunity to strengthen our portfolio. We're very bullish about our SBS technology. So we believe there's a lot of options in that still. But we felt it was a great way to keep optionality. And then I think the last one you had was on how much we built in for the 5-base and for constellation and others. This is still early days. We have seen a very, very strong interest for the products we brought to market already. I don't think it's going to be meaningful here really in '26, but it will start to be meaningful as we talked about before, in '27 and beyond, where we believe 1 or 2 basis of growth -- 1% or 2% growth will come from our new assays in multiomics, both multiomics and our data, the downside business.</td><td>**Jacob Thaysen:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. X ì œí’ˆì˜ ê¸°íšŒì™€ ê³ ê°ë“¤ì˜ í™œìš© ì‚¬ë¡€ë¥¼ ë³´ë©´, ì„ìƒ ê³ ê°ë“¤ì˜ ê²€ì‚¬ëŸ‰ì´ í¬ê²Œ ì¦ê°€í•˜ê³  ìˆëŠ” ê²ƒì„ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë” ë§ì€ ì˜ì‚¬ë“¤ì´ ì•” ì§„ë‹¨ë¿ë§Œ ì•„ë‹ˆë¼ ì§ˆë³‘ ëª¨ë‹ˆí„°ë§ì„ ìœ„í•´ ìœ ì „ì í”„ë¡œíŒŒì¼ë§ì„ ì‚¬ìš©í•˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ëª¨ë©˜í…€ì€ ë§¤ìš° ê°•ë ¥í•©ë‹ˆë‹¤.<br><br>ë˜í•œ ê³ ê°ë“¤ì´ ì ì  ë” í° ê·œëª¨ì˜ íŒ¨ë„ì„ ì„ íƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ ì¼ë¶€ ê³ ê°ë“¤ì€ ì—‘ì†œ(exome)ì—ì„œ ì „ì¥ìœ ì „ì²´(whole genome)ë¡œ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ ìœ ì „í•™ ë¶„ì•¼ì—ì„œ ë‚˜íƒ€ë‚˜ëŠ” í˜„ìƒì…ë‹ˆë‹¤. ë™ì‹œì— ì¹˜ë£Œë²• ì„ íƒì„ ìœ„í•´ ë” í° íŒ¨ë„ì„ êµ¬ì¶•í•˜ëŠ” ê³ ê°ë“¤ë„ ëŠ˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ìŒ ë‹¨ê³„ë¡œëŠ” MRD(ë¯¸ì„¸ì”ì¡´ì§ˆí™˜) ê²€ì‚¬ë¥¼ ìœ„í•œ íŒ¨ë„ í™•ì¥ì´ ì§„í–‰ë  ê²ƒì…ë‹ˆë‹¤. í˜„ì¬ë¡œì„œëŠ” ì´ë¥¼ ì„¸ë¶€ì ìœ¼ë¡œ ë‚˜ëˆ„ì–´ ë³´ê³  ìˆì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì‹¤ì œë¡œ ê°•ë„(intensity), ì¦‰ ë” í° íŒ¨ë„ì´ ì•ìœ¼ë¡œ ì£¼ìš” ì„±ì¥ ë™ë ¥ì´ ë  ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ê·¸ ë¶„ì•¼ì—ì„œ ë§ì€ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. PacBioë¡œë¶€í„°ì˜ IP ì¸ìˆ˜ì™€ ê´€ë ¨í•´ì„œëŠ”, ì´ë¥¼ ìš°ë¦¬ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê°•í™”í•  ìˆ˜ ìˆëŠ” í›Œë¥­í•œ ê¸°íšŒë¡œ ë³´ì•˜ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” SBS ê¸°ìˆ ì— ëŒ€í•´ ë§¤ìš° ë‚™ê´€ì ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì—¬ì „íˆ ë§ì€ ì˜µì…˜ì´ ìˆë‹¤ê³  ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì˜µì…˜ì„ ìœ ì§€í•˜ëŠ” ì¢‹ì€ ë°©ë²•ì´ë¼ê³  ìƒê°í–ˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ 5-baseì™€ constellation ë“±ì— ì–¼ë§ˆë‚˜ ë°˜ì˜í–ˆëŠ”ì§€ì— ê´€í•œ ê²ƒì´ì—ˆëŠ”ë°ìš”. ì•„ì§ ì´ˆê¸° ë‹¨ê³„ì…ë‹ˆë‹¤. ì´ë¯¸ ì¶œì‹œí•œ ì œí’ˆë“¤ì— ëŒ€í•´ ë§¤ìš° ê°•ë ¥í•œ ê´€ì‹¬ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. 26ë…„ì—ëŠ” í¬ê²Œ ì˜ë¯¸ ìˆëŠ” ìˆ˜ì¤€ì€ ì•„ë‹ ê²ƒìœ¼ë¡œ ë³´ì§€ë§Œ, ë§ì”€ë“œë ¸ë“¯ì´ 27ë…„ë¶€í„°ëŠ” ì˜ë¯¸ ìˆëŠ” ê¸°ì—¬ë¥¼ í•˜ê¸° ì‹œì‘í•  ê²ƒì…ë‹ˆë‹¤. ë©€í‹°ì˜¤ë¯¹ìŠ¤(multiomics) ë¶„ì•¼ì˜ ì‹ ê·œ ë¶„ì„ ì„œë¹„ìŠ¤ì™€ ë°ì´í„° ë‹¤ìš´ì‚¬ì´ë“œ ì‚¬ì—…ì„ í†µí•´ 1~2% í¬ì¸íŠ¸ì˜ ì„±ì¥ì´ ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question will come from Michael Ryskin with BofA.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ BofAì˜ Michael Ryskinë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Michael Ryskin: BofA Securities, Research Division I want to dive into some of the pieces of the 2026 guide in terms of the sequencing consumables, sequencing instruments. A little bit surprised that you got them as close. I would have thought that sequencing consumables would have been a little bit better as you -- as you said, as you're moving past some of the headwinds from the price transition. At the same time, sequencing instruments, I thought could have been a little bit worse. So maybe you could just dive into some of the moving pieces there. Are you expecting something similar in terms of Nova X placements next year in the mid- to high 200s range? And just maybe talk about some of the other platforms that make that up, the NextSeq, the mid-throughput platforms, the Nova 6000. Just would love to get more color on the moving pieces there.</td><td>**Michael Ryskin:** 2026ë…„ ê°€ì´ë˜ìŠ¤ì˜ ì„¸ë¶€ í•­ëª©ë“¤, íŠ¹íˆ ì‹œí€€ì‹± ì†Œëª¨í’ˆê³¼ ì‹œí€€ì‹± ì¥ë¹„ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤. ë‘ í•­ëª©ì´ ì´ë ‡ê²Œ ë¹„ìŠ·í•œ ìˆ˜ì¤€ì´ë¼ëŠ” ì ì´ ì¡°ê¸ˆ ì˜ì™¸ì…ë‹ˆë‹¤. ê°€ê²© ì „í™˜ì— ë”°ë¥¸ ì—­í’ì„ ì§€ë‚˜ê°€ê³  ìˆë‹¤ê³  ë§ì”€í•˜ì‹  ë§Œí¼, ì‹œí€€ì‹± ì†Œëª¨í’ˆì´ ì¢€ ë” ë‚˜ì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí–ˆì—ˆê±°ë“ ìš”. ë™ì‹œì— ì‹œí€€ì‹± ì¥ë¹„ëŠ” ì¡°ê¸ˆ ë” ë‚®ì„ ìˆ˜ë„ ìˆë‹¤ê³  ìƒê°í–ˆê³ ìš”. ê·¸ë˜ì„œ ê·¸ ì•ˆì˜ ì—¬ëŸ¬ ìš”ì†Œë“¤ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ë‚´ë…„ì—ë„ Nova X ì„¤ì¹˜ ëŒ€ìˆ˜ê°€ ì˜¬í•´ì™€ ë¹„ìŠ·í•˜ê²Œ 200ëŒ€ ì¤‘í›„ë°˜ ìˆ˜ì¤€ì„ ì˜ˆìƒí•˜ê³  ê³„ì‹  ê±´ê°€ìš”? ê·¸ë¦¬ê³  NextSeq, ì¤‘ê°„ ì²˜ë¦¬ëŸ‰ í”Œë«í¼ë“¤, Nova 6000 ë“± ë‹¤ë¥¸ í”Œë«í¼ë“¤ì— ëŒ€í•´ì„œë„ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ ë¶€ë¶„ì˜ ì„¸ë¶€ ë‚´ìš©ì„ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œë©´ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jacob Thaysen: CEO, Interim Chief Commercial Officer & Director Mike, so thank you for the questions. And I would say, first and foremost, on the high-throughput consumables, especially in the clinical, as we mentioned, we continue to see very strong performance in that. So we don't think that is going to change. We actually think that there is potential upside in that, obviously, if the market continues to be as strong as we have seen in the last part of the year. We do see, of course, in the consumables, if you blend the -- blend consumables that both for the research segment, but also for the mid through, there's still some headwinds in that space. So that's why you see the blend is where it is. I would put it this way. If you think about it, the low end of the guide in the consumables is probably what we saw in Q3, and then we started to see momentum. So there's probably more in the higher end of the guide that we expect us to be for consumables. So that's how to think about it. On the instruments, I mean, we continue to see a lot of momentum in instruments. Right now, we're guiding for 50 to 60 placements, but many of our clinical customers continue to expand their placements. So we continue to believe that this is the strong momentum opportunities here.</td><td>**Jacob Thaysen:** ë¨¼ì € ê³ ì²˜ë¦¬ëŸ‰ ì†Œëª¨í’ˆ(high-throughput consumables), íŠ¹íˆ ì„ìƒ ë¶„ì•¼ì—ì„œ ë§ì”€ë“œë¦¬ë©´, ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´ ë§¤ìš° ê°•ë ¥í•œ ì‹¤ì ì´ ì§€ì†ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¶”ì„¸ëŠ” ë³€í•˜ì§€ ì•Šì„ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ì‘ë…„ í•˜ë°˜ê¸°ì— ë³´ì•˜ë˜ ê²ƒì²˜ëŸ¼ ì‹œì¥ì´ ê³„ì† ê°•ì„¸ë¥¼ ìœ ì§€í•œë‹¤ë©´, ìƒìŠ¹ ì—¬ë ¥ë„ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë‹¤ë§Œ ì†Œëª¨í’ˆ ì „ì²´ë¥¼ ë³´ë©´, ì—°êµ¬ ë¶€ë¬¸ê³¼ ì¤‘ê°„ ì²˜ë¦¬ëŸ‰(mid-throughput) ë¶€ë¬¸ì„ í•©ì³ì„œ ë³´ì•˜ì„ ë•Œ, ì—¬ì „íˆ ì¼ë¶€ ì—­í’ì´ ìˆëŠ” ê²ƒì´ ì‚¬ì‹¤ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì „ì²´ì ìœ¼ë¡œ í˜¼í•©ëœ(blended) ìˆ˜ì¹˜ê°€ í˜„ì¬ ìˆ˜ì¤€ì— ìˆëŠ” ê²ƒì…ë‹ˆë‹¤. ê°€ì´ë˜ìŠ¤ì˜ í•˜ë‹¨ì„ ìƒê°í•´ë³´ì‹œë©´, ì†Œëª¨í’ˆ(consumables)ì˜ ê²½ìš° ì•„ë§ˆë„ 3ë¶„ê¸°ì— ì €í¬ê°€ ë³¸ ìˆ˜ì¤€ì¼ ê²ƒì´ê³ , ê·¸ ì´í›„ ëª¨ë©˜í…€ì´ ì‹œì‘ë˜ëŠ” ê²ƒì„ ë³´ì•˜ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì†Œëª¨í’ˆì˜ ê²½ìš° ê°€ì´ë˜ìŠ¤ ìƒë‹¨ì— ê°€ê¹Œìš´ ì‹¤ì ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë ‡ê²Œ ì´í•´í•˜ì‹œë©´ ë©ë‹ˆë‹¤. ì¥ë¹„(instruments)ì˜ ê²½ìš°, ê³„ì†í•´ì„œ ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ 50~60ëŒ€ì˜ ì„¤ì¹˜ë¥¼ ê°€ì´ë˜ìŠ¤ë¡œ ì œì‹œí•˜ê³  ìˆì§€ë§Œ, ë§ì€ ì„ìƒ ê³ ê°ë“¤ì´ ê³„ì†í•´ì„œ ì„¤ì¹˜ ëŒ€ìˆ˜ë¥¼ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ë¶€ë¶„ì—ì„œ ê°•ë ¥í•œ ëª¨ë©˜í…€ ê¸°íšŒê°€ ìˆë‹¤ê³  ê³„ì† ë¯¿ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: Mike, on the instrumentation side, as I mentioned in my script, for Xs, yes, about 200 to 240 for the year. I said on average; 50 to 60 a quarter is still quite good. The Q4 placements were phenomenal. We got quite a few multipack orders. We do look at several of our customers trying to expand their fleets, sometimes thinking about tens of Xs scenarios. So good instrument demand. As you all know, we made a major software upgrade into X in the early part of 2025. The performance there has been running above the spec for a very large part of our customers. So X is performing at an extremely high level for our clinical customers and the research customers are super excited about some of these new multiomic technologies that get enabled on X. So very pleased and it looks quite good so far.</td><td>**Chief Financial Officer:** ë§ˆì´í¬, ì¥ë¹„ ì¸¡ë©´ì—ì„œ ì œ ë°œí‘œì—ì„œ ë§ì”€ë“œë ¸ë“¯ì´, X ì‹œë¦¬ì¦ˆì˜ ê²½ìš° ì—°ê°„ ì•½ 200~240ëŒ€ë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. í‰ê· ì ìœ¼ë¡œ ë¶„ê¸°ë‹¹ 50~60ëŒ€ ì •ë„ë©´ ì—¬ì „íˆ ìƒë‹¹íˆ ì¢‹ì€ ìˆ˜ì¤€ì…ë‹ˆë‹¤. 4ë¶„ê¸° ì„¤ì¹˜ ì‹¤ì ì€ ì •ë§ ë›°ì–´ë‚¬ìŠµë‹ˆë‹¤. ë‹¤ìˆ˜ì˜ ë©€í‹°íŒ© ì£¼ë¬¸ì„ ë°›ì•˜ê³ ìš”. ì—¬ëŸ¬ ê³ ê°ì‚¬ë“¤ì´ ë³´ìœ  ì¥ë¹„ë¥¼ í™•ëŒ€í•˜ë ¤ëŠ” ì›€ì§ì„ì„ ë³´ì´ê³  ìˆìœ¼ë©°, ë•Œë¡œëŠ” X ì‹œë¦¬ì¦ˆ ìˆ˜ì‹­ ëŒ€ ê·œëª¨ì˜ ì‹œë‚˜ë¦¬ì˜¤ë¥¼ ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¥ë¹„ ìˆ˜ìš”ê°€ ë§¤ìš° ì¢‹ì€ ìƒí™©ì…ë‹ˆë‹¤.<br><br>ì•„ì‹œë‹¤ì‹œí”¼ 2025ë…„ ì´ˆì— X ì‹œë¦¬ì¦ˆì— ëŒ€í•œ ëŒ€ê·œëª¨ ì†Œí”„íŠ¸ì›¨ì–´ ì—…ê·¸ë ˆì´ë“œë¥¼ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. ëŒ€ë‹¤ìˆ˜ ê³ ê°ì‚¬ì—ì„œ ì‚¬ì–‘ ì´ìƒì˜ ì„±ëŠ¥ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. X ì‹œë¦¬ì¦ˆëŠ” ì„ìƒ ê³ ê°ë“¤ì—ê²Œ ë§¤ìš° ë†’ì€ ìˆ˜ì¤€ì˜ ì„±ëŠ¥ì„ ì œê³µí•˜ê³  ìˆìœ¼ë©°, ì—°êµ¬ ê³ ê°ë“¤ì€ X ì‹œë¦¬ì¦ˆì—ì„œ êµ¬í˜„ë˜ëŠ” ìƒˆë¡œìš´ ë©€í‹°ì˜¤ë¯¹ìŠ¤(multiomics) ê¸°ìˆ ë“¤ì— ëŒ€í•´ ìƒë‹¹íˆ ê³ ë¬´ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë§¤ìš° ë§Œì¡±ìŠ¤ëŸ¬ìš´ ìƒí™©ì´ë©° ì§€ê¸ˆê¹Œì§€ ì „ë§ë„ ìƒë‹¹íˆ ì¢‹ì•„ ë³´ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question will come from Kyle Mikson with Canaccord.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Canaccordì˜ Kyle Miksonì´ í•˜ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Kyle Mikson: Canaccord Genuity Corp., Research Division Congrats on an impressive fourth quarter on the clinical side, especially. On that note, I know you're not splitting out clinical into the applications, but could you just speak -- just for some context, it looks like oncology was just under $1 billion in '25, then you have genetic, which was just under $0.5 billion. So which of these will, I guess, grow faster in '26? So just help us frame the different drivers split out just a bit more for us. And then just secondly, you spoke to some of the multiomics aspects before, but maybe BioInsight, is that a needle mover this year?</td><td>**Kyle Mikson:** ì„ìƒ ë¶€ë¬¸ì—ì„œ íŠ¹íˆ ì¸ìƒì ì¸ 4ë¶„ê¸° ì‹¤ì ì„ ë‹¬ì„±í•˜ì‹  ê²ƒ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ê·¸ ì ê³¼ ê´€ë ¨í•´ì„œ, ì„ìƒ ë¶€ë¬¸ì„ ì„¸ë¶€ ì• í”Œë¦¬ì¼€ì´ì…˜ë³„ë¡œ ë‚˜ëˆ„ì–´ ê³µê°œí•˜ì§€ ì•Šìœ¼ì‹ ë‹¤ëŠ” ê±´ ì•Œê³  ìˆìŠµë‹ˆë‹¤ë§Œ, ë§¥ë½ íŒŒì•…ì„ ìœ„í•´ ì—¬ì­¤ë³´ê² ìŠµë‹ˆë‹¤. ì¢…ì–‘í•™(oncology)ì´ 25ë…„ì— 10ì–µ ë‹¬ëŸ¬ ë°”ë¡œ ë°‘ì´ì—ˆê³ , ìœ ì „í•™(genetic)ì´ 5ì–µ ë‹¬ëŸ¬ ë°”ë¡œ ë°‘ì´ì—ˆë˜ ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë°ìš”. 26ë…„ì—ëŠ” ì´ ì¤‘ ì–´ëŠ ë¶„ì•¼ê°€ ë” ë¹ ë¥´ê²Œ ì„±ì¥í•  ê²ƒìœ¼ë¡œ ë³´ì‹œë‚˜ìš”? ê°ê¸° ë‹¤ë¥¸ ì„±ì¥ ë™ë ¥ë“¤ì„ ì¢€ ë” êµ¬ì²´ì ìœ¼ë¡œ ì„¤ëª…í•´ ì£¼ì‹œë©´ ì¢‹ê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‘ ë²ˆì§¸ë¡œ, ì•ì„œ ë©€í‹°ì˜¤ë¯¹ìŠ¤(multiomics) ê´€ë ¨í•´ì„œ ë§ì”€í•˜ì…¨ëŠ”ë°, BioInsightê°€ ì˜¬í•´ ì˜ë¯¸ ìˆëŠ” ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Jacob Thaysen: CEO, Interim Chief Commercial Officer & Director Yes. Thanks, Kyle. I think overall, we, of course, are very pleased with clinical. And from the highest level, clinical is growing on -- from all dimensions, both on the different type of applications, but also from the different regions and different customer types. So a really broad-based performance in clinical, and we expect that to continue, as we've mentioned a few times here. We are still seeing that oncology is the main driver and the main growth driver, but the rare diseases is definitely also growing on a healthy speed. So I do think that over the next year, also oncology will be the main growth driver for us and for our customers.</td><td>**Jacob Thaysen:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Kyle. ì „ë°˜ì ìœ¼ë¡œ ì„ìƒ ë¶€ë¬¸ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê°€ì¥ ë†’ì€ ìˆ˜ì¤€ì—ì„œ ë³´ë©´, ì„ìƒ ë¶€ë¬¸ì€ ëª¨ë“  ì¸¡ë©´ì—ì„œ ì„±ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ì–‘í•œ ì‘ìš© ë¶„ì•¼ë¿ë§Œ ì•„ë‹ˆë¼ ì—¬ëŸ¬ ì§€ì—­ê³¼ ë‹¤ì–‘í•œ ê³ ê° ìœ í˜•ì—ì„œë„ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì •ë§ ê´‘ë²”ìœ„í•œ ê¸°ë°˜ì—ì„œ ì„ìƒ ë¶€ë¬¸ì˜ ì„±ê³¼ê°€ ë‚˜íƒ€ë‚˜ê³  ìˆìœ¼ë©°, ì—¬ê¸°ì„œ ì—¬ëŸ¬ ì°¨ë¡€ ì–¸ê¸‰í–ˆë“¯ì´ ì´ëŸ¬í•œ ì¶”ì„¸ê°€ ê³„ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.<br><br>ì—¬ì „íˆ ì¢…ì–‘í•™(oncology)ì´ ì£¼ìš” ë™ë ¥ì´ì ì£¼ìš” ì„±ì¥ ë™ë ¥ì´ì§€ë§Œ, í¬ê·€ì§ˆí™˜ ë¶„ì•¼ë„ í™•ì‹¤íˆ ê±´ê°•í•œ ì†ë„ë¡œ ì„±ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë‚´ë…„ì—ë„ ì¢…ì–‘í•™ì´ ì €í¬ì™€ ê³ ê°ë“¤ì—ê²Œ ì£¼ìš” ì„±ì¥ ë™ë ¥ì´ ë  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question will come from Dan Arias with Stifel.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Stifelì˜ Dan Ariasë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Daniel Arias: Stifel, Nicolaus & Company, Incorporated, Research Division Jacob, I wanted to ask about messaging to customers as we get ready to down to AGBT here. You guys have talked pretty consistently about the fact that the labs really should focus on the full workflow and that when you look at it that way, it becomes advantageous to use Illumina products. So the question is really when and where should we look to see that in action? Will you be able to lay out for people how the economics of using Fluent plus the NovaSeq plus DRAGEN gives you a better outcome? Or do people just sort of have to figure that out for themselves? Because the idea seems logical, but I don't get the sense that customers can see it or that they can do the math that has them arriving at that conclusion. Is that something that we should expect to change here?</td><td>**Daniel Arias:** AGBTë¥¼ ì•ë‘ê³  ê³ ê°ë“¤ì—ê²Œ ì „ë‹¬í•  ë©”ì‹œì§€ì— ëŒ€í•´ ì—¬ì­¤ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. ì¼ë£¨ë¯¸ë‚˜ëŠ” ì—°êµ¬ì‹¤ë“¤ì´ ì „ì²´ ì›Œí¬í”Œë¡œìš°ì— ì§‘ì¤‘í•´ì•¼ í•˜ë©°, ê·¸ëŸ° ê´€ì ì—ì„œ ë³´ë©´ ì¼ë£¨ë¯¸ë‚˜ ì œí’ˆì„ ì‚¬ìš©í•˜ëŠ” ê²ƒì´ ìœ ë¦¬í•˜ë‹¤ê³  ê¾¸ì¤€íˆ ë§ì”€í•´ ì˜¤ì…¨ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì§ˆë¬¸ì€, ì–¸ì œ ì–´ë””ì„œ ê·¸ê²ƒì„ ì‹¤ì œë¡œ í™•ì¸í•  ìˆ˜ ìˆì„ê¹Œìš”? Fluentì™€ NovaSeq, ê·¸ë¦¬ê³  DRAGENì„ í•¨ê»˜ ì‚¬ìš©í–ˆì„ ë•Œ ë” ë‚˜ì€ ê²°ê³¼ë¥¼ ì–»ì„ ìˆ˜ ìˆë‹¤ëŠ” ê²½ì œì„±ì„ ì‚¬ëŒë“¤ì—ê²Œ ëª…í™•íˆ ì œì‹œí•  ìˆ˜ ìˆì„ê¹Œìš”? ì•„ë‹ˆë©´ ê³ ê°ë“¤ì´ ìŠ¤ìŠ¤ë¡œ ì•Œì•„ë‚´ì•¼ í•˜ëŠ” ê±´ê°€ìš”? ë…¼ë¦¬ì ìœ¼ë¡œëŠ” íƒ€ë‹¹í•´ ë³´ì´ì§€ë§Œ, ê³ ê°ë“¤ì´ ê·¸ê±¸ ì‹¤ì œë¡œ ë³¼ ìˆ˜ ìˆëŠ”ì§€, ë˜ëŠ” ê·¸ëŸ° ê²°ë¡ ì— ë„ë‹¬í•  ìˆ˜ ìˆëŠ” ê³„ì‚°ì„ í•  ìˆ˜ ìˆëŠ”ì§€ì— ëŒ€í•´ì„œëŠ” í™•ì‹ ì´ ì„œì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì´ ì•ìœ¼ë¡œ ë³€í™”í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•´ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>Jacob Thaysen: CEO, Interim Chief Commercial Officer & Director Yes, Dan, I think actually, this is the conversation we have with our customers. We are looking forward here also to the AGBT conference coming up in a few weeks, where, as I mentioned also in the prepared remarks, we have the Gold sponsorship, which gives us a great platform to speak to, not only us, but also key opinion leaders to speak to the usage of the different technologies and how to think about them from the highest quality insight with the lowest end-to-end. Obviously, a part of that is to also show that you can actually do this in a more cost-efficient way but also creating the highest quality insight. So it depends a little bit on the different assays. If you think about our constellation mapped read, where you have really no hands-on on the workflow upfront and you receive a lot of insights with very little workflow -- hands-on on the workflow. So I think that is one element where you can start to eliminate the cost of library prep out and also getting much more insight out. So it's a good example of how you can think about that, where you will actually have great transparency on the pricing from our end because it's really just the cost of sequencing where others have to also do library prep and other things. So that's one example, and we'll talk more about that at AGBT. But the same goes now with the SomaLogic business we just acquired, where we will go out there and present the cost per sample, the cost per experiment, which I think will be another one that is going to be very important. So those conversations are already happening with the customers. We will continue to educate all of you on that also.</td><td>**Jacob Thaysen:** ë„¤, Dan, ì‹¤ì œë¡œ ì´ê²ƒì´ ìš°ë¦¬ê°€ ê³ ê°ë“¤ê³¼ ë‚˜ëˆ„ê³  ìˆëŠ” ëŒ€í™”ì…ë‹ˆë‹¤. ëª‡ ì£¼ í›„ì— ì—´ë¦¬ëŠ” AGBT ì»¨í¼ëŸ°ìŠ¤ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆëŠ”ë°ìš”, ì œê°€ ë°œí‘œ ë‚´ìš©ì—ì„œë„ ì–¸ê¸‰í–ˆë“¯ì´ ìš°ë¦¬ëŠ” ê³¨ë“œ ìŠ¤í°ì„œì‹­ì„ í™•ë³´í–ˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ìš°ë¦¬ë¿ë§Œ ì•„ë‹ˆë¼ ì£¼ìš” ì˜¤í”¼ë‹ˆì–¸ ë¦¬ë”ë“¤ì´ ë‹¤ì–‘í•œ ê¸°ìˆ ì˜ í™œìš© ë°©ì•ˆê³¼ ìµœê³  í’ˆì§ˆì˜ ì¸ì‚¬ì´íŠ¸ë¥¼ ê°€ì¥ ë‚®ì€ ì—”ë“œíˆ¬ì—”ë“œ ë¹„ìš©ìœ¼ë¡œ ì–»ëŠ” ë°©ë²•ì— ëŒ€í•´ ë…¼ì˜í•  ìˆ˜ ìˆëŠ” í›Œë¥­í•œ í”Œë«í¼ì„ ê°–ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì´ ê³¼ì •ì—ì„œ ë” ë¹„ìš© íš¨ìœ¨ì ì¸ ë°©ì‹ìœ¼ë¡œ ìµœê³  í’ˆì§ˆì˜ ì¸ì‚¬ì´íŠ¸ë¥¼ ì°½ì¶œí•  ìˆ˜ ìˆë‹¤ëŠ” ì ë„ ë³´ì—¬ë“œë¦´ ê²ƒì…ë‹ˆë‹¤. ë‹¤ë§Œ ì´ëŠ” ê°ê¸° ë‹¤ë¥¸ ë¶„ì„ë²•(assay)ì— ë”°ë¼ ì¡°ê¸ˆì”© ë‹¬ë¼ì§‘ë‹ˆë‹¤. ìš°ë¦¬ì˜ ì»¨ìŠ¤í…”ë ˆì´ì…˜ ë§µë“œ ë¦¬ë“œ(Constellation mapped read)ë¥¼ ìƒê°í•´ë³´ì‹œë©´, ì›Œí¬í”Œë¡œìš° ì´ˆê¸° ë‹¨ê³„ì—ì„œ ì‹¤ì§ˆì ìœ¼ë¡œ ì†ì´ ê°€ëŠ” ì‘ì—…ì´ ê±°ì˜ ì—†ê³ , ì›Œí¬í”Œë¡œìš°ì— ëŒ€í•œ ìˆ˜ì‘ì—…ì„ ìµœì†Œí™”í•˜ë©´ì„œë„ ë§ì€ ì¸ì‚¬ì´íŠ¸ë¥¼ ì–»ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë¼ì´ë¸ŒëŸ¬ë¦¬ ì¤€ë¹„(library prep) ë¹„ìš©ì„ ì œê±°í•  ìˆ˜ ìˆëŠ” í•œ ê°€ì§€ ìš”ì†Œì´ë©°, ë™ì‹œì— í›¨ì”¬ ë” ë§ì€ ì¸ì‚¬ì´íŠ¸ë¥¼ ì–»ì„ ìˆ˜ ìˆëŠ” ë°©ë²•ì…ë‹ˆë‹¤. <br><br>ì´ëŠ” ê°€ê²© ì¸¡ë©´ì—ì„œ ì–´ë–»ê²Œ ìƒê°í•  ìˆ˜ ìˆëŠ”ì§€ë¥¼ ë³´ì—¬ì£¼ëŠ” ì¢‹ì€ ì‚¬ë¡€ì…ë‹ˆë‹¤. ìš°ë¦¬ ì¸¡ì—ì„œëŠ” ê°€ê²©ì— ëŒ€í•œ íˆ¬ëª…ì„±ì´ ë§¤ìš° ë†’ìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì‹¤ì œë¡œëŠ” ì‹œí€€ì‹± ë¹„ìš©ë§Œ ë°œìƒí•˜ëŠ” ë°˜ë©´, ë‹¤ë¥¸ ì—…ì²´ë“¤ì€ ë¼ì´ë¸ŒëŸ¬ë¦¬ ì¤€ë¹„ ë° ê¸°íƒ€ ì‘ì—…ë“¤ë„ ìˆ˜í–‰í•´ì•¼ í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ê²ƒì´ í•œ ê°€ì§€ ì˜ˆì‹œì´ê³ , AGBTì—ì„œ ì´ì— ëŒ€í•´ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ê°€ ë°©ê¸ˆ ì¸ìˆ˜í•œ SomaLogic ì‚¬ì—…ë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìƒ˜í”Œë‹¹ ë¹„ìš©, ì‹¤í—˜ë‹¹ ë¹„ìš©ì„ ì œì‹œí•  ê²ƒì´ë©°, ì´ê²ƒì´ ë§¤ìš° ì¤‘ìš”í•œ ë˜ ë‹¤ë¥¸ ìš”ì†Œê°€ ë  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ëŒ€í™”ëŠ” ì´ë¯¸ ê³ ê°ë“¤ê³¼ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ê»˜ë„ ê³„ì†í•´ì„œ ì´ ë¶€ë¶„ì— ëŒ€í•´ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question will come from Jack Meehan with Nephron.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Nephronì˜ Jack Meehanë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Nephron Research LLC: I wanted to build on Dan's question there, just continuing on the path of AGBT. It seems like on the competitive front, at least one competitor has talked about the $100 price point per genome. I understand you're trying to change the conversation around that. But I was just curious like if investors see headlines like that, what does that mean for you? I'm not sure how -- we know you list pricing, but there's discounts to that. Like can you just talk about what that would mean for Illumina if we start to see those headlines?</td><td>**Nephron Research LLC:** AGBT ê´€ë ¨í•´ì„œ Danì˜ ì§ˆë¬¸ì— ì´ì–´ì„œ ì¡°ê¸ˆ ë” ì—¬ì­¤ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. ê²½ìŸ ì¸¡ë©´ì—ì„œ ë³´ë©´, ì ì–´ë„ í•œ ê²½ìŸì‚¬ê°€ ê²Œë†ˆë‹¹ 100ë‹¬ëŸ¬ ê°€ê²©ëŒ€ì— ëŒ€í•´ ì–¸ê¸‰í•œ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·€ì‚¬ê°€ ì´ëŸ° ë…¼ì˜ì˜ ë°©í–¥ì„ ë°”ê¾¸ë ¤ê³  ë…¸ë ¥í•˜ê³  ê³„ì‹  ê±´ ì´í•´í•˜ì§€ë§Œ, íˆ¬ììë“¤ì´ ê·¸ëŸ° í—¤ë“œë¼ì¸ì„ ì ‘í–ˆì„ ë•Œ ì¼ë£¨ë¯¸ë‚˜ì—ê²Œ ì–´ë–¤ ì˜ë¯¸ì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·€ì‚¬ì˜ ì •ê°€ëŠ” ì•Œê³  ìˆì§€ë§Œ ê±°ê¸°ì— í• ì¸ì´ ì ìš©ë˜ëŠ” ê±¸ë¡œ ì•„ëŠ”ë°, ê·¸ëŸ° í—¤ë“œë¼ì¸ë“¤ì´ ë‚˜ì˜¤ê¸° ì‹œì‘í•˜ë©´ ì¼ë£¨ë¯¸ë‚˜ì— ì–´ë–¤ ì˜ë¯¸ê°€ ìˆì„ì§€ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Jacob Thaysen: CEO, Interim Chief Commercial Officer & Director Yes. I think we are looking forward to AGBT. I think that it will be the conference, of course, that all our competitors will put their best foot forward. We will do the same. As I've mentioned, our customers are thinking way beyond just one parameter, one feature. They are more sophisticated than just looking at one element. So I think you will see also us really highlighting some of the things that our customers are really excited about from the whole workflow perspective. That said, I would say that we feel we have the portfolio, we have the pipeline. We have the capability to compete on all parameters. So I feel really good about who we are and what we can do. And obviously, if there are opportunities for us to address market segments with a different price point, where there's a significant number of elasticity, we are all for it. And we have those conversations with our customers on a regular basis, and we'll continue to do so.</td><td>**Jacob Thaysen:** ë„¤, AGBTë¥¼ ì •ë§ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¹ì—°íˆ ëª¨ë“  ê²½ìŸì‚¬ë“¤ì´ ìµœì„ ì„ ë‹¤í•´ ì¤€ë¹„í•  ì»¨í¼ëŸ°ìŠ¤ê°€ ë  ê²ƒì´ê³ , ì €í¬ë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ë§ì”€ë“œë ¸ë“¯ì´, ê³ ê°ë“¤ì€ ë‹¨ìˆœíˆ í•˜ë‚˜ì˜ íŒŒë¼ë¯¸í„°ë‚˜ ê¸°ëŠ¥ë§Œì„ ë„˜ì–´ì„œ í›¨ì”¬ ë” í­ë„“ê²Œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¨ì¼ ìš”ì†Œë§Œ ë³´ëŠ” ê²ƒë³´ë‹¤ í›¨ì”¬ ë” ì •êµí•œ ì‹œê°ì„ ê°€ì§€ê³  ê³„ì‹­ë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ë„ ì „ì²´ ì›Œí¬í”Œë¡œìš° ê´€ì ì—ì„œ ê³ ê°ë“¤ì´ ì •ë§ í¥ë¯¸ë¡œì›Œí•˜ëŠ” ë¶€ë¶„ë“¤ì„ ì§‘ì¤‘ì ìœ¼ë¡œ ë¶€ê°ì‹œí‚¬ ì˜ˆì •ì…ë‹ˆë‹¤. <br><br>ê·¸ë ‡ê¸´ í•˜ì§€ë§Œ, ì €í¬ëŠ” í¬íŠ¸í´ë¦¬ì˜¤ë„ ê°–ì¶”ê³  ìˆê³ , íŒŒì´í”„ë¼ì¸ë„ ìˆìœ¼ë©°, ëª¨ë“  íŒŒë¼ë¯¸í„°ì—ì„œ ê²½ìŸí•  ìˆ˜ ìˆëŠ” ì—­ëŸ‰ì„ ë³´ìœ í•˜ê³  ìˆë‹¤ê³  ìì‹ í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ê°€ ëˆ„êµ¬ì´ê³  ë¬´ì—‡ì„ í•  ìˆ˜ ìˆëŠ”ì§€ì— ëŒ€í•´ ì •ë§ ìì‹ ê°ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ê°€ê²©ëŒ€ë¥¼ ë‹¬ë¦¬í•´ì„œ ì‹œì¥ ì„¸ê·¸ë¨¼íŠ¸ë¥¼ ê³µëµí•  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ìˆê³ , ìƒë‹¹í•œ ìˆ˜ìš” íƒ„ë ¥ì„±ì´ ì¡´ì¬í•˜ëŠ” ê²½ìš°ë¼ë©´ ì €í¬ëŠ” ì ê·¹ì ìœ¼ë¡œ ê²€í† í•  ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë…¼ì˜ëŠ” ê³ ê°ë“¤ê³¼ ì •ê¸°ì ìœ¼ë¡œ ì§„í–‰í•˜ê³  ìˆìœ¼ë©°, ì•ìœ¼ë¡œë„ ê³„ì† ì´ì–´ê°ˆ ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question will come from Casey Woodring with JPMorgan.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ JPëª¨ê±´ì˜ Casey Woodringì´ í•˜ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Casey Woodring: JPMorgan Chase & Co, Research Division So I guess you said you would revisit your China assumptions as you work with the government on imports. Maybe just walk us through how conversations are going there and the range of outcomes. And then my follow-up is just on BioInsight. I was hoping you could elaborate on some of the comments you made earlier there, just given how much airtime AI is getting currently. Curious how you plan to monetize these capabilities over time, the level of enthusiasm you're seeing from pharma customers and any sort of way to quantify the revenue opportunity over the next few years?</td><td>**Casey Woodring:** ì¤‘êµ­ ê°€ì •ì— ëŒ€í•´ì„œëŠ” ì •ë¶€ì™€ ìˆ˜ì… ê´€ë ¨ ë…¼ì˜ë¥¼ ì§„í–‰í•˜ë©´ì„œ ì¬ê²€í† í•˜ê² ë‹¤ê³  ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. í˜„ì¬ ì •ë¶€ì™€ì˜ ëŒ€í™”ê°€ ì–´ë–»ê²Œ ì§„í–‰ë˜ê³  ìˆëŠ”ì§€, ê·¸ë¦¬ê³  ê°€ëŠ¥í•œ ê²°ê³¼ì˜ ë²”ìœ„ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? <br><br>ê·¸ë¦¬ê³  í›„ì† ì§ˆë¬¸ì€ BioInsightì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. í˜„ì¬ AIê°€ ë§ì€ ì£¼ëª©ì„ ë°›ê³  ìˆëŠ” ìƒí™©ì—ì„œ, ì•ì„œ ë§ì”€í•˜ì‹  ë‚´ìš©ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œë©´ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤. ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì´ëŸ¬í•œ ì—­ëŸ‰ì„ ì–´ë–»ê²Œ ìˆ˜ìµí™”í•  ê³„íšì´ì‹ ì§€, ì œì•½ ê³ ê°ë“¤ë¡œë¶€í„° ë°›ê³  ìˆëŠ” ë°˜ì‘ì´ ì–´ëŠ ì •ë„ì¸ì§€, ê·¸ë¦¬ê³  í–¥í›„ ëª‡ ë…„ê°„ ë§¤ì¶œ ê¸°íšŒë¥¼ ìˆ˜ì¹˜í™”í•  ìˆ˜ ìˆëŠ” ë°©ë²•ì´ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Jacob Thaysen: CEO, Interim Chief Commercial Officer & Director Yes. Thanks, Casey. So for the first -- thanks for the questions on China here. So we -- as just a reminder, it's still less than 5% of our business. I'm actually very pleased with what Jenny and the team have been able to do, our General Manager in China and the Chinese team have been able to serve our customers over the past year and continue to do so. As we have also updated all of you on over the last period of time, we have had great conversations and collaboration with the Chinese regulators to ensure that we can continue to run our business in China. While we're still on the UEL, we feel good about our relationship and how we can work through to be able to import or export instruments back into China. Now of course, when you, for a long period of time, have not sold an instrument, it takes time to build up a funnel again. And I think that's more the reflection of what we're seeing right now. But as Ankur mentioned also, we have a target for China, but I think if we -- if there's a way to get off the list or see improvements in that, I think there's upside to the China business. But we do believe that we have a good line of sight at least to '26 at this point. If you think about the BioInsight business, we're very excited about the opportunity. It's still in the early days. But as we came out presenting the $1 billion -- excuse me, 1 Billion Cell Atlas here at JPMorgan, and it was very well received. As I mentioned also, there has been a lot of conversation with pharma companies that wants to get access to the Cell Atlas. It provides deep insight for the drug discovery for them to choose the right targets to work on. So we clearly see momentum in that space. As we mentioned also earlier, we do believe that this will, together with our multiomics business start to create at least a 1% to 2% growth in '27, but we think that, that will actually be an accelerating momentum at this point. Ankur, maybe you have more to share.</td><td>**Jacob Thaysen:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Casey. ì¤‘êµ­ ê´€ë ¨ ì§ˆë¬¸ ì£¼ì…”ì„œ ê³ ë§™ìŠµë‹ˆë‹¤. ë¨¼ì € ë§ì”€ë“œë¦¬ë©´, ì¤‘êµ­ ì‚¬ì—…ì€ ì—¬ì „íˆ ì „ì²´ ë§¤ì¶œì˜ 5% ë¯¸ë§Œì…ë‹ˆë‹¤. Jennyì™€ ì¤‘êµ­ íŒ€, ê·¸ë¦¬ê³  ì¤‘êµ­ ì´ê´„ ë§¤ë‹ˆì €ê°€ ì§€ë‚œ 1ë…„ê°„ ê³ ê°ë“¤ì—ê²Œ ì œê³µí•œ ì„œë¹„ìŠ¤ì™€ í˜„ì¬ê¹Œì§€ ì´ì–´ì§€ê³  ìˆëŠ” ì„±ê³¼ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ê·¸ë™ì•ˆ ì—¬ëŸ¬ë¶„ê»˜ ì§€ì†ì ìœ¼ë¡œ ì—…ë°ì´íŠ¸í•´ë“œë¦° ë°”ì™€ ê°™ì´, ì¤‘êµ­ì—ì„œ ì‚¬ì—…ì„ ê³„ì† ìš´ì˜í•  ìˆ˜ ìˆë„ë¡ ì¤‘êµ­ ê·œì œ ë‹¹êµ­ê³¼ í›Œë¥­í•œ ëŒ€í™”ì™€ í˜‘ë ¥ì„ ì§„í–‰í•´ì™”ìŠµë‹ˆë‹¤. ì•„ì§ UEL(ë¯¸ê²€ì¦ ë¦¬ìŠ¤íŠ¸)ì— ë“±ì¬ë˜ì–´ ìˆì§€ë§Œ, ì¤‘êµ­ê³¼ì˜ ê´€ê³„ì— ëŒ€í•´ ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìœ¼ë©°, ì¤‘êµ­ìœ¼ë¡œ ì¥ë¹„ë¥¼ ìˆ˜ì¶œì…í•  ìˆ˜ ìˆëŠ” ë°©ì•ˆì„ í•¨ê»˜ ëª¨ìƒ‰í•´ë‚˜ê°ˆ ìˆ˜ ìˆë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤. ë¬¼ë¡  ì¥ê¸°ê°„ ì¥ë¹„ë¥¼ íŒë§¤í•˜ì§€ ëª»í–ˆì„ ë•ŒëŠ” ë‹¤ì‹œ íŒŒì´í”„ë¼ì¸ì„ êµ¬ì¶•í•˜ëŠ” ë° ì‹œê°„ì´ ê±¸ë¦½ë‹ˆë‹¤. ì§€ê¸ˆ ìš°ë¦¬ê°€ ë³´ê³  ìˆëŠ” ìƒí™©ì´ ë°”ë¡œ ê·¸ëŸ° ê²ƒì„ ë°˜ì˜í•˜ëŠ” ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ Ankurê°€ ì–¸ê¸‰í–ˆë“¯ì´, ì¤‘êµ­ì— ëŒ€í•œ ëª©í‘œì¹˜ëŠ” ìˆì§€ë§Œ, ë§Œì•½ ë¦¬ìŠ¤íŠ¸ì—ì„œ ì œì™¸ë˜ê±°ë‚˜ ìƒí™©ì´ ê°œì„ ëœë‹¤ë©´ ì¤‘êµ­ ì‚¬ì—…ì—ëŠ” ìƒìŠ¹ ì—¬ë ¥ì´ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ë‹¤ë§Œ í˜„ ì‹œì ì—ì„œ ìµœì†Œí•œ 26ë…„ê¹Œì§€ëŠ” ì¶©ë¶„íˆ ê°€ì‹œì„±ì„ í™•ë³´í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. BioInsight ì‚¬ì—…ì˜ ê²½ìš°, ê·¸ ê¸°íšŒì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•„ì§ ì´ˆê¸° ë‹¨ê³„ì´ê¸´ í•˜ì§€ë§Œ, JPëª¨ê±´ ì»¨í¼ëŸ°ìŠ¤ì—ì„œ 10ì–µ ì„¸í¬ ì•„í‹€ë¼ìŠ¤(1 Billion Cell Atlas)ë¥¼ ë°œí‘œí–ˆì„ ë•Œ ë°˜ì‘ì´ ë§¤ìš° ì¢‹ì•˜ìŠµë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, Cell Atlasì— ì ‘ê·¼í•˜ê³ ì í•˜ëŠ” ì œì•½íšŒì‚¬ë“¤ê³¼ ë§ì€ ë…¼ì˜ê°€ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ê·¸ë“¤ì´ ì‘ì—…í•  ì ì ˆí•œ íƒ€ê²Ÿì„ ì„ íƒí•˜ëŠ” ë° ìˆì–´ ì•½ë¬¼ ë°œê²¬(drug discovery)ì„ ìœ„í•œ ê¹Šì´ ìˆëŠ” ì¸ì‚¬ì´íŠ¸ë¥¼ ì œê³µí•©ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ì´ ë¶„ì•¼ì—ì„œ ë¶„ëª…í•œ ëª¨ë©˜í…€ì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´, ì´ê²ƒì´ ë©€í‹°ì˜¤ë¯¹ìŠ¤(multiomics) ì‚¬ì—…ê³¼ í•¨ê»˜ 27ë…„ì—ëŠ” ìµœì†Œ 1~2%ì˜ ì„±ì¥ì„ ì°½ì¶œí•  ê²ƒìœ¼ë¡œ ë¯¿ê³  ìˆìœ¼ë©°, í˜„ ì‹œì ì—ì„œ ì‹¤ì œë¡œ ê°€ì†í™”ë˜ëŠ” ëª¨ë©˜í…€ì´ ë  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. Ankur, ì¶”ê°€ë¡œ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Chief Financial Officer: Yes. On BioInsight, a couple of more things, as Jacob was saying, we do think -- our intention on BioInsight is to work directly with our pharma customers and effectively adding a third customer base here. And we think we take a 5-year view, that's a very meaningful opportunity. The billion Cell Atlas has been received very well and the interest since the conference has been tremendous. So we're very pleased with some of the early steps that we've taken here. The monetization strategy here would be in 2 or 3 different ways. One is around very specialized data and AI tool constructions. And then over time, we see significant subscription-based models where we can help pharma companies, both on the discovery as well as on the development side of things. But that's a multiyear opportunity there.</td><td>**Chief Financial Officer:** ë„¤, BioInsightì— ëŒ€í•´ ëª‡ ê°€ì§€ ë” ë§ì”€ë“œë¦¬ìë©´, Jacobì´ ì–¸ê¸‰í–ˆë“¯ì´ ì €í¬ëŠ” ì œì•½ì‚¬ ê³ ê°ë“¤ê³¼ ì§ì ‘ í˜‘ë ¥í•˜ì—¬ ì‚¬ì‹¤ìƒ ì„¸ ë²ˆì§¸ ê³ ê° ê¸°ë°˜ì„ ì¶”ê°€í•˜ë ¤ëŠ” ì˜ë„ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  5ë…„ ì •ë„ì˜ ê´€ì ì—ì„œ ë³´ë©´ ì´ê²ƒì´ ë§¤ìš° ì˜ë¯¸ ìˆëŠ” ê¸°íšŒë¼ê³  ìƒê°í•©ë‹ˆë‹¤. 10ì–µ ì„¸í¬ ì•„í‹€ë¼ìŠ¤(Billion Cell Atlas)ëŠ” ë§¤ìš° ì¢‹ì€ ë°˜ì‘ì„ ì–»ì—ˆê³ , ì»¨í¼ëŸ°ìŠ¤ ì´í›„ ê´€ì‹¬ì´ ì—„ì²­ë‚¬ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ê°€ ì—¬ê¸°ì„œ ì·¨í•œ ì´ˆê¸° ì¡°ì¹˜ë“¤ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì—¬ê¸°ì„œì˜ ìˆ˜ìµí™” ì „ëµì€ 2~3ê°€ì§€ ë°©ì‹ì´ ë  ê²ƒì…ë‹ˆë‹¤. í•˜ë‚˜ëŠ” ë§¤ìš° íŠ¹í™”ëœ ë°ì´í„°ì™€ AI íˆ´ êµ¬ì¶•ê³¼ ê´€ë ¨ëœ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì œì•½ì‚¬ë“¤ì´ ì‹ ì•½ ë°œê²¬ë¿ë§Œ ì•„ë‹ˆë¼ ê°œë°œ ì¸¡ë©´ì—ì„œë„ ë„ì›€ì„ ë°›ì„ ìˆ˜ ìˆëŠ” ìƒë‹¹í•œ ê·œëª¨ì˜ êµ¬ë… ê¸°ë°˜ ëª¨ë¸(subscription-based model)ì„ ë³´ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ê·¸ê²ƒì€ ìˆ˜ë…„ì— ê±¸ì¹œ ê¸°íšŒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question will come from Dave Westenberg with Piper Sandler.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Piper Sandlerì˜ Dave Westenbergë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Westenberg: Piper Sandler & Co., Research Division Can you discuss the conversations you're having with academic core labs in terms of investments in instruments? I have to imagine you were -- they weren't the biggest buyers of instruments in 2025. What are the assumptions in your guidance for academic, both consumables and instruments? And you did hire Eric Green. So is there anything he can do to spur kind of confidence in your academics? I know the NIH is slightly up. Are they going to actually believe it? And sorry, I'm going to tag one more on to Jack and Dan's question on pricing versus competitors. You are seeing much better specs, I believe, which means more output. That is a direct cost reduction to a lot of your customers in terms of cost per G, right? So even if they're getting 25p at $200, they're actually getting less than that because the output has been greater. And I just want to ask if that assumption is correct.</td><td>**David Westenberg:** í•™ê³„ í•µì‹¬ ì—°êµ¬ì‹¤ë“¤ê³¼ ì¥ë¹„ íˆ¬ì ê´€ë ¨í•´ì„œ ì–´ë–¤ ëŒ€í™”ë¥¼ ë‚˜ëˆ„ê³  ê³„ì‹ ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? 2025ë…„ì— í•™ê³„ê°€ ì¥ë¹„ì˜ ìµœëŒ€ êµ¬ë§¤ìëŠ” ì•„ë‹ˆì—ˆì„ ê²ƒìœ¼ë¡œ ìƒê°ë©ë‹ˆë‹¤. í•™ê³„ ê´€ë ¨í•´ì„œ ì†Œëª¨í’ˆê³¼ ì¥ë¹„ ëª¨ë‘ì— ëŒ€í•œ ê°€ì´ë˜ìŠ¤ ê°€ì •ì€ ì–´ë–»ê²Œ ë˜ë‚˜ìš”? ê·¸ë¦¬ê³  Eric Greenì„ ì˜ì…í•˜ì…¨ëŠ”ë°, ê·¸ê°€ í•™ê³„ì˜ ì‹ ë¢°ë¥¼ ë†’ì´ëŠ” ë° ê¸°ì—¬í•  ìˆ˜ ìˆëŠ” ë¶€ë¶„ì´ ìˆì„ê¹Œìš”? NIH ì˜ˆì‚°ì´ ì†Œí­ ì¦ê°€í•œ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆëŠ”ë°, í•™ê³„ì—ì„œ ì‹¤ì œë¡œ ì´ë¥¼ ë¯¿ê³  íˆ¬ìí• ê¹Œìš”? ê·¸ë¦¬ê³  ì£„ì†¡í•˜ì§€ë§Œ Jackê³¼ Danì˜ ì§ˆë¬¸ì— í•˜ë‚˜ ë” ì¶”ê°€í•˜ìë©´, ê²½ìŸì‚¬ ëŒ€ë¹„ ê°€ê²© ì±…ì • ê´€ë ¨í•´ì„œìš”. ê·€ì‚¬ì˜ ì‚¬ì–‘ì´ í›¨ì”¬ ë” ìš°ìˆ˜í•œ ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë°, ì´ëŠ” ë” ë§ì€ ì‚°ì¶œëŸ‰ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì´ê²ƒì€ ë§ì€ ê³ ê°ë“¤ì—ê²Œ Gë‹¹ ë¹„ìš© ì¸¡ë©´ì—ì„œ ì§ì ‘ì ì¸ ë¹„ìš© ì ˆê° íš¨ê³¼ê°€ ìˆì§€ ì•ŠìŠµë‹ˆê¹Œ? ë”°ë¼ì„œ 200ë‹¬ëŸ¬ì— 25pë¥¼ ë°›ëŠ”ë‹¤ê³  í•´ë„, ì‹¤ì œë¡œëŠ” ìƒì‚°ëŸ‰ì´ ë” ë§ê¸° ë•Œë¬¸ì— ê·¸ë³´ë‹¤ ì ê²Œ ë°›ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ ê°€ì •ì´ ë§ëŠ”ì§€ í™•ì¸í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jacob Thaysen: CEO, Interim Chief Commercial Officer & Director So Dave, thank you for your one question. Let me start with the first one here on -- we have, I think, over the last 18 months, really built out our relationship with the academic core labs and really focusing on ensuring that we can support them also, of course, in a very tough environment. So obviously, they have been challenged with, of course, the impact from NIH funding and other types of funding. But we have done a very good job, I think, and that's also the feedback we're getting from them to support both from when they have opportunities to acquire instruments, we have made sure that we can place access in those types of labs also so they can get all the benefit from the access. And I do think now with Dr. Eric Green on board here, there's more opportunities for help them and navigate also through a challenging situation. As we said, and you also mentioned, at least now we have better line of sight to NIH funding, but there's still some -- in the detail still things that needs to get into place before we really start to see the different institutes, the different collabs continue to move ahead. You are right that if you look at -- we have, and this is our -- we have a tradition for going out and deliver on par or better than our specs. This is something we're proud of and something that our customers know from Illumina is that we are not going out and commit to something we can't keep. We will actually keep it and also overperform. And I think that is something that many could learn from. So we will continue to do so. And in the meantime, customers are enjoying those benefits.</td><td>**Jacob Thaysen:** ë°ì´ë¸Œ, í•œ ê°€ì§€ ì§ˆë¬¸ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì²« ë²ˆì§¸ ì§ˆë¬¸ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì§€ë‚œ 18ê°œì›” ë™ì•ˆ í•™ìˆ  ì½”ì–´ë©(academic core labs)ë“¤ê³¼ì˜ ê´€ê³„ë¥¼ ì •ë§ ë§ì´ êµ¬ì¶•í•´ì™”ìŠµë‹ˆë‹¤. íŠ¹íˆ ì´ë“¤ì´ ë§¤ìš° ì–´ë ¤ìš´ í™˜ê²½ì—ì„œë„ ìš°ë¦¬ê°€ ì§€ì›í•  ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ë° ì§‘ì¤‘í–ˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì´ë“¤ì€ NIH í€ë”©ê³¼ ë‹¤ë¥¸ ìœ í˜•ì˜ í€ë”© ì˜í–¥ìœ¼ë¡œ ì–´ë ¤ì›€ì„ ê²ªì–´ì™”ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ëŠ” ì •ë§ ì˜ í•´ëƒˆë‹¤ê³  ìƒê°í•˜ê³ , ì‹¤ì œë¡œ ê·¸ë“¤ë¡œë¶€í„°ë„ ê·¸ëŸ° í”¼ë“œë°±ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ì¥ë¹„ë¥¼ êµ¬ë§¤í•  ê¸°íšŒê°€ ìˆì„ ë•Œë¶€í„° ì§€ì›í–ˆê³ , ì´ëŸ¬í•œ ìœ í˜•ì˜ ë©ì—ë„ ì•¡ì„¸ìŠ¤(Access) ì¥ë¹„ë¥¼ ë°°ì¹˜í•  ìˆ˜ ìˆë„ë¡ í•´ì„œ ì•¡ì„¸ìŠ¤ì˜ ëª¨ë“  ì´ì ì„ ëˆ„ë¦´ ìˆ˜ ìˆê²Œ í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§€ê¸ˆ ë°•ì‚¬ë‹˜ê³¼ í•¨ê»˜... ì—ë¦­ ê·¸ë¦°ì´ í•©ë¥˜í•˜ë©´ì„œ ê³ ê°ë“¤ì´ ì–´ë ¤ìš´ ìƒí™©ì„ í—¤ì³ë‚˜ê°ˆ ìˆ˜ ìˆë„ë¡ ë„ìš¸ ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ë” ë§ì•„ì¡ŒìŠµë‹ˆë‹¤. ë§ì”€ë“œë ¸ë“¯ì´, ê·¸ë¦¬ê³  ì–¸ê¸‰í•˜ì‹  ê²ƒì²˜ëŸ¼, ì ì–´ë„ ì§€ê¸ˆì€ NIH í€ë”©ì— ëŒ€í•œ ê°€ì‹œì„±ì´ ë” ì¢‹ì•„ì¡ŒìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì—¬ì „íˆ ì„¸ë¶€ì ìœ¼ë¡œëŠ” ì—¬ëŸ¬ ì—°êµ¬ì†Œë“¤ê³¼ ë‹¤ì–‘í•œ í˜‘ë ¥ í”„ë¡œì íŠ¸ë“¤ì´ ì‹¤ì œë¡œ ì§„í–‰ë˜ê¸° ì „ì— ì œìë¦¬ë¥¼ ì¡ì•„ì•¼ í•  ë¶€ë¶„ë“¤ì´ ìˆìŠµë‹ˆë‹¤.<br><br>ë§ì”€í•˜ì‹  ëŒ€ë¡œ, ìš°ë¦¬ê°€ ë³´ë©´ - ì´ê±´ ìš°ë¦¬ì˜ ì „í†µì¸ë°ìš” - ìš°ë¦¬ëŠ” ìŠ¤í™ê³¼ ë™ë“±í•˜ê±°ë‚˜ ê·¸ ì´ìƒì˜ ì„±ê³¼ë¥¼ ë‚´ëŠ” ê²ƒì„ ì „í†µìœ¼ë¡œ ì‚¼ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ ìš°ë¦¬ê°€ ìë‘ìŠ¤ëŸ½ê²Œ ì—¬ê¸°ëŠ” ë¶€ë¶„ì´ê³ , ì¼ë£¨ë¯¸ë‚˜ì˜ ê³ ê°ë“¤ì´ ì˜ ì•Œê³  ìˆëŠ” ì ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì§€í‚¬ ìˆ˜ ì—†ëŠ” ì•½ì†ì„ í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ì•½ì†ì„ ì§€í‚¤ê³  ê·¸ ì´ìƒì˜ ì„±ê³¼ë¥¼ ëƒ…ë‹ˆë‹¤. ì´ê²ƒì€ ë§ì€ ê¸°ì—…ë“¤ì´ ë°°ì›Œì•¼ í•  ì ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì•ìœ¼ë¡œë„ ê³„ì† ê·¸ë ‡ê²Œ í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¸ ì‚¬ì´ì— ê³ ê°ë“¤ì€ ì´ëŸ¬í•œ í˜œíƒì„ ëˆ„ë¦¬ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question will come from Subbu Nambi with Guggenheim.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ êµ¬ê²í•˜ì„ì˜ ìˆ˜ë¶€ ë‚¨ë¹„ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Subhalaxmi Nambi: Guggenheim Securities, LLC, Research Division It appears that NovaSeq 6000 pull-through is holding up a lot better than expected. Has that leveled off moving forward? Or is that still a material headwind? And then my separate question is, there has been a lot of focus on U.S. clinical strength for good reasons. But can you speak to how Europe and Asia might look this year from a growth perspective? And are there any differences you would expect from the U.S. market throughout this year?</td><td>**Subhalaxmi Nambi:** NovaSeq 6000ì˜ í’€ìŠ¤ë£¨(pull-through)ê°€ ì˜ˆìƒë³´ë‹¤ í›¨ì”¬ ì˜ ìœ ì§€ë˜ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì•ìœ¼ë¡œ ì´ ìˆ˜ì¤€ì´ ì•ˆì •í™”ë  ê²ƒì¸ê°€ìš”, ì•„ë‹ˆë©´ ì—¬ì „íˆ ìƒë‹¹í•œ ì—­í’ ìš”ì¸ìœ¼ë¡œ ì‘ìš©í• ê¹Œìš”? ê·¸ë¦¬ê³  ë³„ë„ì˜ ì§ˆë¬¸ìœ¼ë¡œ, ë¯¸êµ­ ì„ìƒ ë¶€ë¬¸ì˜ ê°•ì„¸ì— ë§ì€ ê´€ì‹¬ì´ ì§‘ì¤‘ë˜ê³  ìˆëŠ”ë° ì¶©ë¶„í•œ ì´ìœ ê°€ ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ìœ ëŸ½ê³¼ ì•„ì‹œì•„ ì‹œì¥ì˜ ì„±ì¥ ì „ë§ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ê·¸ë¦¬ê³  ì˜¬í•´ ë¯¸êµ­ ì‹œì¥ê³¼ ë¹„êµí•´ ì–´ë–¤ ì°¨ì´ì ì„ ì˜ˆìƒí•˜ì‹œëŠ”ì§€ìš”?</td></tr>
<tr><td>Jacob Thaysen: CEO, Interim Chief Commercial Officer & Director Yes. So Subbu, let me start on the 6000. And what you are seeing is that and we've spoken to that before that many of our customers that are transitioning is either building their new assays on the X platform. And then they keep the NovaSeq 6000 for their traditional assays that are already built, they have already validated, and they want to keep that. So that's also what you're seeing, the customers that have decided to stay with assays on the platform, keep running those assays on that platform, and that's why we continue to see up a pull-through. There's, of course, customers that have shifted away from the 6000 and is now moving on to the X, and they are seeing substantial growth on the X platform. So that's why we're seeing the pull-through continue to be sitting up there. But we still believe, of course, that there will be fewer and fewer 6000 customers over time. What was another question? Geography. Yes, I mean, Europe have done tremendously well, I think, holding up very nice growth over the past years. And we expect that to continue here into 2026. And we also expect that our APAC region and EMEA region will rebound somewhat.</td><td>**Jacob Thaysen:** ë„¤, Subbu, 6000 ê´€ë ¨ ì§ˆë¬¸ë¶€í„° ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í˜„ì¬ ë³´ì‹œëŠ” ìƒí™©ì€ ì´ì „ì—ë„ ë§ì”€ë“œë¦° ë°” ìˆëŠ”ë°, ì „í™˜ ì¤‘ì¸ ë§ì€ ê³ ê°ë“¤ì´ X í”Œë«í¼ì—ì„œ ìƒˆë¡œìš´ ë¶„ì„ë²•(assay)ì„ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  NovaSeq 6000ì€ ì´ë¯¸ êµ¬ì¶•ë˜ê³  ê²€ì¦ì´ ì™„ë£Œëœ ê¸°ì¡´ ë¶„ì„ë²•ì„ ìœ„í•´ ê³„ì† ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë”°ë¼ì„œ í•´ë‹¹ í”Œë«í¼ì—ì„œ ë¶„ì„ë²•ì„ ê³„ì† ì‚¬ìš©í•˜ê¸°ë¡œ ê²°ì •í•œ ê³ ê°ë“¤ì€ ê·¸ í”Œë«í¼ì—ì„œ ê³„ì† ë¶„ì„ì„ ì‹¤í–‰í•˜ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ ì§€ì†ì ìœ¼ë¡œ í’€ìŠ¤ë£¨(pull-through) ì¦ê°€ë¥¼ ë³´ê³  ìˆëŠ” ì´ìœ ì…ë‹ˆë‹¤. ë¬¼ë¡  6000ì—ì„œ ë²—ì–´ë‚˜ Xë¡œ ì´ë™í•œ ê³ ê°ë“¤ë„ ìˆìœ¼ë©°, ì´ë“¤ì€ X í”Œë«í¼ì—ì„œ ìƒë‹¹í•œ ì„±ì¥ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ í’€ìŠ¤ë£¨(pull-through)ê°€ ê³„ì†í•´ì„œ ë†’ì€ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ê³  ìˆëŠ” ê²ë‹ˆë‹¤. í•˜ì§€ë§Œ ë¬¼ë¡  ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ 6000 ê³ ê°ì€ ì ì  ì¤„ì–´ë“¤ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë¥¸ ì§ˆë¬¸ì´ ë­ì˜€ì£ ? ì§€ì—­ ë§ì”€ì´ì‹œì£ . ë„¤, ìœ ëŸ½ì€ ì •ë§ í›Œë¥­í•œ ì„±ê³¼ë¥¼ ë³´ì—¬ì™”ìŠµë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë…„ê°„ ë§¤ìš° ê²¬ì¡°í•œ ì„±ì¥ì„¸ë¥¼ ìœ ì§€í•´ì™”ê³ ìš”. 2026ë…„ì—ë„ ì´ëŸ¬í•œ íë¦„ì´ ì´ì–´ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  APAC ì§€ì—­ê³¼ EMEA ì§€ì—­ë„ ì–´ëŠ ì •ë„ ë°˜ë“±í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Financial Officer: Subbu, on the 6000s and the transition, as you know, we've substantially -- on the research side, the transition is substantially complete and clinical is now moving into the latter part of the transition here. Our expectation is by the time we get to end of 2026, the 6000 transition should be mostly substantially done from a volume perspective, similar to the trends that we have been seeing. So that's how we think about it.</td><td>**Chief Financial Officer:** 6000 ì‹œë¦¬ì¦ˆì™€ ì „í™˜ì— ê´€í•´ ë§ì”€ë“œë¦¬ë©´, ì•„ì‹œë‹¤ì‹œí”¼ ì—°êµ¬ìš© ë¶„ì•¼ì—ì„œëŠ” ì „í™˜ì´ ìƒë‹¹ ë¶€ë¶„ ì™„ë£Œë˜ì—ˆê³ , ì„ìƒ ë¶„ì•¼ëŠ” í˜„ì¬ ì „í™˜ì˜ í›„ë°˜ë¶€ë¡œ ì ‘ì–´ë“¤ê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ ë§ê¹Œì§€ëŠ” ë¬¼ëŸ‰ ê´€ì ì—ì„œ 6000 ì‹œë¦¬ì¦ˆ ì „í™˜ì´ ëŒ€ë¶€ë¶„ ì™„ë£Œë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ìš°ë¦¬ê°€ ì§€ê¸ˆê¹Œì§€ ë³´ì•„ì˜¨ ì¶”ì„¸ì™€ ìœ ì‚¬í•œ íë¦„ì…ë‹ˆë‹¤. ì´ê²ƒì´ ìš°ë¦¬ê°€ ë³´ê³  ìˆëŠ” ì „ë§ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: This concludes the Q&A section of the call. I would now like to turn the call back to Conor McNamara for closing remarks.</td><td>**Operator:** ì´ê²ƒìœ¼ë¡œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì´ì œ Conor McNamaraì—ê²Œ ë§ˆë¬´ë¦¬ ë§ì”€ì„ ë¶€íƒë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Conor Noel McNamara: VP of Investor Relations Thank you for joining us today. A replay of this call will be available in the Investor section of our website. This concludes our call, and we look forward to seeing you at upcoming events.</td><td>**Conor Noel McNamara:** ì˜¤ëŠ˜ ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ë²ˆ ì»¨í¼ëŸ°ìŠ¤ ì½œì˜ ë‹¤ì‹œë“£ê¸°ëŠ” ì €í¬ ì›¹ì‚¬ì´íŠ¸ íˆ¬ìì ì„¹ì…˜ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ë‹¤ê°€ì˜¤ëŠ” í–‰ì‚¬ì—ì„œ ëµ™ê¸°ë¥¼ ê¸°ëŒ€í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: This concludes today's call. We thank you for your participation. You may disconnect at this time and have a great day.</td><td>**Operator:** ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë˜ë©°, ì¢‹ì€ í•˜ë£¨ ë³´ë‚´ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Illumina ì‹¤ì  ë°œí‘œ ìš”ì•½<br><br>## ì£¼ìš” ì¬ë¬´ ì§€í‘œ ë° ê°€ì´ë˜ìŠ¤<br>- **2026ë…„ ì˜ì—…ì´ìµë¥  ê°€ì´ë˜ìŠ¤**: 130bp ê°œì„  ëª©í‘œ, ì¤‘êµ­ ì œì™¸ ì‹œ ì•½ 24.5% ìˆ˜ì¤€ ì˜ˆìƒ (Q4 ì¢…ë£Œ ì‹œì ì€ ì´ë³´ë‹¤ ë†’ì„ ì „ë§)<br>- **2027ë…„ ì¥ê¸° ëª©í‘œ**: ê³ ê¸‰ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥  ë° 26% ì˜ì—…ì´ìµë¥  ëª©í‘œ ìœ ì§€, SomaLogic ì¸ìˆ˜ë¡œ ì¸í•œ í¬ì„ íš¨ê³¼ ì¡´ì¬í•˜ë‚˜ ì‹œë„ˆì§€ ì°½ì¶œ ë…¸ë ¥ ì¤‘<br>- **2026ë…„ ì„±ì¥ë¥  ê°€ì´ë˜ìŠ¤**: ì¤‘êµ­ ì œì™¸ 2~4% ì„±ì¥ (2025ë…„ í•˜ë°˜ê¸° í‰ê·  ê¸°ì¤€, Q3 2%, Q4 7%)<br>- **ì„ìƒ ì‚¬ì—…**: ì¤‘ë°˜ 10%ëŒ€ ì„±ì¥ ì˜ˆìƒ, ì†Œëª¨í’ˆ 20% ì„±ì¥ ëª¨ë©˜í…€ ì§€ì†<br>- **ì—°êµ¬ ë¶€ë¬¸**: NIH ì˜ˆì‚° ê°€ì‹œì„± í™•ë³´í–ˆìœ¼ë‚˜ í•™ìˆ  ì—°êµ¬ í™˜ê²½ì€ ì—¬ì „íˆ ë¶ˆí™•ì‹¤<br><br>## ê²½ì˜ì§„ ì–´ì¡° ë° ì „ëµ<br>- **ê¸ì •ì  ëª¨ë©˜í…€**: Q4 ì„ìƒ ì†Œëª¨í’ˆ 20% ì„±ì¥, NovaSeq X 100ëŒ€ ì´ìƒ ì„¤ì¹˜ (60% ì´ìƒì´ ì„ìƒìš©)<br>- **ì „ì²´ ì›Œí¬í”Œë¡œìš° ê°•ì¡°**: ë‹¨ìˆœ ê°€ê²© ê²½ìŸì´ ì•„ë‹Œ Fluent + NovaSeq + DRAGEN í†µí•© ì†”ë£¨ì…˜ì˜ ì´ë¹„ìš© ìš°ìœ„ ê°•ì¡°<br>- **ì‹ ê·œ ì„±ì¥ ë™ë ¥**: ë©€í‹°ì˜¤ë¯¹ìŠ¤(Constellation, 5-base), ê³µê°„ ë¶„ì„, BioInsight(AI ê¸°</p>
    <hr style="margin:50px 0;">
    
</body></html>